VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 26 (1-15 noviembre / 2023)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas Covid.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

VaCyT

CUBA

Noticias en la Web

Accelerating AMR vaccine development

Nov 1. Dr Neil Murray, Chief Executive of ReNewVax, explores the importance of new bacterial vaccines in the context of antimicrobial resistance and examines how the principle of reverse vaccinology could help to create more accessible and cost-effective vaccines.

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens.

WHO's analysis was stark. It asserted the need to accelerate trials for AMR-related vaccines in late-stage development and maximise the use of those already on the market.

WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development. While the late-stage vaccine candidates listed in the report were described as having a high development feasibility, the report noted that most will not be available any time soon.

I believe it is therefore incumbent upon those of us working in vaccine development to confound this expectation.

Prior to COVID-19, Streptococcus pneumoniae (also known as the pneumococcus) represented the biggest vaccine market in the world.

And for good reason – this is a disease which kills more children under the age of five than measles, malaria and HIV-AIDS combined. It is one of the leading causes of death associated with AMR globally.

In the immediate turmoil of the pandemic, it was not surprising that pneumococcus and AMR took a backseat in the rush to find a vaccine for COVID-19.

However, now that researchers, investors and governments have seen how the vaccines created for COVID-19 have allowed large parts of the world to start moving again, it is vital we leverage this impetus to expedite the vaccines that the AMR crisis so badly needs.

The threat of AMR continues to accelerate, spurred by the overuse and misuse of antibiotics.

Bacterial vaccines: challenges and opportunities

Bacterial vaccines have the potential to be a key component in fighting AMR. The great benefit of vaccines is that they are a proactive approach to disease prevention, compared to the reactive use of antibiotics. Additionally, by reducing disease levels, you reduce the need for antibiotics, which slows the evolution of antibiotic-resistant bacteria.

Historically, the development of bacterial vaccines has been challenging; it is not practical to develop a vaccine against each individual pathogen nor to vaccinate everyone against everything. However, for key pathogens, which carry a high disease burden and play a key part in the development of AMR, vaccines can be a critical tool. Slowing the development of resistance in just one class of bacteria increases the useful life of broad-spectrum antibiotics.

In particular, vaccines could be a way forward in treating gram-negative infections, where developing small molecule antibiotics has been challenging.

Another important consideration in the development of bacterial vaccines is cost. Many existing bacterial

vaccines rely on expensive conjugation technologies in their manufacture; consequently routine vaccination largely remains beyond the reach of low- and middle-income countries, where AMR is prevalent.

However, there are potential cost advantages to rationally designed protein-based vaccines developed using reverse vaccinology. These vaccines are cheaper to manufacture, and could potentially be more accessible in developing countries.

Reverse vaccinology

Our strategy at ReNewVax is based on the principle of reverse vaccinology, employing rational design in lieu of the classical hypothesis-led approach, which carries substantial risk until clinical evidence is generated. Analysis of large databases of clinical samples enables us to identify protein antigens with potential to form the basis of an effective vaccine.

In addition to the normal range of efficacy and safety studies, our approach is then further de-risked by including ex vivo human cell testing to confirm the immunologic properties of our vaccines before they are tested in clinic, increasing the likelihood of clinical success.

Using this approach, our lead programme – RVX 001, a protein-based vaccine against invasive pneumococcal disease – has been designed with antigens common to all pneumococcus serotypes. This makes RVX-001, potentially, the first universal pneumococcal vaccine – a key step forward in the immunisation strategy against this critical pathogen.

We look forward to taking our programme through to late-stage development as trials progress. Yet clinical trial costs for late-stage vaccines are high and more can be done to adapt trial designs to alleviate these costs.

There have been several previous failed attempts at developing a universal pneumococcal vaccine associated with late-stage termination of clinical trials, incurring significant costs, both financially and in human resource.6 Most recently, the development of a whole cell-based vaccine was abandoned on the basis of reports showing unacceptably high reactogenicity in young children.7 ReNewVax's development pipeline is significantly differentiated from any previous or existing pneumococcal programmes in that we have used a rational rather than a hypothesis-led approach.

While regulatory support, such as breakthrough therapy designations, can help in this regard, there is a critical need to collaborate with regulatory agencies to agree efficient clinical trial designs that maintain appropriate demonstration of safety and efficacy.

AMR has the potential to be just as devastating for the world as COVID-19. However, unlike COVID-19, it is advancing with stealth and action must be taken before it is too late. We believe the development of bacterial vaccines can be a key weapon in the fight against AMR.

"unlike COVID-19, [AMR] is advancing with stealth and action must be taken before it is too late".

If it were necessary, the pandemic has reminded us of the incredible power of vaccines as we are able to go about our day-to-day lives after years of disruption.

It is imperative that our industry does not waste this vital opportunity and capitalises on advances made in vaccine technology to prevent AMR spiralling further into a crisis that could debilitate our lives once again.

Fuente: European Pharmaceutical Review. Disponible en https://acortar.link/CUCqZ5

Combination vaccines are coming for respiratory diseases

Nov 1. Combination vaccines are nothing new for the healthcare industry. Childhood vaccines, as well as a single shot for tetanus, diphtheria and pertussis for adults, have long been combined for ease of administration and increased compliance rates.

Now, as vaccines for COVID-19 and, for older people, RSV and pneumococcal disease join the annual flu shot as routine care recommendations for adults, healthcare professionals are increasingly concerned over getting the word out, vaccine fatigue and logistical hurdles. Biopharma companies are betting there will be a market for vaccines that combine protection against two or more diseases in a single jab.

"The data are pretty unequivocal that when there are combo vaccines available, people generally prefer them."

Andrea C. Love, immunologist and microbiologist

Benefit to the Population

"The data are pretty unequivocal that when there are combo vaccines available, people generally prefer [them]," said Andrea C. Love, an immunologist and microbiologist and founder of the Unbiased Science Podcast.

Love pointed out the convenience of the combination vaccines is a big positive for patients. She and others in the industry anticipate that a more streamlined process will increase vaccination compliance. Additionally, timely vaccination reduces the burden of illness for recipients.

Despite its benefits, vaccinations for COVID-19 have been on the decline. In October, Pfizer cut its revenue outlook for 2023 by $2 billion due to lower demand for Comirnaty. The CDC reported that as of October 14, only 7% of adults and 2% of children had obtained the latest bivalent booster shot against COVID-19.

And just under half of adults received a vaccine against flu in the most recent year for which the agency has released data. Uptake has fallen, particularly in the 18 to 49 age group. Yet the flu remains a deadly illness: The CDC reported 290,000 hospitalizations and 19,000 deaths from influenza in the 2022-2023 flu season as pediatric hospitalizations and mortality rates reached highs that haven't been seen in years.

Respiratory syncytial virus (RSV) is the newest addition to the vaccine lineup. The virus leads to 100–300 deaths in children under 5 and 6,000–10,000 deaths in adults over 65 each year. Two vaccines have now been approved to prevent RSV in people over 60, with other companies in late-stage testing. Pfizer's Abrysvo is also indicated for use during pregnancy to protect infants from birth to 6 months of age. Analysts estimate the market will exceed $9 billion by 2029.

Combo Vaccines in the Pipeline

In the face of dwindling vaccination rates, multiple biopharma companies are now developing shots that combine protection against two or even three respiratory illnesses.

Moderna has a handful of combos in the pipeline for flu plus COVID-19; flu, COVID-19 and RSV; and flu plus RSV. Phase I/II data from its quadrivalent influenza and COVID-19 vaccine were reported in early October, showing strong immunogenicity with an acceptable safety profile compared to standalone vaccines. The company is now moving into Phase III. Likewise, Pfizer and BioNTech announced positive topline data for an mRNA-based vaccine targeting influenza A, B and COVID-19, and it will be headed into Phase III.

Novavax has a vaccine for COVID-19 already on the market and a seasonal influenza shot in Phase III. The company is now working on combining the two into a single shot, hoping that decreasing the number of medical contact visits required will increase the number of people willing to get vaccinated, said Novavax President of R&D Filip Dubovsky.

Novavax's platform leaves the door open to potentially add in protection against other viruses as well, such as RSV, for which it already has a candidate in the pipeline.

"It's our understanding from discussing both with consumers as well as healthcare providers that there's a strong demand for a combination product, and it makes all the sense in the world," Dobovsky said.

The path for Novavax has been much quicker than traditional R&D because components of the vaccines have already been in use, allowing the company to move rapidly into human testing.

As these companies look to combine their already-approved or nearing-approval products, smaller player Icosavax came straight out of the gate with a combo vaccine candidate for RSV and human metapneumovirus (hMPV), a cousin to RSV. The candidate is in Phase II and has already received Fast Track Designation from the FDA.

"We've been able to go right to a combination approach," Icosavax CEO Adam Simpson told BioSpace, pointing out that the FDA seems open to this based on the designation.

The company put RSV and hMPV together because the viruses don't change every year. Simpson said Icosavax is hoping for a longer-acting vaccine with the right technology, foregoing the need for annual dosing.

Andy Hsieh, a William Blair analyst who covers Icosavax, noted that while the pediatric population has been rife with combination vaccines, the elderly population "has not been mature" in this market. "I think it makes very logical sense that the same benefit that was conferred to the pediatric population should also be extended for the elderly population," Hsieh said.

The market for RSV protection might take some time to build, he told BioSpace, as it's not as commonly known as flu or COVID-19. At this point, the Advisory Committee on Immunization Practices (ACIP) recommendations for RSV vaccination are not as strong as those for COVID-19. Rather than recommending vaccination for everyone who is eligible, ACIP recommends that it be a shared decision for those 60 and older to make with their healthcare providers.

Pfizer CEO Albert Bourla told investors on a recent call that he believes the combo shots will "unlock a significant potential by improving the vaccination rates." Whether these combination shots will really move the needle on public vaccination rates remains to be seen.

Fuente: PharmaLive.com. Disponible en https://acortar.link/jgHvpV

Moderna reins in 2023 COVID vaccine forecast, shares tumble

Nov 2. Moderna (MRNA.O) on Thursday said its 2023 sales would only hit the low end of its $6 billion to $8 billion forecast, reflecting weaker demand for COVID-19 vaccines, and its shares slumped 8%.

The vaccine maker also pushed back to 2025 the launch of its flu shot, which it had previously said it expected to be available in 2024.

Analysts had estimated over $100 million in sales for each of Moderna's not yet approved vaccines against RSV and flu in 2024, according to LSEG data.

Concerns around waning demand for COVID vaccines and anticipation of a loss this year has led to a 60% drop in the company's shares year to date. The stock on Thursday plunged as much as 18% to a three-year low of $62.55 in early trade before trimming some of those losses.



A woman receives a booster dose of Moderna coronavirus disease (COVID-19) vaccine at a vaccination centre in Antwerp, Belgium, February 1, 2022. REUTERS/Johanna Geron/File Photo Acquire Licensing Rights

Moderna said its $6 billion 2023 revenue forecast was based on the expectation that at least 50 million COVID-19 vaccines would be administered in the United States. Moderna's COVID-19 vaccine is its lone marketed product.

TD Cowen analyst Tyler Van Buren in a research note said he is not convinced Moderna's full-year expectations for the overall market is achievable.

COVID vaccine sales have declined in recent weeks, he said, citing IQVIA (IQV.N) data, adding that Moderna's expectations of roughly 50 million shots in the U.S. are only achievable if sales stay roughly flat from here on out.

The company reported third-quarter sales of $1.8 billion, topping analysts' estimates of $1.32 billion, according to LSEG data.

U.S. market share for Spikevax, the COVID vaccine's brand name, had increased to 45% from 36% in 2022, according to Moderna.

So far, more than 15 million people in the U.S. have received an updated COVID-19 shot, including Pfizer's (PFE.N) rival vaccine, according to the Department of Health and Human Services. That compares to around 23 million by this time in last year's campaign, which started 10 days earlier.

Moderna said it expects to return to sales growth in 2025 with the help of new vaccines and break even the following year.

The Cambridge, Massachusetts company forecast $4 billion in revenue next year from sales of its COVID and respiratory syncytial virus (RSV) vaccines. Moderna hopes to launch the RSV vaccine in 2024 based on positive data from a late-stage trial.

Analysts, on average, are looking for nearly $6 billion in revenue next year.

Moderna's 2025 sales growth expectation is based on anticipated revenue from those shots, as well as from a forthcoming combination COVID-flu vaccine, Chief Financial Officer Jamey Mock said in an interview.

"We believe 2024 is the low point, and we laid out some of the pieces to that. We're going to launch two or three new products on top of that in 2025, and have RSV out in 2024, and it'll continue to grow thereafter," he said.

The company posted a third-quarter net loss of $3.6 billion, driven by non-cash charges of $3.1 billion related to manufacturing capacity resizing and on a tax reserve it had to take.

The resizing, which included scaling down production by contract manufacturer Lonza (LONN.S), will improve future cost of sales, Moderna said.

A $9.53 per share loss for the quarter was much larger than expectations for a $1.93 loss, according to LSEG data.

Fuente: Reuters. Disponible en https://acortar.link/J8VAh0

Serotypes 3, 19A Most Common for Pneumococcal Community-Acquired Pneumonia

Nov 3. Despite vaccination with pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23; Merck), serotypes 3 and 19A were still the most common serotypes of pneumococcal community-acquired pneumonia (pCAP) among children and older adults, according to results of a new study.

In the study, conducted in South Korea, PPSV23 vaccination could still reduce the risk of mortality among those with pCAP. Investigators of the study noted that even though the targeted risk population has been vaccinated against pneumococcal diseases, the serotypes are still evolving in South Korea, which can affect the rollout of the vaccines.

Bernard Chantal - tock.adobe.com

In the study, individuals aged 19 and older with community-acquired pneumonia (CAP) were included between September 2018 and July 2021. The individuals were from 5 university hospitals in South Korea. A total of 5009 individuals, with a mean age of 70.3 years and 63.1% men, were included. Approximately 71.3% had at least 1 comorbidity and 44.4% and 7.7% were vaccinated with PPSV23 and pneumococcal conjugate vaccine 13, respectively.

The study investigators analyzed data around demographic and clinical characteristics of the individuals, pneumococcal serotype distribution, and risk factors of 30-day mortality of patents with pCAP. They specifically analyzed the clinical characteristics of serotype 3 pCAP.

The study authors said that the leading cause of CAP was Streptococcus pneumoniae with 11.8% in the overall population and 17.7% in individuals less than 65 years of age with chronic medical conditions. Among the 280 serotypes of Streptococcus pneumococcus, the study authors reported that serotype 3 was most common at 10%, followed by 19A, 34, and 35B at 8.9% each.

Investigators also found that the proportion of pCAP was significantly higher in those who were male, those with comorbidities, those in long-term care facility residence, and concomitant respiratory viral infections when compared to non-pCAP infection.

Among 180 individuals who were vaccinated with PPSV23, the non-vaccine serotypes 35B and 34 were the most prevalent at 13.9% and 12%, respectively. There were no differences between the 2 vaccination groups. However, serotype 3 was still prevalent, regardless of vaccination status, and the most common in those with

chronic lung disease. Serotype 3 was also more common in the spring at 50%.

Furthermore, the investigators found that advanced age, long-term care facility residence, and bacteremia were all independent risk factors that contributed to mortality for those with pCAP.

The study authors said that S. pneumoniae was most prevalent for those less than 65 years of age with chronic medical conditions, noting that the vaccine uptake rate in this group was low. Further, individuals who received PPSV23 had lower rates of pCAP caused by PPSV23 or 20-valent pneumococcal conjugate vaccine serotypes when compared to individuals who were not vaccinated. They suggested that vaccination with PPSV23 could potentially lower the 30-day mortality risk for patients.

Additionally, the investigators stated, that their study demonstrating that pneumococcus was the most common cause of CAP, was consistent with studies in the United States, Canada, and Italy.

The study authors also added that there were limitations to the study. Serotyping data was limited, with information about only 280 of the 598 cases being available. Further, reparatory viral PCR tests were conducted in only 35.2% of individuals.

Fuente: Pharmacy Times. Disponible en https://acortar.link/DvxbZ2

El neumococo se podría erradicar en el planeta dentro de 25 años con vacunas asociadas que incluyan a todos los serotipos

6 nov. El neumococo es una bacteria compuesta por más de 100 serotipos que afecta principalmente a niños y personas mayores. Una de las principales patologías que produce es la neumonía, una infección respiratoria que anualmente afecta a millones de personas en todo el mundo. La investigación y el trabajo desarrollado en materia de prevención ha logrado disminuir considerablemente la carga de la enfermedad, las hospitalizaciones y consecuencias de mayor gravedad para la salud de las personas. En una jornada organizada por MSD, dos especialistas han analizado los principales retos y oportunidades de la enfermedad, así como la importancia de la prevención a través de la vacunación.



GettyImages

"La interrelación entre virus y bacterias es muy interesante porque, con la prevención de las infecciones virales se pueden prevenir muchas infecciones neumocócicas", ha afirmado Fernando Baquero Artigao, coordinador de la Unidad de Infectología Pediátrica del Hospital del Universitario La Paz de Madrid. Por su parte, Fernando Baquero Mochales, profesor de Investigación en el Servicio de Microbiología del Hospital Ramón y Cajal e investigador del grupo 33 de CIBERESP, ha añadido que "el neumococo se podría erradicar en el planeta dentro de 20 o 25 años con vacunas asociadas que incluyan a todos los serotipos".

Las polisacáridas, desarrolladas a mediados de los 80, fueron las primeras vacunas disponibles para tratar las enfermedades neumocócicas. En los primeros años del siglo XXI empezaron a comercializarse las

vacunas conjugadas, que producen una mayor respuesta inmunológica frente al neumococo que las primeras. Dentro de esta categoría, la primera que se desarrolló fue la 7-valente. “El descubrimiento de la vacuna 7-valente supuso una revolución”, ha pronunciado Baquero Mochales. Posteriormente, la vacuna 13-valente también fue un éxito rotundo.

Las primeras vacunas disponibles consiguieron disminuir de forma drástica las infecciones respiratorias altas en los niños y las resistencias a los antibióticos. Por esta razón, ambos expertos consideran que la historia de las vacunas neumocócicas es una historia de éxito. “La vacunación frente al neumococo es el equivalente al descubrimiento de la penicilina en términos de reducción de la morbimortalidad”, ha recalcado Baquero Mochales.

Nuevas vacunas

Hay nuevos serotipos que han ocupado nuevamente el lugar que han dejado los otros. Por esta razón, ambos han coincidido en que son necesarias nuevas vacunas de cara al futuro. Hace apenas un año llegó a España la vacuna conjugada antineumocócica 15-valente contra los serotipos 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F y 33F. En Aragón y Cataluña ya está disponible. “La 15-valente incluye dos nuevos serotipos que están emergiendo: el 22F y el 23F. Esta vacuna genera más respuesta de anticuerpos frente al serotipo 3 y podría abrir una esperanza para el control de este serotipo en la población”, ha apuntado Baquero Artigao. Otra de las últimas en llegar ha sido la 20-valente, pero esta cuenta solo con aprobación en adultos.

Problemas con el serotipo 3

Los neumococos comúnmente colonizan el tracto respiratorio del ser humano, en especial en el invierno y a comienzos de la primavera. La diseminación se produce a través de las gotas que se transmiten por el aire. La cápsula de los neumococos está formada por un polisacárido complejo que determina el tipo serológico y contribuye a su virulencia y potencial patogénico. La virulencia varía un poco dentro de cada tipo serológico debido a la diversidad genética.

Las cepas del serotipo 3, que están encapsuladas en forma más estrecha y tienden a formar más colonias mucoides que otros serotipos, son causas comunes de enfermedad neumocócica invasora en adultos. Según MSD, la mayoría de las infecciones graves son causadas por los serotipos 3, 4, 6B, 9V, 14, 18C, 19F y 23F, que se incluyen en las vacunas antineumocócicas conjugadas PCV15 y PCV20 administradas inicialmente con mayor frecuencia. Estos producen aproximadamente el 90 por ciento de las infecciones graves en niños, y el 60 por ciento de las observadas en adultos. “El serotipo 3 nos causó mucho miedo. Es un serotipo que ha persistido a pesar de la vacunación con 13-valente y es el número uno causante de enfermedad invasora en niños y adultos”, ha explicado Baquero Artigao.

“El serotipo 3 no es muy resistente a los antibióticos. Paradójicamente, su cápsula impide que le entre información de bacterias resistentes a los antibióticos, pero es tan patógeno que, a veces, la respuesta de citoquinas o de interferón del hombre produce lesiones trombóticas o neumonías con tal rapidez que los antibióticos no son muy eficaces”, ha sostenido Baquero Mochales.

El papel de MSD

Durante la jornada también se ha puesto de manifiesto el compromiso y contribución de MSD en el abordaje de esta bacteria. “MSD es una compañía que lleva más de 100 años dedicados a poder desarrollar y

distribuir antibióticos y vacunas", ha explicado Gonzalo Fernández, director médico de la Unidad de Vacunas de MSD en España. Para ello se ha apoyado en una serie de datos: en el siglo XIX aportó las vacunas de la listeria y la viruela, y en el XX fueron muchas más, entre ellas la del neumococo. "En 1977 se presentaron los resultados de dos ensayos clínicos donde se demuestra que eran claramente eficaz", ha detallado. La primera vacuna se comercializó ese mismo año. La siguiente fue la de Pneumovax 23, que aún está disponible. A partir de ese momento, la compañía desarrolló otra tecnología de vacunas con la 15-valente.

"Es importante la estrategia de desarrollo de vacunas porque esta vacuna tenía el objetivo de mantener la inmunogenicidad de la vacuna anterior de 13 serotipos, añadir serotipos nuevos y producir una respuesta para ese serotipo 3. MSD sigue comprometida con el neumococo y está desarrollando una vacuna antineumocócica conjugada de 21 serotipos para la población adulta. De hecho, cuenta con ocho serotipos que no disponen ninguna de las vacunas anteriores. Los resultados de la fase III se van a presentar en las próximas semanas o meses", ha concluido.

Fuente: Gaceta Médica. Disponible en https://acortar.link/G0mEob

Moderna Launches mRNA Platform Incubator Network to Boost

Nov 6. US-based biotechnology company Moderna has taken a significant step in advancing mRNA (messenger RNA) research by introducing the mRNA Platform Incubator Network in Australia. This collaborative network brings together prominent Australian organizations with expertise in translational and pharmaceutical science, early-phase clinical trials, and regulatory science. The primary goal is to promote scientific excellence in clinical translation and further harness the therapeutic potential of the mRNA platform.

Promising Potential of mRNA

Moderna has officially partnered with the Australian Federal Government to establish an advanced domestic mRNA vaccine manufacturing facility in Melbourne, Victoria. This collaboration, following the initial announcement in December 2021, underscores Moderna's commitment to supporting Australia's mRNA research and global public health efforts. The facility will focus on producing mRNA vaccines for respiratory viruses like COVID-19, influenza, and RSV. Construction is set to begin by the end of 2022, with operational status expected by the end of 2024, subject to approvals. Moderna's extensive mRNA pipeline includes 28 vaccine candidates targeting respiratory and latent viruses, addressing global health challenges.

Moderna's Regional Research Centre, inaugurated in August, will serve as the headquarters for this network of excellence. It includes prestigious institutions like Monash University, the Monash Institute of Pharmaceutical Sciences (MIPS), the Peter Doherty Institute, and The Peter MacCallum Cancer Centre. By combining the knowledge and expertise of these esteemed organizations, the Network aims to overcome specific clinical platform challenges and enhance mRNA therapeutics.

mRNA technology has been at the forefront of medical innovation, particularly in the development of COVID-19 vaccines like Spikevax. The Network's mission involves developing scientific strategies to tackle challenges in the mRNA field. It also focuses on overseeing the practical implementation of these strategies, using non-clinical and computational quantitative pharmacology investigations, as well as translational clinical trials, led from Australia. This approach demonstrates the commitment to exploring mRNA's therapeutic potential fully.

Elevating Australia as an mRNA Research Leader

Dr. Craig Rayner, Director of Moderna's Regional Research Centre, emphasizes that the creation of the mRNA Platform Incubator Network underscores Australia's emerging leadership in mRNA research. Professor Chris Porter, Director of the Monash Institute of Pharmaceutical Sciences, also highlights the importance of bringing together leaders in mRNA science from academia, industry, and clinical evaluation. This collaboration represents a significant step toward realizing the full potential of mRNA therapeutics. As mRNA technology continues to evolve and offer promising therapeutic options, this initiative is poised to contribute significantly to medical advancements and innovation in Australia.

Fuente: GENE ONLINE. Disponible en https://acortar.link/S03sfN

International Scientists Launch Human Trials for Strep A Vaccine



Nov 7. In a significant stride toward combating the deadly Group A Streptococcus bacteria, commonly known as Strep A, an international collaboration of scientists from the University of Alberta in Canada and Griffith University in Australia has initiated the first phase of human clinical trials for a potential Strep A vaccine. This development offers a ray of hope in the battle against a pathogen responsible for claiming more than 500,000 lives annually, particularly affecting vulnerable populations such as children and marginalized communities.

The Vaccine Development Breakthrough

Griffith University researchers, under the lead of Professor Michael F. Good from Griffith's Institute for Glycomics, have pioneered a groundbreaking approach to Strep A vaccine development. Previous research efforts were hampered by the pathogen's enormous diversity, but this new vaccine design targets specific key epitopes present in every Strep A strain.

By presenting these crucial components to the immune system, researchers hope to bolster the body's ability to fight off even the most virulent Strep A strains. This innovative strategy has the potential to unlock a successful vaccine, offering protection against multiple Strep A strains, a feat previously considered challenging due to the pathogen's variability.

International Collaboration and Funding Support

The collaborative effort began when Distinguished Professor Lorne Tyrrell and Nobel laureate Sir Michael Houghton from the Li Ka Shing Applied Virology Institute recognized the potential in Griffith University's Strep A vaccine program. Griffith University's vaccine, formulated by combining two universal molecules found in all

Strep A strains, attracted significant interest due to its innovative approach. The University of Alberta's state-of-the-art facilities and expertise provided an ideal platform for the vaccine's clinical trials.

The Li Ka Shing Applied Virology Institute took a crucial step by funding the initial phase of clinical trials, with Griffith University retaining the intellectual property rights. Lawrence Richer, the center director of the Northern Alberta Clinical Trials and Research Centre, highlighted the University of Alberta's commitment to providing a safe and innovative environment for these critical trials. The institution's dedication to constant innovation and support for researchers significantly facilitated the translation of laboratory discoveries into human trials.

Promising Prospects and Future Trials

The Phase 1 clinical trial, expected to involve 10 to 20 patients, aims to establish the vaccine's safety and efficacy. If successful, the Li Ka Shing Applied Virology Institute plans to support Phase 2 trials, encompassing a larger patient cohort. This progression offers hope for the development of a groundbreaking vaccine that could prevent a spectrum of Strep A-related diseases, including rheumatic fever, necrotizing fasciitis, and neurological disorders like Sydenham chorea.

The launch of human trials for the Strep A vaccine signifies a pivotal moment in the quest to save lives and enhance global health. By targeting the Achilles heel of the Strep A pathogen, scientists have embarked on a journey that holds immense promise for preventing severe diseases and complications, as well as reducing fatalities, particularly in vulnerable populations.

Fuente: GENE ONLINE. Disponible en https://acortar.link/UnNIMi

31-Valent Pneumococcal Conjugate Vaccine Candidate Doses First Person

Nov 9. Vaxcyte, Inc. today announced that the first participants were dosed in a Phase 1/2 clinical study for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) in adults.

Vaxcyte stated it expects to announce topline data from the Phase 1/2 study in the second half of 2024.

"We are pleased to initiate the first adult clinical study of VAX-31, which is the broadest-spectrum PCV to enter the clinic, with the potential to protect against approximately 95 percent of IPD circulating in the U.S. adult population," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte, in a press release on November 9, 2023.

"Leveraging the foundation established by our lead PCV candidate, VAX-24, we believe we have an opportunity to deliver a best-in-class PCV franchise that provides the broadest spectrum of coverage and improved immune responses compared to the standard-of-care in adults today."

The VAX-31 Phase 1/2 clinical study is a randomized, observer-blind, active-controlled, dose-finding clinical study designed to evaluate the safety, tolerability, and immunogenicity of VAX-31 compared to Prevnar 20® in healthy adults aged 50 and older.

Pneumococcal disease (PD) is an infection caused by Streptococcus pneumoniae bacteria. It can result in IPD, including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media, and sinusitis.

The U.S. National Center for Health Statistics Mortality Surveillance reported on October 27, 2023, that most

respiratory disease deaths were recently related to pneumonia, not COVID-19 or influenza. Precision Vax posts additional PCV vaccine and candidate news.

The U.S. CDC's pneumococcal vaccine schedules were updated in 2023.

Fuente: Precision Vaccinations. Disponible en https://acortar.link/buVEQd

La vacuna contra el dengue llegó a la Argentina: la palabra del científico que lideró el estudio global

9 nov. Infobae dialogó en exclusiva con el doctor Derek Wallace, jefe del equipo de investigación que desarrolló y evaluó la eficacia de la fórmula tetravalente del laboratorio japonés Takeda que protege contra los cuatro serotipos del virus. Quiénes pueden recibirla y cómo será su aplicación en el país.

La vacuna tetravalente contra el dengue se administra en dos dosis con un intervalo de 3 meses (Imagen ilustrativa Infobae).

Quién iba a decir que los mosquitos iban a ocupar el centro de la escena científica convirtiéndose en el vector de una de las infecciones virales que amenaza al mundo.

El dengue es endémico en más de 100 países y causa 390 millones de nuevas infecciones y 20.000 muertes por año a nivel global, según la Organización Mundial de la Salud (OMS). El cambio climático y el avance de la urbanización no planificada alteraron el comportamiento del vector -el mosquito Aedes aegypti- y el virus que causa el dengue dejó de tener alta circulación sólo en zonas tropicales y subtropicales para propagarse por nuevas regiones, como Estados Unidos y Europa.

Este avance implica que el dengue se convirtió en una enfermedad con alto riesgo de pandemia.

De esa realidad no escapa la Argentina, que en la última temporada de dengue marcó cifras récord, con 132.237 infecciones y 65 muertes registradas en lo que va del 2023.

Ahora, la buena noticias es que la vacuna tetravalente -aprobada por la ANMAT en abril- que disminuye 84% el riesgo de hospitalización y reduce 61% los casos de dengue sintomático, está disponible en el país desde principios de este mes en los centros de vacunación privados, según informó hoy el laboratorio Takeda, responsable del desarrollo de la vacuna.

Esta formulación tetravalente protege contra los cuatro serotipos del virus del dengue y, además, demostró una eficacia general que se eleva a 80,2% para prevenir los casos de dengue sintomáticos en los 12 meses siguientes a la aplicación.

Infobae entrevistó en exclusiva al doctor Derek Wallace, jefe del Programa Global de Dengue de Takeda que desarrolló la fórmula tetravalente, y quien lideró la investigación global sobre la seguridad y eficacia de la vacuna contra el dengue en un ensayo clínico que se prolongó por 5 años y contó con más de 20 mil voluntarios.

El doctor Wallace es médico especialista en vacunología y es uno de los científicos que más sabe de dengue en el mundo. En 2009 visitó un hospital en Tailandia durante un brote de la enfermedad y quedó shockeado por los niños hospitalizados y sus padres cuidándolos con colchones en el piso, desde entonces encontrar la vacuna contra la enfermedad fue su norte.

“Las vacunas son una herramienta muy potente de la salud pública. Y brindan beneficios a más de una generación, es un orgullo que esta vacuna ayude a reducir la carga de la enfermedad de dengue para las generaciones venideras”, señaló Wallace a Infobae.

El experto nació en Papúa Nueva Guinea, creció en Brisbane, Australia, ahora reside en Massachusetts, EEUU. Como ciudadano del mundo, conoce bien los riesgos de una enfermedad que avanza y que puede convertirse en pandemia si no se mitiga su circulación.

¿Quiénes pueden recibir la vacuna contra el dengue?

La vacuna tetravalente contra el dengue del laboratorio japonés Takeda (TAK-003), conocida como Qdenga, fue aprobada a fines de abril en Argentina por la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) y desde el 1 de noviembre está disponible en el país.

También fue aprobada por la Agencia Europea de Medicamentos (EMA), el Reino Unido, Islandia, Brasil, Colombia, Indonesia y Tailandia.

La vacuna se administra en dos dosis de 0,5 ml que deben aplicarse con un intervalo de 3 meses. Brinda protección contra los cuatro serotipos del dengue y está destinada para mayores de 4 años (y sin límite de edad) que hayan tenido o no la infección. Está contraindicada en embarazadas, mujeres en período de lactancia y en pacientes con inmunocompromiso.

Se aplica bajo prescripción médica, por eso la persona debe acercarse a los principales centros de vacunación privados del país y presentar la receta para recibir la dosis.

La vacuna Qdenga está compuesta por virus vivo atenuado y se desarrolló a partir del serotipo 2 del dengue, que conforma la base genética para ofrecer protección contra todos los serotipos.

El doctor Wallace, tras más de una década de investigación, sintetiza la elaboración de esta vacuna por virus vivo atenuado como una delicada combinación de “arte y ciencia”.

“La idea es atenuar el virus a un nivel que no sea muy escaso pero tampoco demasiado fuerte. Porque la vacuna tiene que prevenir que se produzca en el organismo síntomas similares a los que produce el dengue, pero, al mismo tiempo, se busca lograr una respuesta inmunitaria robusta”, detalló.

Existen cuatro serotipos distintos del virus del dengue: DEN-1, DEN- 2, DEN-3 y DEN-4 y en América circulan todos. Cualquiera de los cuatro serotipos de dengue provocan la enfermedad y la prevalencia de cada serotipo varía según los diferentes países, regiones, temporadas y a lo largo del tiempo.

En Argentina, en la última temporada, el 79% de las infecciones fueron por DEN-2 y el 20% por DEN-1, y solo un grupo reducido de casos por DEN-3.

“De los cuatro serotipos del virus del dengue, solamente DEN-2 es el que tiene ese nivel de atenuación y por eso lo usamos como base (genética) para combatir los otros tres serotipos. El desafío fue identificar la atenuación correcta del virus”, explicó Wallace.

El nivel adecuado de atenuación del virus —que se corroboró en el ensayo clínico con humanos y con

mosquitos— es una cantidad de virus en sangre tan pequeña que cuando el Aedes aegypti pica a una persona vacunada luego el mosquito no transmite ninguna carga viral a otro humano.

Un estudio de cinco años para evaluar la eficacia

El doctor Wallace lideró la investigación global detrás del desarrollo de la vacuna Qdenga: el Estudio de Eficacia de la Inmunización Tetravalente contra el Dengue (TIDES, por sus siglas en inglés), que evaluó la eficacia y seguridad de la vacuna en ocho países, se realizó durante 5 años y contó con la participación de más de 20 mil voluntarios.

Para el ensayo fueron elegidos cinco países endémicos de dengue de América Latina (Brasil, Colombia, República Dominicana, Nicaragua y Panamá) y tres de Asia (Sri Lanka, Tailandia y Filipinas).

La decisión de realizar un seguimiento durante cinco años a 20 mil voluntarios en ocho naciones con distintas realidades de circulación de virus del dengue fue clave para fue evaluar la fórmula tetravalente: "Lo desafiante fue lograr una heterogeneidad en la situación epidemiológica. Si hubiéramos hecho el estudio en un único país, hubiéramos tenido la información de solamente uno o dos serotipos. En cambio, de esta manera logramos un panorama global con distintos huéspedes (las personas voluntarias) de los cuatro serotipos", detalla Wallace.

La vacuna tetravalente contra el dengue está destinada para mayores de 4 años y sin límite de edad que hayan tenido o no la infección. (iStock)

Los resultados del estudio TIDES mostraron una disminución del 84% de las hospitalizaciones por dengue y una reducción del 61% los casos de dengue sintomático.

Además, a los 12 meses de la aplicación de las dosis la eficacia general se elevó al 80,2% para prevenir los casos sintomáticos. Ya que con el tiempo, la vacuna logra que la respuesta inmune se haga más robusta, por eso Qdenga cumplió un criterio de valoración clave al prevenir 90,4 % las hospitalizaciones un año y medio después de la vacunación.

Después de haber contraído la enfermedad de dengue, la recuperación de la infección causada por uno de los serotipos ofrece inmunidad de por vida únicamente contra ese serotipo, y la exposición posterior a cualquiera de los otros serotipos está asociada con un mayor riesgo de padecer la enfermedad grave.

Una de las grandes ventajas de esta vacuna es que puede aplicarse en las personas que ya hayan cursado la enfermedad de dengue, que son quienes están en riesgo de desarrollar cuadros más severos.

Wallace describió a Infobae que si una persona está con la enfermedad activa al momento de acercarse al vacunatorio —por ejemplo, si tiene fiebre— se posterga la aplicación de la dosis, pero si ha tenido dengue hace dos semanas puede vacunarse sin problemas.

Protección extra prolongada

Respecto a si se está evaluando un calendario de refuerzos tras las dos dosis, el doctor Wallace explica que

la respuesta inmune es tan prolongada tras las dos dosis que aún falta determinarlo.

“Con la vacuna tetravalente estamos hablando de una protección contra el dengue de cuatro años y medio o más”, dice contundente.

“Nuestro estudio TIDES evaluó la inmunidad hasta 4,5 años después de la segunda dosis y sabemos que la protección se mantiene en ese lapso”, completó.

La vacuna del dengue en Argentina

El dengue se ha urbanizado y amplió su zonas de circulación. Ya no afecta solo a las áreas del norte argentino, aunque la región del NOA (Catamarca, Jujuy, La Rioja, Salta, Santiago del Estero y Tucumán) sigue concentrando casi la mitad de la infecciones registradas, según las cifras actualizadas del Ministerio de Salud de la Nación.

“El dengue se ha transformado en la enfermedad transmitida por insectos más importante en el mundo y continúa mostrando que lo seguirá siendo en los próximos años. Su crecimiento es permanente, tanto en cantidad de pacientes como en la extensión geográfica afectada”, dijo el doctor Tomás Orduna, médico infectólogo tropicalista y ex Jefe de Medicina Tropical y Medicina del Viajero del Hospital Muñiz, durante la presentación de la vacuna.

Fuente: Infobae. Disponible en https://acortar.link/2y3Bfx

La FDA aprueba la primera vacuna contra el virus chikungunya

10 nov. La Administración de Alimentos y Medicamentos de Estados Unidos dijo este jueves que aprobó la primera vacuna para prevenir la enfermedad causada por el virus chikungunya.

La vacuna de dosis única, Ixchiq , fabricada por Valneva Austria GmbH, está aprobada para adultos que tienen un mayor riesgo de exposición al virus. Ixchiq recibió designaciones de terapia innovadora y de vía rápida.

El chikungunya, una enfermedad transmitida por mosquitos cuyo nombre en el dialecto makonde de África significa “agacharse de dolor”, no tiene tratamiento específico y puede ser debilitante e incluso mortal para los recién nacidos. Los expertos en salud lo consideran una amenaza emergente para la salud global agravada por el cambio climático, con al menos 5 millones de casos en los últimos 15 años, aunque las muertes y las enfermedades graves son raras, según la Organización Mundial de la Salud .

Las personas con mayor riesgo de infección viven en África, el sudeste asiático y partes de América, donde los mosquitos portadores de chikungunya son endémicos, pero la crisis climática llevó el virus a nuevas partes del mundo.

Antes de 2006, el virus rara vez se identificaba incluso en viajeros estadounidenses, según los Centros para el Control y la Prevención de Enfermedades de EE. UU., pero los estudios identificaron un par de docenas de casos en viajeros estadounidenses entre 2006 y 2013. A finales de 2014, los casos que surgieron de la

transmisión local fueron reportado en partes más cálidas de los EE. UU.: Florida, Texas, Puerto Rico y las Islas Vírgenes de los EE. UU.

Las personas que contraen chikungunya suelen tener fiebre y pueden desarrollar dolor en las articulaciones. También pueden tener dolor de cabeza, dolor muscular y sarpullido. Para algunas personas, el dolor articular puede ser debilitante y puede durar años. Se espera que alrededor del 20% al 30% de los casos se vuelvan crónicos, según muestra la investigación. Para los recién nacidos, el chikungunya puede ser una amenaza potencialmente mortal.

Ixchiq contiene una versión viva y debilitada del virus, por lo que puede causar síntomas similares a los de una infección.

La FDA dijo que en un estudio, el virus de la vacuna se detectó en la sangre de las personas en las primeras semanas después de haber sido vacunadas. La información de prescripción que viene con la vacuna incluye una advertencia para asegurarse de que los proveedores de atención médica informen a sus pacientes que no se sabe si el virus de la vacuna puede transmitirse de una persona embarazada a su recién nacido, y no está claro si el virus de la vacuna puede transmitirse y lastimar a un recién nacido. La advertencia indica a los proveedores que sopesen la amenaza del virus para el paciente, así como la edad gestacional y los riesgos de la enfermedad para el feto o el recién nacido.

Debido a que no existe un tratamiento específico para el chikungunya, los médicos suelen indicar a los pacientes que descansen, beban muchos líquidos y tomen medicamentos de venta libre para controlar la fiebre o el dolor. Pero los científicos dicen que una vacuna es la mejor opción para las personas vulnerables al virus.

"La infección por el virus chikungunya puede provocar enfermedades graves y problemas de salud prolongados, especialmente en adultos mayores e individuos con afecciones médicas subyacentes", dijo el Dr. Peter Marks, director del Centro de Evaluación e Investigación de Productos Biológicos de la FDA, en un comunicado de la agencia.

"La aprobación de hoy aborda una necesidad médica no cubierta y es un avance importante en la prevención de una enfermedad potencialmente debilitante con opciones de tratamiento limitadas", agregó.

La FDA exige que el fabricante de vacunas Valneva realice un estudio posterior a la comercialización para asegurarse de que la vacuna no presente riesgos graves.

Los efectos secundarios más comunes informados en los estudios presentados a la FDA para la aprobación de la vacuna incluyeron dolor de cabeza, dolor muscular y articular, fiebre, sensibilidad en el lugar de la inyección y cansancio. Casi el 2% de las personas que recibieron la vacuna tuvieron reacciones adversas graves similares a las del chikungunya que requirieron intervención médica. Solo dos de las casi 3.500 personas que participaron en los ensayos tuvieron que ir a un hospital debido a la reacción. Algunos también tuvieron una reacción adversa similar al chikungunya que duró al menos 30 días. La vacuna viene con una advertencia para alentar a los proveedores a discutir cualquier posible reacción que un paciente pueda tener a la vacuna.

Fuente: CNN Salud. Disponible en https://acortar.link/GN6pqd

Éxito de la vacuna cubana Abdala, pese a campaña en contra



13 nov. En Cuba no se han registrado muertes por COVID-19 desde hace año y medio, como resultado de las acciones que, a pesar del bloqueo económico, se han realizado para frenar la pandemia; entre éstas destacan el desarrollo de vacunas cuya eficacia contra el virus SARS-CoV2 está demostrada, incluso contra las nuevas variantes que la Organización Mundial de la Salud (OMS) ha clasificado de preocupación.

La experiencia de los científicos de la isla en el desarrollo de Abdala, su primer biológico, es peculiar porque las diferentes etapas del ensayo clínico coincidieron con los periodos en que circulaban las variantes beta, delta y ómicron. Así que en cada fase se comprobó la capacidad del producto para neutralizarlas, explicó Gerardo Guillén, director de Investigación Biomédica del Centro de Ingeniería Genética y Biotecnología (CIGB) de Cuba.

El especialista y Miladys Limonta, directora de Desarrollo de Negocios del CIGB, estuvieron en México la semana pasada para participar en el Congreso Nacional e Internacional de Ciencias Farmacéuticas. Antes de regresar a su país concedieron una entrevista a La Jornada para exponer la eficacia de Abdala y responder a los cuestionamientos que han revivido en las semanas recientes por ser, hasta ahora, el único biológico contra el covid disponible en México para la actual temporada de invierno.

Sin degradación

Mucho se ha discutido sobre la caducidad de la vacuna, pues la etiqueta de los frascos que se han empezado a aplicar en territorio nacional dice que la vigencia terminó en agosto de 2023. Limonta explicó que los registros para uso de emergencia fueron otorgadas por la autoridad sanitaria de Cuba con una vigencia de 12 meses, pero periódicamente, a los 18 y 24 meses, se han realizado pruebas, las cuales confirmaron que los lotes mantienen las condiciones de estabilidad y calidad para contrarrestar la infección por el coronavirus.

Debido a que las condiciones iniciales de producción de la vacuna no se han modificado, las que se han ido fabricando posteriormente salen con una fecha de caducidad de un año, pero se tiene la evidencia de que no se degradan, conservan la pureza y propiedades biológicas para prevenir complicaciones graves y muertes hasta dos años en la actualidad.

Otra crítica recurrente a la vacuna cubana es que no ha sido certificada por la OMS. Limonta informó que el expediente respectivo consta de cinco módulos y se retrasó la entrega del relativo a la caracterización físico-química y la producción.

Pendiente de aprobación, no rechazada

La razón de esto fue que por la emergencia sanitaria, al inicio Cuba utilizó una fábrica que ya tenía para producir Abdala, pero estaba en proceso la instalación de otra planta donde se daría continuidad a la manufactura del biológico. Con la información de estas nuevas instalaciones se completaría el expediente para la OMS.

El proceso de certificación se retrasó varios meses porque se requiere la validación de entidades internacionales y de la autoridad regulatoria de los sistemas, la tecnología y las pruebas de producción de los primeros lotes. De estos, además, se necesitan estudios de comparabilidad respecto a las vacunas fabricadas previamente.

El mayor problema, expuso, se dio con las instancias externas por la dificultad de Cuba para realizar las transacciones financieras y todavía se mantenía la emergencia sanitaria por la pandemia de COVID-19.

Limonta destacó que la OMS no rechazó en ningún momento la vacuna, sino que el proceso está pendiente. El CIGB está por presentar los documentos faltantes, pero ahora el organismo sanitario ya no tiene la necesidad ni urgencia de evaluar vacunas, y como Abdala, hay más de 30 biológicos en proceso de evaluación.

En el CIGB se crearon las vacunas durante 2021, cuando en los países desarrollados ya se aplicaban los biológicos de empresas trasnacionales. La isla decidió realizar investigaciones científicas propias, como se ha hecho por décadas, porque a causa del bloqueo económico impuesto por Estados Unidos, las compras y transacciones financieras son muy complicadas, en ocasiones imposibles de realizar. Estaba claro que a Cuba no llegarían las vacunas, señaló Guillén.

Para lograr el objetivo en el CIGB se suspendieron los 30 proyectos de investigación en curso y todos nos enfocamos en COVID-19. Los científicos plantearon 16 líneas de investigación, de las cuales progresaron dos: Abdala y Soberana.

Ambas vacunas están disponibles en Cuba y se aplican de manera indistinta, ahora como refuerzo a los niños a partir de dos años de edad, adultos mayores y personas que viven con enfermedades crónicas.

Los estudios de eficacia de Abdala demostraron 92.28 por ciento de capacidad para neutralizar la acción del coronavirus.

Después, en los estudios de efectividad, cuando la vacuna ya se aplicaba ampliamente en la población, predominaba la variante delta y ya empezaba a circular ómicron. En esa oleada de transmisión del coronavirus, a escala global la cantidad de enfermos fue mucho más alta que con delta, mientras en Cuba, la incidencia y mortalidad fue 10 veces más baja, aseguró el experto.

Otros estudios efectuados para comprobar la eficacia de Abdala frente a las variantes y subvariantes de ómicron –que siguen siendo predominantes–, se hicieron con muestras de sangre tomadas de los participantes en el ensayo clínico y se corroboró que la vacuna reduce 50 por ciento la capacidad de contagio de SARS-CoV-2, lo cual es aceptable a escala internacional, pues se evitan las complicaciones graves y defunciones.

Seguridad garantizada

Guillén explicó que la plataforma tecnológica utilizada por el CIGB se conoce hace 30 años y con ella Cuba fabrica la vacuna contra hepatitis B, de la cual se han vendido cientos de millones de dosis en 50 países. Desde ahí está garantizada la seguridad de Abdala.

Todavía más, dijo, no requiere condiciones especiales de refrigeración, pues se conserva entre 2 y 8 grados centígrados y en la investigación se demostró que mantiene su estabilidad por un mes a 37 grados y por una semana a 45 grados. Esto es una ventaja para los países de ingresos medios y bajos, la mayoría de los cuales han tenido poco acceso a los inmunógenos contra el coronavirus, sostuvo.

En México, la vacuna Abdala tiene autorización de uso de emergencia para aplicarse en personas de 5 años de edad en adelante.

Fuente: La Jornada. Disponible en https://acortar.link/YbQl9o

Ministra Aguilera dice que nueva vacuna contra el Covid-19 llegará al país "probablemente a fines de esta semana o a inicios de la que viene"

15 nov. A poco más de un año desde que inició la campaña de inmunización con la vacuna bivalente contra el Covid-19, las autoridades chilenas decidieron implementar un nuevo refuerzo anual. Así lo adelantaba La Tercera ayer martes.

La ministra de Salud, Ximena Aguilera, oficializó la medida este miércoles, ante el incremento de casos en las últimas semanas. "Desde el año pasado, cuando yo llegué como ministra y pasamos a la fase de apertura en la pandemia, también informamos que nuestra política de inoculación iba a ser vacunar una vez al año la población de riesgo", señaló tras participar de la ceremonia de inicio de obras de un nuevo Cesfam en Providencia.

La secretaria de Estado detalló que la nueva dosis, que reemplazará a la bivalente, "va a llegar probablemente a fines de esta semana o a principios de la semana que viene para ser incorporada al programa de vacunación".

Es así como desde la próxima semana los grupos de riesgo -mayores de 60 años, pacientes inmunocomprometidos, profesionales de salud y personas con enfermedades crónicas- podrán inocularse con la vacuna monovalente contra la cepa XBB 1.5, la subvariante de ómicron que es la que más circula actualmente, dosis que el Instituto de Salud Pública en Chile autorizó el pasado 3 de noviembre.

"Chile se va a transformar en el primer país de Latinoamérica en tener a disposición la vacuna más actualizada disponible en el mundo, que es la vacuna monovalente contra la subvariante XBB 1.5. Por lo tanto, esta dosis entrega una mayor protección a las variantes actuales que están circulando a nivel comunitario", afirmó ayer a La Tercera la subsecretaria de Salud Pública, Andrea Albagli.

Consultada respecto al laboratorio de procedencia de la inoculación, la ministra Aguilar informó que próximamente estarán publicando más especificaciones: "Lo vamos a dar en un comunicado, no tiene tanto sentido entrar en ese detalle en este momento".

"Afortunadamente, el incremento de casos que hemos observado no es acompañado, como era en el pasado, de una presión asistencial en las camas críticas, sino que es con una forma mucho más fácil de responder. Eso es producto de la inmunidad que ha alcanzado la población gracias a las vacunas y también a la infección natural. Ciertamente que dentro del trabajo que se hace en relación a los programas de vacunación, las vacunas tienen que ir adaptadas. Y eso es lo que estamos tratando de hacer", complementó.

Además, hizo un llamado a que las personas "recuerden que tienen que vacunarse, que vayan a la plataforma, que miren cuando se vacunaron, y empiecen nuevamente con este trabajo (...). Están los consultorios trabajando en ello, probablemente estos últimos días se estén agotando las vacunas anteriores y puede haber algún problema de acceso, pero justamente se está esperando la llegada de la nueva vacuna, a principios de la semana, que viene con más seguridad".

Fuente: La Tercera. Disponible en https://acortar.link/NxCG8F

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

Artículos científicos publicados en Medline

Filters activated: Publication date from 2023/11/01 to 2023/11/15. “covid-19 vaccine” (Title/Abstract) 418 records.

Malaria.
Poespoprodjo JR, Douglas NM, Ansong D, Kho S, Anstey NM. Lancet. 2023 Nov 1:S0140-6736(23)01249-7. doi: 10.1016/S0140-6736(23)01249-7. Online ahead of print. PMID: 37924827

An Update in COVID-19 Vaccine Reactions in 2023: Progress and Understanding.
Blumenthal KG, Greenhawt M, Phillips EJ, Agmon-Levin N, Golden DBK, Shaker M. J Allergy Clin Immunol Pract. 2023 Nov;11(11):3305-3318. doi: 10.1016/j.jaip.2023.06.057. Epub 2023 Jul 4. PMID: 37414339

COVID-19 and SLE: Infection and autoimmunity at its best.
Mahroum N, Elsalti A, Ozkan MF, Shoenfeld Y. Lupus. 2023 Nov 5:9612033231213914. doi: 10.1177/09612033231213914. Online ahead of print. PMID: 37927085

Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects.
Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D. Nat Rev Clin Oncol. 2023 Nov;20(11):739-754. doi: 10.1038/s41571-023-00811-9. Epub 2023 Aug 16. PMID: 37587254

Vaccine Preventable Disease and Vaccine Hesitancy.
Hotez PJ. Med Clin North Am. 2023 Nov;107(6):979-987. doi: 10.1016/j.mcna.2023.05.012. Epub 2023 Jul 11. PMID: 37806729

Stem cell-based therapy for COVID-19.
Chen X, Liu B, Li C, Wang Y, Geng S, Du X, Weng J, Lai P. Int Immunopharmacol. 2023 Nov;124(Pt A):110890. doi: 10.1016/j.intimp.2023.110890. Epub 2023 Sep 7. PMID: 37688914

COVID-19 Vaccine Accessibility, Perceptions, and Attitudes in the LGBTQ+ Community.
Traister T. West J Nurs Res. 2023 Dec;45(12):1130-1138. doi: 10.1177/01939459231211473. Epub 2023 Nov 1. PMID: 37909671

The influenza and COVID-19 season approaches….
While A. Br J Community Nurs. 2023 Nov 2;28(11):528-529. doi: 10.12968/bjcn.2023.28.11.528. PMID: 37930862

Rituximab for COVID-19 Vaccine-Associated Pemphigus Vulgaris.
Hui HZ, Wang YJ, Cheng JR, Mao H, Guo HX, Diao QC, Shi BJ. Am J Ther. 2023 Nov-Dec 01;30(6):e544-e546. doi: 10.1097/MJT.0000000000001620. Epub 2023 Mar 7. PMID: 36881440

Kikuchi-Fujimoto Disease and COVID-19 vaccination: pharmacovigilance approach.
Rodríguez-Ferreras A, Maray I, Coya-Fernández C, Octavio-Bocigas MM, Fernández-Del Río MF, Casares-López S, Ruiz-Salazar J. Eur Ann Allergy Clin Immunol. 2023 Nov;55(6):278-282. doi: 10.23822/EurAnnACI.1764-1489.273. Epub 2022 Nov 15. PMID: 36458479

Autoimmune hepatitis following mRNA COVID-19 vaccine.
Zaiem A, Ferchichi K, Lakhoua G, Kaabi W, Aouinti I, Rebii Debbiche S, Kastalli S, Kallel L, Charfi O, El Aidli S. Therapie. 2023 Nov-Dec;78(6):760-761. doi: 10.1016/j.therap.2022.12.014. Epub 2023 Aug 29. PMID: 37704459

Discovery and development of COVID-19 vaccine from laboratory to clinic.
Saravanan V, Chagaleti BK, Narayanan PL, Anandan VB, Manoharan H, Anjana GV, Peraman R, Namasivayam SKR, Kavisri M, Arockiaraj J, Muthu Kumaradoss K, Moovendhan M. Chem Biol Drug Des. 2023 Nov 13. doi: 10.1111/cbdd.14383. Online ahead of print. PMID: 37953736

Covid and the coalfield: Covid-19 vaccine hesitance in Wales and Appalachia.
Saville CWN, Mann R, Lockard AS, Bark-Connell A, Gabuljah SG, Young AM, Thomas DR. Soc Sci Med. 2023 Nov;337:116295. doi: 10.1016/j.socscimed.2023.116295. Epub 2023 Oct 13. PMID: 37857241

Culinary spices and herbs in managing early and long-COVID-19 complications: A comprehensive review.
Maurya DK, Sharma D. Phytother Res. 2023 Nov;37(11):4908-4931. doi: 10.1002/ptr.7957. Epub 2023 Jul 19. PMID: 37468320

COVID-19 Vaccine Hesitancy Among Parents: A Qualitative Study.
Honcoop A, Roberts JR, Davis B, Pope C, Dawley E, McCulloh RJ, Garza MY, Greer ML, Snowden J, Fu LY, Young H, Dehority W, Enlow PT, Watts DJ, Queen K, Costello LM, Alamarat Z, Darden PM. Pediatrics. 2023 Nov 1;152(5):e2023062466. doi: 10.1542/peds.2023-062466. PMID: 37867449

SARS-CoV-2 infection (COVID-19) and male fertility: Something we should be worried about?
Zeginiadou T, Symeonidis EN, Symeonidis A, Vakalopoulos I. Urologia. 2023 Nov;90(4):726-734. doi: 10.1177/03915603231175941. Epub 2023 Jun 5. PMID: 37278004

A Webinar to Improve Parental COVID-19 Vaccine Hesitancy.
Arrigoni L, Boogaard C, Strohm-Farber J. J Pediatr Health Care. 2023 Nov-Dec;37(6):590-598. doi: 10.1016/j.pedhc.2023.03.003. Epub 2023 Mar 16. PMID: 37024370

The risk of miscarriage after COVID-19 vaccination before and during pregnancy.
de Feijter M, van Gelder MMHJ, Vissers LCM, Kant AC, Woestenberg PJ. Pharmacoepidemiol Drug Saf. 2023 Nov 9. doi: 10.1002/pds.5724. Online ahead of print. PMID: 37946587

Pediatric glomerulopathy after COVID-19 vaccination: A case series and review of the literature.
Chuang GT, Lin WC, Chang LY, Tsai IJ, Tsau YK. J Formos Med Assoc. 2023 Nov;122(11):1125-1131. doi: 10.1016/j.jfma.2023.04.014. Epub 2023 Apr 26. PMID: 37147241

Susceptibility of SARS-CoV2 infection in children.
Cotugno N, Amodio D, Buonsenso D, Palma P. Eur J Pediatr. 2023 Nov;182(11):4851-4857. doi: 10.1007/s00431-023-05184-w. Epub 2023 Sep 13. PMID: 37702769

The COVID-19 Pandemic and Parental Attitudes Toward Routine Childhood Vaccines.
Higgins DM, Moss A, Blackwell S, O'Leary ST. Pediatrics. 2023 Nov 1;152(5):e2023062927. doi: 10.1542/peds.2023-062927. PMID: 37867454

Bell's Palsy After Vaccination Against Covid-19: A Systematic Review and Meta-analysis.
Gordon AJ, Varelas A, Eytan DF. Otolaryngol Head Neck Surg. 2023 Nov;169(5):1114-1121. doi: 10.1002/ohn.385. Epub 2023 Jun 5. PMID: 37272720

Factors underlying COVID-19 booster vaccine uptake among adults in Belgium.
Vermeiren E, van Loenhout JAF, Nasiadka L, Stouten V, Billuart M, Van Evercooren I, Catteau L, Hubin P. BMC Res Notes. 2023 Nov 11;16(1):328. doi: 10.1186/s13104-023-06608-4. PMID: 37951923

The Global Network COVID-19 studies: a review.
Naqvi S, Saleem S, Billah SM, Moore J, Mwenechanya M, Carlo WA, Esamai F, Bucher S, Derman RJ, Goudar SS, Somannavar M, Patel A, Hibberd PL, Figueroa L, Krebs NF, Petri WA, Lokangaka A, Bauserman M, Koso-Thomas M, McClure EM, Goldenberg RL. BJOG. 2023 Nov;130 Suppl 3:134-139. doi: 10.1111/1471-0528.17610. Epub 2023 Aug 2. PMID: 37530467

Cardiovascular Safety of the COVID-19 Vaccine in Team USA Athletes.
Shah AB, Rizzo SM, Finnoff JT, Baggish AL, Adams WM. Sports Health. 2023 Nov 9:19417381231208677. doi: 10.1177/19417381231208677. Online ahead of print. PMID: 37946492

Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis.
Holm-Yildiz S, Dysgaard T, Krag T, Pedersen BS, Hamm SR, Pérez-Alós L, Hansen CB, Pries-Heje MM, Heftdal LD, Hasselbalch RB, Fogh K, Madsen JR, Frikke-Schmidt R, Hilsted LM, Sørensen E, Ostrowski SR, Bundgaard H, Garred P, Iversen K, Nielsen SD, Vissing J. J Neuroimmunol. 2023 Nov 15;384:578215. doi: 10.1016/j.jneuroim.2023.578215. Epub 2023 Sep 28. PMID: 37797472

Cancer management during the COVID-19 world pandemic.
Sobhani N, Mondani G, Roviello G, Catalano M, Sirico M, D'Angelo A, Scaggiante B, Generali D. Cancer Immunol Immunother. 2023 Nov;72(11):3427-3444. doi: 10.1007/s00262-023-03524-1. Epub 2023 Aug 29. PMID: 37642709

The last word on COVID-19 vaccines and breastfeeding?
Balduit A, Bulla R, Agostinis C. EBioMedicine. 2023 Nov;97:104830. doi: 10.1016/j.ebiom.2023.104830. Epub 2023 Oct 12. PMID: 37837934

Prevalence, predictors and reasons for COVID-19 vaccine hesitancy: Results of a global online survey.
Candio P, Violato M, Clarke PM, Duch R, Roope LS. Health Policy. 2023 Nov;137:104895. doi: 10.1016/j.healthpol.2023.104895. Epub 2023 Aug 19. PMID: 37666080

COVID-19 update: New Novavax vaccine formulation for 2023-2024.
[No authors listed] Med Lett Drugs Ther. 2023 Nov 13;65(1689):182-183. doi: 10.58347/tml.2023.1689b. PMID: 37935019

Cardiac sequelae in athletes following COVID-19 vaccination: evidence and misinformation.
Daems JJN, van Hattum JC, Verwijs SM, Bijsterveld NR, Groenink M, Wilde AAM, Pinto YM, Jorstad HT. Br J Sports Med. 2023 Nov;57(21):1400-1402. doi: 10.1136/bjsports-2023-106847. Epub 2023 Aug 10. PMID: 37562938

Vaccination during pregnancy: A golden opportunity to embrace.
Amaral E, Money D, Jamieson D, Pasupathy D, Aronoff D, Jacobsson B, Lizcano EIO; FIGO Committee on Infections During Pregnancy*. Int J Gynaecol Obstet. 2023 Nov;163(2):476-483. doi: 10.1002/ijgo.14981. Epub 2023 Jul 7. PMID: 37417315

Maternal first trimester COVID-19 vaccination and risk of major non-genetic congenital anomalies.
Woestenberg PJ, de Feijter M, Bergman JEH, Lutke LR, Passier AJLM, Kant AC. Birth Defects Res. 2023 Nov 1;115(18):1746-1757. doi: 10.1002/bdr2.2251. Epub 2023 Sep 22. PMID: 37737482

Cancer Patients' Attitudes Towards the Anti-Covid-19 Vaccine: A Collective Case Study.
Mirandola M, Andreis F, Deori C, Abdel Kader S, Wedenissow AC, Malighetti C, Meriggi F, Zaniboni A. Rev Recent Clin Trials. 2023 Nov 6. doi: 10.2174/0115748871258981231024103349. Online ahead of print. PMID: 37937577

Effectiveness of monovalent and bivalent COVID-19 vaccines.
Cerqueira-Silva T, Boaventura VS, Barral-Netto M. Lancet Infect Dis. 2023 Nov;23(11):1208-1209. doi: 10.1016/S1473-3099(23)00379-1. Epub 2023 Jul 12. PMID: 37453442

Bringing COVID-19 vaccine to medically underserved populations utilizing a community-guided mobile vaccine program.
Ketel C, Clouse K, Jordan H, Uroza S, Kirby J, Adams K, Davis T, Janbakhsh D, Green M, Hopkins P, James B, Rahman N, Thomas A, Plummer C. Public Health Nurs. 2023 Nov-Dec;40(6):925-930. doi: 10.1111/phn.13249. Epub 2023 Aug 25. PMID: 37622842

Tuberculosis in Spain: An opinion paper.
Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, González Del Castillo J, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Santiago B, Caminero JA, Barros C, García de Viedma D, Martín C, Bouza E. Rev Esp Quimioter. 2023 Nov 2:moreno02nov2023. doi: 10.37201/req/115.2023. Online ahead of print. PMID: 37922367

Immune imprinting and next-generation coronavirus vaccines.
Huang CQ, Vishwanath S, Carnell GW, Chan ACY, Heeney JL. Nat Microbiol. 2023 Nov;8(11):1971-1985. doi: 10.1038/s41564-023-01505-9. Epub 2023 Nov 6. PMID: 37932355

A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19.
Kushwaha ND, Mohan J, Kushwaha B, Ghazi T, Nwabuife JC, Koorbanally N, Chuturgoon AA. Eur J Med Chem. 2023 Nov 15;260:115719. doi: 10.1016/j.ejmech.2023.115719. Epub 2023 Aug 10. PMID: 37597435

SARS-CoV-2 vaccination in children and adolescents with and without type 1 diabetes mellitus.
Karavanaki K, Karanasios S, Soldatou A, Tsolia M. Endocrine. 2023 Nov;82(2):226-236. doi: 10.1007/s12020-023-03471-y. Epub 2023 Aug 16. PMID: 37587391

Mucosal antibody responses following Vaxzevria vaccination.
Selva KJ, Ramanathan P, Haycroft ER, Tan CW, Wang LF, Downie LE, Davis SK, Purcell RA, Kent HE, Juno JA, Wheatley AK, Davenport MP, Kent SJ, Chung AW. Immunol Cell Biol. 2023 Nov-Dec;101(10):975-983. doi: 10.1111/imcb.12685. Epub 2023 Sep 5. PMID: 37670482

Preparing the Allergist/Immunologist for the Next Pandemic.
Williams PV, Fasano MB, Fleisher T. J Allergy Clin Immunol Pract. 2023 Nov;11(11):3373-3379. doi: 10.1016/j.jaip.2023.07.037. Epub 2023 Aug 3. PMID: 37541618

Inflammatory and cytotoxic mediators in COVID-19 patients and in ChAdOx1 nCoV-19 (AZD1222) vaccine recipients.
Familiar-Macedo D, Vieira Damasco P, Fiestas Solórzano VE, Carnevale Rodrigues J, Sampaio de Lemos ER, Barreto Dos Santos F, Agudo Mendonça Teixeira de Siqueira M, Leal de Azeredo E, de-Oliveira-Pinto LM. Cytokine. 2023 Nov;171:156350. doi: 10.1016/j.cyto.2023.156350. Epub 2023 Sep 4. PMID: 37672863

Health and Healthcare Access for Essential, Nonessential, and Nonworkers During the COVID-19 Pandemic.
Tilhou AS, Saloner B, DeLeire T, Chakraborty S, Dague L. J Occup Environ Med. 2023 Nov 1;65(11):e703-e709. doi: 10.1097/JOM.0000000000002953. Epub 2023 Aug 26. PMID: 37641177

What Are the Risks of Guillain-Barré Syndrome After SARS-CoV-2 Infection and COVID-19 Vaccination?
Bourdette D, Silbermann E. Neurology. 2023 Nov 14;101(20):875-876. doi: 10.1212/WNL.0000000000207998. Epub 2023 Oct 18. PMID: 37852787

Message Fatigue and COVID-19 Vaccine Booster Uptake in the United States.
Zhao X, Kadono M, Kranzler EC, Pavisic I, Miles S, Maher M, Strausser L, Cai X, Hoffman L. J Health Commun. 2023 Nov 14:1-11. doi: 10.1080/10810730.2023.2282036. Online ahead of print. PMID: 37962284

The immunology of PF4 polyanion interactions.
Ngo ATP, Bochenek V, Gollomp K. Curr Opin Hematol. 2023 Nov 1;30(6):219-229. doi: 10.1097/MOH.0000000000000782. Epub 2023 Aug 28. PMID: 37603711

Influenza and Up-to-Date COVID-19 Vaccination Coverage Among Health Care Personnel - National Healthcare Safety Network, United States, 2022-23 Influenza Season.
Bell J, Meng L, Barbre K, Haanschoten E, Reses HE, Soe M, Edwards J, Massey J, Tugu Yagama Reddy GR, Woods A, Stuckey MJ, Kuhar DT, Bolden K, Dubendris H, Wong E, Rowe T, Lindley MC, Kalayil EJ, Benin A. MMWR Morb Mortal Wkly Rep. 2023 Nov 10;72(45):1237-1243. doi: 10.15585/mmwr.mm7245a5. PMID: 37943704

Impact of COVID-19 on Patients With Psoriasis or Psoriatic Arthritis.
Mease PJ, Nash P, Grieb S, Chandran V. J Rheumatol. 2023 Nov;50(Suppl 2):27-30. doi: 10.3899/jrheum.2023-0521. Epub 2023 Aug 1. PMID: 37527863

Pediatric COVID-19 Vaccination in the Inpatient Setting.
Rush M, Hyman C, Yonts A, Szeles R, Boogaard C. Hosp Pediatr. 2023 Nov 1;13(11):e329-e332. doi: 10.1542/hpeds.2022-006804. PMID: 37807862

"Direct and indirect impacts of the COVID-19 pandemic on operational conduct of pediatric vaccine clinical trials".
McArthur MA, Bchir S, Dubois E, Gan L, Gerchman E, Gupta S, Liabis O, Perez L, Roche F, Vasquez G, Zambrano B, Gurunathan S, Dhingra MS. Hum Vaccin Immunother. 2023 Dec 15;19(3):2272535. doi: 10.1080/21645515.2023.2272535. Epub 2023 Nov 9. PMID: 37942563

The impact of national income and vaccine hesitancy on country-level COVID-19 vaccine uptake.
Moradpour J, Shajarizadeh A, Carter J, Chit A, Grootendorst P. PLoS One. 2023 Nov 2;18(11):e0293184. doi: 10.1371/journal.pone.0293184. eCollection 2023. PMID: 37917650

COVID-19 vaccine hesitancy among pregnant women attending public antenatal clinics in Dar es Salaam, Tanzania.
Yussuph ZH, Alwy Al-Beity FM, August F, Anaeli A. Hum Vaccin Immunother. 2023 Dec 15;19(3):2269777. doi: 10.1080/21645515.2023.2269777. Epub 2023 Nov 9. PMID: 37942618

Association Between Guillain-Barré Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study.
Bishara H, Arbel A, Barnett-Griness O, Bloch S, Cohen S, Najjar-Debbiny R, Gronich N, Auriel E, Saliba W. Neurology. 2023 Nov 14;101(20):e2035-e2042. doi: 10.1212/WNL.0000000000207900. Epub 2023 Oct 18. PMID: 37852786

COVID-19 Vaccine Seroresponse Based on The Timing of The Primary Series; Pre- versus Post-Renal Transplantation.
Weinberg AR, Caeg CO, DePalma R, Hernandez F, Rogers JH, Ibrahim HN, Bynon SJ, Nigo M. Clin Transplant. 2023 Nov;37(11):e15072. doi: 10.1111/ctr.15072. Epub 2023 Jul 11. PMID: 37434417

Side effects of COVID-19 vaccination and breast cancer.
Kleebayoon A, Wiwanitkit V. Clin Exp Med. 2023 Nov;23(7):4035-4036. doi: 10.1007/s10238-023-01086-1. Epub 2023 May 15. PMID: 37184601

Optimizing the COVID-19 cold chain vaccine distribution network with medical waste management: A robust optimization approach.
Ensar Işık E, Topaloglu Yildiz S. Expert Syst Appl. 2023 Nov 1;229:120510. doi: 10.1016/j.eswa.2023.120510. Epub 2023 May 19. PMID: 37251535

Pitfalls and biases in neuroepidemiological studies of COVID-19 and the nervous system: a critical appraisal of the current evidence and future directions.
Beghi E, Ivashynka A, Logroscino G, de Oliveira FF, Fleisher JE, Dumitrascu OM, Patel R, Savica R, Kim YJ. J Neurol. 2023 Nov;270(11):5162-5170. doi: 10.1007/s00415-023-11981-y. Epub 2023 Sep 8. PMID: 37682315

Pregnancy and *SARS-CoV-2* infection with a focus on its vertical transmission, breastfeeding, cord blood banking, and vaccination during COVID-19 infection.

Ketabi K, Soleimanjahi H, Habibian A, Abroun S. J Immunoassay Immunochem. 2023 Nov 2;44(5-6):361-380. doi: 10.1080/15321819.2023.2259454. Epub 2023 Oct 31. PMID: 37794764

COVID-19 vaccine and incidence of Stevens-Johnson syndrome & toxic epidermal necrolysis.
Taramian S, Joukar F. Burns. 2023 Nov;49(7):1778-1779. doi: 10.1016/j.burns.2023.08.004. Epub 2023 Aug 11. PMID: 37833148

Factors associated with COVID-19 vaccine hesitancy among healthcare workers in Cameroon and Nigeria: a web-based cross-sectional study.
Aseneh JB, Agbor VN, Kadia BM, Okolie EA, Ofomata CJ, Etombi CL, Ekaney DSM, Joko Fru YW. Int Health. 2023 Nov 3;15(6):702-714. doi: 10.1093/inthealth/ihad013. PMID: 36905293

Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2-18 years: an updated systematic review and meta-analysis.
Gao P, Kang LY, Liu J, Liu M. World J Pediatr. 2023 Nov;19(11):1041-1054. doi: 10.1007/s12519-022-00680-9. Epub 2023 Feb 1. PMID: 36723827

Vaccine Mandates and Influenza Vaccination During the Pandemic.
Abraham C, Garabedian LF, LeCates RF, Galbraith AA. Pediatrics. 2023 Nov 1;152(5):e2023061545. doi: 10.1542/peds.2023-061545. PMID: 37814817

How prevalent is COVID-19 vaccine hesitancy in low-income and middle-income countries and what are the key drivers of hesitancy? Results from 53 countries.
Dayton Eberwein J, Edochie IN, Newhouse D, Cojocaru A, Bopahbe GD, Kakietek JJ, Kim YS, Montes J. BMJ Open. 2023 Nov 6;13(11):e069152. doi: 10.1136/bmjopen-2022-069152. PMID: 37931970

Capitalizing on Opportunities: Evaluating an Inpatient COVID-19 Vaccination Program.
Ramazani SN, Fallon A, Sosa T. Hosp Pediatr. 2023 Nov 1;13(11):e348-e350. doi: 10.1542/hpeds.2023-007450. PMID: 37807880

Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients.
Kared H, Alirezaylavasani A, Lund KP, Chopra A, Tietze L, de Matos Kasahara T, Goll GL, Grødeland G, Kaarbø M, Reisæter AV, Hovd M, Heldal K, Vaage JT, Lund-Johansen F, Midtvedt K, Åsberg A, Munthe LA. EBioMedicine. 2023 Nov;97:104833. doi: 10.1016/j.ebiom.2023.104833. Epub 2023 Oct 14. PMID: 37844534

RNA-based medicine: from molecular mechanisms to therapy.
Sparmann A, Vogel J. EMBO J. 2023 Nov 2;42(21):e114760. doi: 10.15252/embj.2023114760. Epub 2023 Sep 20. PMID: 37728251

A quantitative clinical pharmacology-based framework for model-informed vaccine development.
Desikan R, Germani M, van der Graaf PH, Magee M. J Pharm Sci. 2023 Nov 2:S0022-3549(23)00468-9. doi: 10.1016/j.xphs.2023.10.043. Online ahead of print. PMID: 37924975

Association between social isolation and loneliness with COVID-19 vaccine uptake in Japan: a nationwide cross-sectional internet survey.

Ukai T, Tabuchi T. BMJ Open. 2023 Nov 1;13(11):e073008. doi: 10.1136/bmjopen-2023-073008. PMID: 37914296

Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant.
Mehta G, Riva A, Ballester MP, Uson E, Pujadas M, Carvalho-Gomes Â, Sahuco I, Bono A, D'Amico F, Viganò R, Diago E, Lanseros BT, Inglese E, Vazquez DM, Sharma R, Tsou HLP, Harris N, Broekhoven A, Kikkert M, Morales SPT, Myeni SK, Riveiro-Barciela M, Palom A, Zeni N, Brocca A, Cussigh A, Cmet S, Escudero-García D, Stocco M, Natola LA, Ieluzzi D, Paon V, Sangiovanni A, Farina E, di Benedetto C, Sánchez-Torrijos Y, Lucena-Varela A, Román E, Sánchez E, Sánchez-Aldehuelo R, López-Cardona J, Canas-Perez I, Eastgate C, Jeyanesan D, Morocho AE, Di Cola S, Lapenna L, Zaccherini G, Bongiovanni D, Zanaga P, Sayaf K, Hossain S, Crespo J, Robles-Díaz M, Madejón A, Degroote H, Fernández J, Korenjak M, Verhelst X, García-Samaniego J, Andrade RJ, Iruzubieta P, Wright G, Caraceni P, Merli M, Patel VC, Gander A, Albillos A, Soriano G, Donato MF, Sacerdoti D, Toniutto P, Buti M, Duvoux C, Grossi PA, Berg T, Polak WG, Puoti M, Bosch-Comas A, Belli L, Burra P, Russo FP, Coenraad M, Calleja JL, Perricone G, Berenguer M, Claria J, Moreau R, Arroyo V, Angeli P, Sánchez C, Ampuero J, Piano S, Chokshi S, Jalan R; COBALT Consortium. Hepatol Commun. 2023 Oct 18;7(11):e0273. doi: 10.1097/HC9.0000000000000273. eCollection 2023 Nov 1. PMID: 37870985

Reactive arthritis after COVID-19 vaccination: 17 cases.
Golstein MA, Fagnart O, Steinfeld SD. Rheumatology (Oxford). 2023 Nov 2;62(11):3706-3709. doi: 10.1093/rheumatology/kead169. PMID: 37084272

Myopericarditis following COVID-19 vaccination in adolescent triplets.
Wong JW, Bock E, Kee WS, Anderson AJ, Kothari D, Tarca AJ. Cardiol Young. 2023 Nov;33(11):2379-2383. doi: 10.1017/S1047951123001105. Epub 2023 May 8. PMID: 37154289

Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared.
Parums DV. Med Sci Monit. 2023 Nov 1;29:e942960. doi: 10.12659/MSM.942960. PMID: 37908161

Predictors of COVID-19 vaccine uptake among persons aged 18 years and above in Ga North Municipality, Ghana using the Health Belief Model: A community-based cross-sectional study.
Nasiratu I, Pencille LB, Khuzwayo N, Aboagye RG, Tarkang EE. PLoS One. 2023 Nov 7;18(11):e0293350. doi: 10.1371/journal.pone.0293350. eCollection 2023. PMID: 37934776

RNA vaccines in infectious diseases: A systematic review.
Beirigo EF, Franco PIR, do Carmo Neto JR, Guerra RO, de Assunção TFS, de Sousa IOF, Obata MMS, Rodrigues WF, Machado JR, da Silva MV. Microb Pathog. 2023 Nov;184:106372. doi: 10.1016/j.micpath.2023.106372. Epub 2023 Sep 23. PMID: 37743026

Deep Learning Analysis of COVID-19 Vaccine Hesitancy and Confidence Expressed on Twitter in 6 High-Income Countries: Longitudinal Observational Study.
Zhou X, Song S, Zhang Y, Hou Z. J Med Internet Res. 2023 Nov 6;25:e49753. doi: 10.2196/49753. PMID: 37930788

Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine.
McGrath LJ, Malhotra D, Miles AC, Welch VL, Di Fusco M, Surinach A, Barthel A, Alfred T, Jodar L, McLaughlin JM. JAMA Netw Open. 2023 Nov 1;6(11):e2342151. doi: 10.1001/jamanetworkopen.2023.42151. PMID: 37938846

Does COVID-19 or COVID-19 vaccination worsen migraines?
[No authors listed] Saudi Med J. 2023 Nov;44(11):1214. PMID: 37926457

Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study.
Liu B, Stepien S, Dobbins T, Gidding H, Henry D, Korda R, Mills L, Pearson SA, Pratt N, Vajdic CM, Welsh J, Macartney K. Lancet Reg Health West Pac. 2023 Oct 7;40:100928. doi: 10.1016/j.lanwpc.2023.100928. eCollection 2023 Nov. PMID: 37854458

COVID-19 vaccination of patients with chronic immune-mediated inflammatory disease.
Yanfang W, Jianfeng C, Changlian L, Yan W. Adv Rheumatol. 2023 Nov 1;63(1):54. doi: 10.1186/s42358-023-00335-x. PMID: 37915078

A Review of the Data Supporting Use of COVID-19 Vaccinations in the Pediatric Population.
Stultz JS, Eiland LS. Ann Pharmacother. 2023 Nov;57(11):1328-1340. doi: 10.1177/10600280231156625. Epub 2023 Feb 27. PMID: 36847285

Electroencephalographic findings post-COVID-19 vaccination: A systematic review of case reports and case series.
Fazlollahi A, Zahmatyar M, Shamekh A, Motamedi A, Seyedi F, Seyedmirzaei H, Mousavi SE, Nejadghaderi SA, Sullman MJM, Kolahi AA, Arshi S, Safiri S. Rev Med Virol. 2023 Nov;33(6):e2484. doi: 10.1002/rmv.2484. Epub 2023 Oct 9. PMID: 37807809

The Brazilian vaccine divide: How some municipalities were left behind in the Covid-19 vaccine coverage.
Boing AF, Boing AC, Barberia L, Borges ME, Subramanian SV. PLOS Glob Public Health. 2023 Nov 10;3(11):e0002493. doi: 10.1371/journal.pgph.0002493. eCollection 2023. PMID: 37948353

Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events.
Montes-Grajales D, Garcia-Serna R, Mestres J. Sci Rep. 2023 Nov 1;13(1):18817. doi: 10.1038/s41598-023-46275-w. PMID: 37914862

Risks of COVID-19-related hospitalisation and mortality among individuals with mental disorders following BNT162b2 and CoronaVac vaccinations: A case-control study.
Yiu HHE, Yan VKC, Wei Y, Ye X, Huang C, Castle DJ, Chui CSL, Lai FTT, Li X, Wong CKH, Wan EYF, Wong ICK, Chan EW. Psychiatry Res. 2023 Nov;329:115515. doi: 10.1016/j.psychres.2023.115515. Epub 2023 Oct 4. PMID: 37820573

Trends in occurrence of takotsubo syndrome and association with SARS-CoV-2 infection and COVID-19 vaccination.

Rosh B, Naoum I, Stein N, Jaffe R, Saliba W. J Cardiovasc Med (Hagerstown). 2023 Nov 1;24(11):815-821. doi: 10.2459/JCM.0000000000001541. Epub 2023 Aug 7. PMID: 37577873

A single-center review of outcomes between COVID-19 vaccinated and unvaccinated liver transplant recipients.
Nolan A, McGowan M, Von Stein L, Ross A, Kaur M, Pesavento T, Singh P. Clin Transplant. 2023 Nov 8:e15185. doi: 10.1111/ctr.15185. Online ahead of print. PMID: 37937389

The importance of COVID-19 vaccination during lactation.
Isabel Valverde-Merino M, Gomez-Guzman M, Piquer-Martinez C, Dolores Cabezas Lopez M, Jose Zarzuelo M. Infect Dis Now. 2023 Nov 10:104831. doi: 10.1016/j.idnow.2023.104831. Online ahead of print. PMID: 37952583

Safety profile of paediatric COVID-19 vaccines: An analysis of the US Vaccine Adverse Event Reporting System.
Nikitina V, Santi Laurini G, Montanaro N, Motola D. Acta Paediatr. 2023 Nov;112(11):2426-2433. doi: 10.1111/apa.16954. Epub 2023 Aug 22. PMID: 37608686

Multisystem Inflammatory Syndrome (MIS) following SARS-CoV-2 vaccinations; a systematic review.
Elsaid M, Nune A, Hesham D, Fouad FM, Hassan H, Hamouda H, Sherif H, Abdelwahab MM, Hegazi N, El-Rahman YA. Trop Dis Travel Med Vaccines. 2023 Nov 5;9(1):19. doi: 10.1186/s40794-023-00204-x. PMID: 37925466

Chronicling the 3-year evolution of the COVID-19 pandemic: analysis of disease management, characteristics of major variants, and impacts on pathogenicity.
Pitsillou E, Yu Y, Beh RC, Liang JJ, Hung A, Karagiannis TC. Clin Exp Med. 2023 Nov;23(7):3277-3298. doi: 10.1007/s10238-023-01168-0. Epub 2023 Aug 24. PMID: 37615803

Sociodemographic disparities affect COVID-19 vaccine uptake in non-elderly adults with increased risk of severe COVID-19.
Hedberg P, Sotoodeh A, Askling HH, Nauclér P. J Intern Med. 2023 Nov;294(5):640-652. doi: 10.1111/joim.13700. Epub 2023 Jul 16. PMID: 37424218

Changes in anxiety and depression among public health workers during the COVID-19 pandemic response.
Stone KW, Jagger MA, Horney JA, Kintziger KW. Int Arch Occup Environ Health. 2023 Nov;96(9):1235-1244. doi: 10.1007/s00420-023-02002-6. Epub 2023 Jul 20. PMID: 37474659

Preventing infections in immunocompromised patients with kidney diseases: vaccines and antimicrobial prophylaxis.
Windpessl M, Kostopoulou M, Conway R, Berke I, Bruchfeld A, Soler MJ, Sester M, Kronbichler A. Nephrol Dial Transplant. 2023 Nov 8;38(Supplement_2):ii40-ii49. doi: 10.1093/ndt/gfad080. PMID: 37218705

Interventions to increase vaccination against COVID-19, influenza and pertussis during pregnancy: a systematic review and meta-analysis.

Razai MS, Mansour R, Goldsmith L, Freeman S, Mason-Apps C, Ravindran K, Kooner P, Berendes S, Morris J, Majeed A, Ussher M, Hargreaves S, Oakeshott P. J Travel Med. 2023 Nov 2:taad138. doi: 10.1093/jtm/taad138. Online ahead of print. PMID: 37934788

Need for open data on COVID-19 vaccine uptake among pregnant people in the Caribbean: a call to action.
Pinkney JA, Carroll KN, Rich KM, Hurtado RM, Ciaranello AL, Bogart LM, Ojikutu BO, Hyle EP. Rev Panam Salud Publica. 2023 Nov 6;47:e155. doi: 10.26633/RPSP.2023.155. eCollection 2023. PMID: 37937312

Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.
Li X, Song Y. Eur J Med Chem. 2023 Nov 15;260:115772. doi: 10.1016/j.ejmech.2023.115772. Epub 2023 Aug 28. PMID: 37659195

Acute Necrotizing Myelitis Associated with COVID-19.
Yoo JE, Shin HJ, Kang HC, Lee JS, Kim HD, Lee HN. Yonsei Med J. 2023 Nov;64(11):692-695. doi: 10.3349/ymj.2023.0202. PMID: 37880851

Neuro-ophthalmic complications of varicella-zoster virus.
Tofade TO, Chwalisz BK. Curr Opin Ophthalmol. 2023 Nov 1;34(6):470-475. doi: 10.1097/ICU.0000000000000996. Epub 2023 Aug 21. PMID: 37603549

Ocular posterior segment complications following COVID-19 vaccination.
Sadeghi E, Mahmoudzadeh R, Garg SJ, Nowroozzadeh MH. Int Ophthalmol. 2023 Nov;43(11):4343-4357. doi: 10.1007/s10792-023-02795-y. Epub 2023 Jul 11. PMID: 37432598

Hybrid health regimes: Access to primary care physicians and COVID-19 vaccine uptake across municipalities in Romania.
Petrovici N, Belbe SȘ, Mare CC, Cotoi CC. Soc Sci Med. 2023 Nov;337:116305. doi: 10.1016/j.socscimed.2023.116305. Epub 2023 Oct 13. PMID: 37857237

Increasing COVID-19 Immunization Awareness in Rural Communities Through a Multimedia Campaign.
Skuras A, Iseler J. Clin Nurse Spec. 2023 Nov-Dec 01;37(6):291-298. doi: 10.1097/NUR.0000000000000781. PMID: 37870515

The US Federal Retail Pharmacy Program: Optimizing COVID-19 Vaccine Delivery Through a Strategic Public-Private Partnership.
Kim C, Guo A, Yassanye D, Link-Gelles R, Yates K, Duggar C, Moore L, El Kalach R, Jones-Jack N, Walker C, Gibbs Scharf L, Pillai SK, Patel A. Public Health Rep. 2023 Nov-Dec;138(6):870-877. doi: 10.1177/00333549231186606. Epub 2023 Jul 28. PMID: 37503697

COVID-19 Vaccine Hesitancy Among US Adults: Safety and Effectiveness Perceptions and Messaging to Increase Vaccine Confidence and Intent to Vaccinate.
Weinstein N, Schwarz K, Chan I, Kobau R, Alexander R, Kollar L, Rodriguez L, Mansergh G, Repetski T, Gandhi P, Pechta L. Public Health Rep. 2023 Nov 4:333549231204419. doi: 10.1177/00333549231204419. Online ahead of print. PMID: 37924246

COVID-19 vaccine immune response and plasma cell dyscrasia.
Kleebayoon A, Wiwanitkit V. Ther Adv Vaccines Immunother. 2023 Nov 9;11:25151355231209733. doi: 10.1177/25151355231209733. eCollection 2023. PMID: 37954638

XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
Patel N, Trost JF, Guebre-Xabier M, Zhou H, Norton J, Jiang D, Cai Z, Zhu M, Marchese AM, Greene AM, Mallory RM, Kalkeri R, Dubovsky F, Smith G. Sci Rep. 2023 Nov 6;13(1):19176. doi: 10.1038/s41598-023-46025-y. PMID: 37932354

Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics.
Gubernot D, Menis M, Whitaker B. Vaccine. 2023 Nov 13;41(47):6922-6929. doi: 10.1016/j.vaccine.2023.10.025. Epub 2023 Oct 25. PMID: 37891051

Adoption and Discontinuance of Innovation Packages: A Longitudinal Study of Transitions in COVID-19 Mitigation.
Smith RA, Gall Myrick J, Martin MA, Lennon RP, Van Scoy LJ, Small ML. Health Commun. 2023 Nov 7:1-12. doi: 10.1080/10410236.2023.2275911. Online ahead of print. PMID: 37936518

New-onset chronic spontaneous urticaria post-COVID-19 vaccination-South African case series.
Craffert V, Day C, Peter J. J Allergy Clin Immunol Glob. 2023 Jul 24;2(4):100154. doi: 10.1016/j.jacig.2023.100154. eCollection 2023 Nov. PMID: 37781658

Can psychological distress account for the associations between COVID-19 vaccination acceptance and socio-economic vulnerability?
Yuan J, Dong M, Wong IOL, Cowing BJ, Lam WWT, Ni MY, Liao Q. Appl Psychol Health Well Being. 2023 Nov;15(4):1583-1602. doi: 10.1111/aphw.12452. Epub 2023 May 4. PMID: 37142547

Effectiveness of COVID-19 vaccination during pregnancy by circulating viral variant.
Zerbo O, Ray GT, Fireman B, Layefsky E, Goddard K, Ross P, Greenberg M, Klein NP. AJOG Glob Rep. 2023 Aug 25;3(4):100264. doi: 10.1016/j.xagr.2023.100264. eCollection 2023 Nov. PMID: 37719643

COVID-19 presenting as a non-arteritic anterior ischemic optic neuropathy.
Romozzi M, Amorelli G, Savastano MC, Fedele AL, Amorelli F, Rizzo S, Lucchini M, Mirabella M, Nociti V. Eur J Ophthalmol. 2023 Nov;33(6):NP133-NP136. doi: 10.1177/11206721221149762. Epub 2023 Jan 9. PMID: 36624618

Anti-SARS-CoV-2 (COVID-19) vaccination efficacy in patients with severe neuromuscular diseases.
Damour A, Delalande P, Cordelières F, Lafon ME, Faure M, Segovia-Kueny S, Stalens C, Mathis S, Spinazzi M, Violleau MH, Wodrich H, Solé G. Rev Neurol (Paris). 2023 Nov;179(9):983-992. doi: 10.1016/j.neurol.2023.04.003. Epub 2023 Aug 24. PMID: 37633734

Effective Vaccination and Education Strategies for Emerging Infectious Diseases Such as COVID-19.
Wie SH, Jung J, Kim WJ. J Korean Med Sci. 2023 Nov 13;38(44):e371. doi: 10.3346/jkms.2023.38.e371. PMID: 37967881

The more symptoms the better? Covid-19 vaccine side effects and long-term neutralizing antibody response.
Dutcher EG, Epel ES, Mason AE, Hecht FM, Robinson JE, Drury SS, Prather AA. medRxiv. 2023 Nov 3:2023.09.26.23296186. doi: 10.1101/2023.09.26.23296186. Preprint. PMID: 37808819

Impact of sex and age on vaccine-related side effects and their progression after booster mRNA COVID-19 vaccine.
Mori M, Yokoyama A, Shichida A, Sasuga K, Maekawa T, Moriyama T. Sci Rep. 2023 Nov 7;13(1):19328. doi: 10.1038/s41598-023-46823-4. PMID: 37935801

Diagnostic stewardship and the coronavirus disease 2019 (COVID-19) pandemic: Lessons learned for prevention of emerging infectious diseases in acute-care settings.
Epstein L, Diekema DJ, Morgan DJ, Fakih MG, Lee F, Gottlieb L, Leung E, Yen C, Sullivan KV, Hayden MK. Infect Control Hosp Epidemiol. 2023 Nov 7:1-7. doi: 10.1017/ice.2023.195. Online ahead of print. PMID: 37933951

Risk of Coronavirus Disease 2019 (COVID-19) among those up-to-date and not up-to-date on COVID-19 vaccination by US CDC criteria.
Shrestha NK, Burke PC, Nowacki AS, Gordon SM. PLoS One. 2023 Nov 8;18(11):e0293449. doi: 10.1371/journal.pone.0293449. eCollection 2023. PMID: 37939032

Measuring Motivation for COVID-19 Vaccination: An Application of the Transtheoretical Model.
Sacco A, Robbins ML, Paiva AL, Monahan K, Lindsey H, Reyes C, Rusnock A. Am J Health Promot. 2023 Nov;37(8):1109-1120. doi: 10.1177/08901171231197899. Epub 2023 Aug 23. PMID: 37612233

Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.
Lin DY, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, Moore Z, Sunny SK. Lancet Infect Dis. 2023 Nov;23(11):1257-1265. doi: 10.1016/S1473-3099(23)00272-4. Epub 2023 Jun 16. PMID: 37336222

Healthcare provider perspectives on COVID-19 vaccination for children in India.
Mehta K, Kaur A, Banerjee P, Gupta P, Thacker N, Saxena V, Shet A. BMJ Paediatr Open. 2023 Nov;7(1):e002165. doi: 10.1136/bmjpo-2023-002165. PMID: 37940342

COVID-19 vaccination improved outcomes in the treatment of geriatric hip fractures between December 2020 and January 2022.
Konda SR, Meltzer Bruhn AT, Esper GW, Solasz SJ, Ganta A, Egol KA. Hip Int. 2023 Nov;33(6):1133-1139. doi: 10.1177/11207000231151617. Epub 2023 Jan 26. PMID: 36703257

Citrobacter freundii-associated osteomyelitis and thromboembolic events following Moderna COVID-19 vaccination: a rare case report from Nepal.
Adhikari S, Kc S, Dev S, Bhandari S, Parajuli P, Poudel MB, Adhikari YR, Poudel B. Ann Med Surg (Lond). 2023 Oct 2;85(11):5789-5794. doi: 10.1097/MS9.0000000000001351. eCollection 2023 Nov. PMID: 37915646

A natural language processing approach for analyzing COVID-19 vaccination response in multi-language and geo-localized tweets.

Canaparo M, Ronchieri E, Scarso L. Healthc Anal (N Y). 2023 Nov;3:100172. doi: 10.1016/j.health.2023.100172. Epub 2023 Apr 11. PMID: 37064254

Summer 2023 ACIP Update: RSV Prevention and Updated Recommendations on Other Vaccines.
O'Leary ST, Yonts AB, Gaviria-Agudelo C, Kimberlin DW, Paulsen GC. Pediatrics. 2023 Nov 1;152(5):e2023063955. doi: 10.1542/peds.2023-063955. PMID: 37641189

The fourth COVID-19 vaccine dose increased the neutralizing antibody response against the SARS-CoV-2 Omicron (B.1.1.529) variant in a diverse Brazilian population.
Pires Farias J, Andreata-Santos R, Dalety da Silva Brito R, Silva Souza M, Moreira Costa Fogaça M, Ramos Pinheiro J, Ferreira da Cruz E, Liang W, Simões RdC, Barros Luiz W, Birbrair A, Oliveira Vidal P, Terzi Maricato J, Torres Braconi C, Ferreira LCdS, Ramos Janini LM, Amorim JH. Microbiol Spectr. 2023 Nov 1:e0285723. doi: 10.1128/spectrum.02857-23. Online ahead of print. PMID: 37909777

New bovine coronavirus vaccine.
[No authors listed] Vet Rec. 2023 Nov 4;193(9):351. doi: 10.1002/vetr.3630. PMID: 37921304

Rise of the RNA machines - self-amplification in mRNA vaccine design.
Comes JDG, Pijlman GP, Hick TAH. Trends Biotechnol. 2023 Nov;41(11):1417-1429. doi: 10.1016/j.tibtech.2023.05.007. Epub 2023 Jun 14. PMID: 37328401

Side effects of COVID-19 vaccinations in patients treated for breast cancer.
Juhel BC, Brunelle CL, Bernstein MC, Smith LH, Jung AW, Ababneh HS, Hausman EK, Bucci LK, Bernstein T, Naoum GE, Taghian AG. Clin Exp Med. 2023 Nov;23(7):3671-3680. doi: 10.1007/s10238-023-01050-z. Epub 2023 Apr 8. PMID: 37031282

Revolutionizing drug formulation development: The increasing impact of machine learning.
Bao Z, Bufton J, Hickman RJ, Aspuru-Guzik A, Bannigan P, Allen C. Adv Drug Deliv Rev. 2023 Nov;202:115108. doi: 10.1016/j.addr.2023.115108. Epub 2023 Sep 27. PMID: 37774977

Adverse events after first and second doses of COVID-19 vaccination in England: a national vaccine surveillance platform self-controlled case series study.
Tsang RS, Agrawal U, Joy M, Byford R, Robertson C, Anand SN, Hinton W, Mayor N, Kar D, Williams J, Victor W, Akbari A, Bradley DT, Murphy S, O'Reilly D, Owen RK, Chuter A, Beggs J, Howsam G, Sheikh A, Richard Hobbs FD, Lusignan S. J R Soc Med. 2023 Nov 3:1410768231205430. doi: 10.1177/01410768231205430. Online ahead of print. PMID: 37921538

Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France.
de Germay S, Singier A, Salvo F, Pariente A; French Pharmacovigilance Network. Drug Saf. 2023 Nov 5. doi: 10.1007/s40264-023-01359-4. Online ahead of print. PMID: 37926785

Devaluing Incarcerated Populations: Deprioritizing Incarcerated Populations for COVID-19 Vaccination.
Merss K, Bowers BJ. West J Nurs Res. 2023 Nov;45(11):986-992. doi: 10.1177/01939459231199312. Epub 2023 Sep 13. PMID: 37702205

Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study.

Mar J, Ibarrondo O, Estadilla CDS, Stollenwerk N, Antoñanzas F, Blasco-Aguado R, Larrañaga I, Bidaurrazaga J, Aguiar M. Pharmacoeconomics. 2023 Nov 1. doi: 10.1007/s40273-023-01326-y. Online ahead of print. PMID: 37910377

Association Between COVID-19 Vaccination and Quality of Life Among University Students.
ElBarazi A. Asia Pac J Public Health. 2023 Nov;35(8):576-579. doi: 10.1177/10105395231199348. Epub 2023 Sep 12. PMID: 37700576

Nosocomial SARS-CoV-2 Infections and Mortality During Unique COVID-19 Epidemic Waves.
Dave N, Sjöholm D, Hedberg P, Ternhag A, Granath F, Verberk JDM, Johansson AF, van der Werff SD, Nauclér P. JAMA Netw Open. 2023 Nov 1;6(11):e2341936. doi: 10.1001/jamanetworkopen.2023.41936. PMID: 37948082

The invisible frontline of the COVID-19 pandemic: Examining sourcing and the underrepresentation of female expertise in pandemic news coverage.
Hubner AY. Public Underst Sci. 2023 Nov;32(8):1021-1032. doi: 10.1177/09636625231193123. Epub 2023 Aug 26. PMID: 37632421

Is Covid-19 "vaccine uptake" in postsecondary education a "problem"? A critical policy inquiry.
Chaufan C. Health (London). 2023 Nov 15:13634593231204169. doi: 10.1177/13634593231204169. Online ahead of print. PMID: 37968946

A Case of Glomerular Microangiopathy-like Nephropathy Caused by Hyperthyroidism.
Katayama Y, Sawa N, Kurihara S, Ikuma D, Oba Y, Sekine A, Yamanouchi M, Hasegawa E, Suwabe T, Wada T, Kono K, Kinowaki K, Ohashi K, Tsuchiya Y, Ubara Y. Intern Med. 2023 Nov 6. doi: 10.2169/internalmedicine.2436-23. Online ahead of print. PMID: 37926548

Antibody response to ChAdOx1 nCoV-19 (Covishield®) vaccine in people on maintenance hemodialysis.
Bhadauria DS, Tiwari P, Goel A, Katiyar H, Kaul A, Mayank, Aggarwal A, Verma A, Khetan D, Yachha M, Behera MR, Yadav B, Agarwal K, Prasad N. Semin Dial. 2023 Nov-Dec;36(6):477-482. doi: 10.1111/sdi.13149. Epub 2023 Feb 26. PMID: 36843062

Comment on self-reported symptoms after COVID-19 vaccination.
Kleebayoon A, Wiwanitkit V. Intern Emerg Med. 2023 Nov;18(8):2457-2458. doi: 10.1007/s11739-023-03421-6. Epub 2023 Sep 15. PMID: 37715065

Efficacy of the COVID-19 vaccine in pediatric systemic lupus erythematosus patients.
Shi Y, Sule S, Park C, Ahn SY. Lupus. 2023 Nov 6:9612033231208336. doi: 10.1177/09612033231208336. Online ahead of print. PMID: 37931076

Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.
Xu JW, Wang BS, Gao P, Huang HT, Wang FY, Qiu W, Zhang YY, Xu Y, Gou JB, Yu LL, Liu X, Wang RJ, Zhu T, Hou LH, Qing-Wang A. Emerg Microbes Infect. 2023 Nov 6:2281355. doi: 10.1080/22221751.2023.2281355. Online ahead of print. PMID: 37933089

Organizations affect their employees' vaccine readiness: A self-perception theory perspective.
Roswag M, Häusser JA, Abdel Hadi S, Hubert P, Mojzisch A. Appl Psychol Health Well Being. 2023 Nov;15(4):1603-1618. doi: 10.1111/aphw.12457. Epub 2023 May 17. PMID: 37194474

SARS-CoV-2 Hybrid Immunity: The Best of Both Worlds.
Lasrado N, Barouch DH. J Infect Dis. 2023 Nov 11;228(10):1311-1313. doi: 10.1093/infdis/jiad353. PMID: 37592872

Optimizing Education to Improve COVID-19 Vaccination Rates in a Federally Qualified Health Center.
Perkins JR, Jaqua EE, Nguyen VT, Franz DA, Elkins J, Morton KR. Perm J. 2023 Nov 1:1-8. doi: 10.7812/TPP/23.088. Online ahead of print. PMID: 37908131

Lessons learned from COVID-19 vaccination implementation: How psychological antecedents of vaccinations mediate the relationship between vaccine literacy and vaccine hesitancy.
Lu Y, Wang Q, Zhu S, Xu S, Kadirhaz M, Zhang Y, Zhao N, Fang Y, Chang J. Soc Sci Med. 2023 Nov;336:116270. doi: 10.1016/j.socscimed.2023.116270. Epub 2023 Sep 26. PMID: 37778145

Vaccine conspiracy association with higher COVID-19 vaccination side effects and negative attitude towards booster COVID-19, influenza and monkeypox vaccines: A pilot study in Saudi Universities.
Alshehri S, Sallam M. Hum Vaccin Immunother. 2023 Dec 15;19(3):2275962. doi: 10.1080/21645515.2023.2275962. Epub 2023 Nov 9. PMID: 37941437

Believing in science: Linking religious beliefs and identity with vaccination intentions and trust in science during the COVID-19 pandemic.
Tippins E, Ysseldyk R, Peneycad C, Anisman H. Public Underst Sci. 2023 Nov;32(8):1003-1020. doi: 10.1177/09636625231174845. Epub 2023 Jun 5. PMID: 37278005

What are effective vaccine distribution approaches for equity-deserving and high-risk populations during COVID-19? Exploring best practices and recommendations in Canada: protocol for a mixed-methods multiple case codesign study.
Aggarwal M, Katz A, Kokorelias KM, Wong ST, Aghajafari F, Ivers NM, Martin-Misener R, Aubrey-Bassler K, Breton M, Upshur REG, Kwong JC. BMJ Open. 2023 Nov 8;13(11):e072238. doi: 10.1136/bmjopen-2023-072238. PMID: 37940159

Champions for School Health-An NASN Initiative to Increase Vaccine Confidence, Equity, and Uptake in COVID-19 and School-Required Vaccinations: Part 2.
D'Souza-Vazirani D, Behrmann E, Alvarez C, Walsh C, Griffin AR, White S. NASN Sch Nurse. 2023 Nov;38(6):301-309. doi: 10.1177/1942602X231202745. PMID: 37926933

A synthetic delivery vector for mucosal vaccination.
Billet A, Hadjerci J, Tran T, Kessler P, Ulmer J, Mourier G, Ghazarian M, Gonzalez A, Thai R, Urquia P, Van Baelen AC, Meola A, Fernandez I, Deville-Foillard S, MacDonald E, Paolini L, Schmidt F, Rey FA, Kay MS, Tartour E, Servent D, Johannes L. Biomaterials. 2023 Nov;302:122298. doi: 10.1016/j.biomaterials.2023.122298. Epub 2023 Sep 5. PMID: 37713762

Heterologous prime-boost with mRNA-1273 stimulates persistent neutralising antibodies in BBIBP-CorV-vaccinated individuals.

Sharif H, Ghani H, Ahmad L, Bagol S, Wong J, Tan CW, Zhu F, Wang LF, Naing L, Cunningham AC. Vaccine. 2023 Nov 13;41(47):6910-6913. doi: 10.1016/j.vaccine.2023.10.044. Epub 2023 Oct 24. PMID: 37880070

Perceptions of COVID-19 Among Unvaccinated Hispanics.
Molina R, Olmedo Y; El Corazon de la Tierra (Kansas City) Chapter of NAHN. Hisp Health Care Int. 2023 Nov 15:15404153231212656. doi: 10.1177/15404153231212656. Online ahead of print. PMID: 37968854

An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance.
Micallef B, Dogné JM, Sultana J, Straus SMJM, Nisticò R, Serracino-Inglott A, Borg JJ. Drug Saf. 2023 Nov;46(11):1089-1103. doi: 10.1007/s40264-023-01346-9. Epub 2023 Sep 14. PMID: 37707778

MDA5-autoimmunity and Interstitial Pneumonitis Contemporaneous with the COVID-19 Pandemic (MIP-C).
Iqbal K, Sinha S, David P, De Marco G, Taheri S, McLaren E, Maisuria S, Arumugakani G, Ash Z, Buckley C, Coles L, Hettiarachchi C, Smithson G, Slade M, Shah R, Marzo-Ortega H, Keen M, Lawson C, Mclorinan J, Nizam S, Reddy H, Sharif O, Sultan S, Tran G, Wood M, Wood S, Ghosh P, McGonagle D. medRxiv. 2023 Nov 5:2023.11.03.23297727. doi: 10.1101/2023.11.03.23297727. Preprint. PMID: 37961408

A Comprehensive review on Pharmacokinetic Studies of Vaccines: Impact of delivery route, carrier-and its modulation on immune response.
Jha SK, Imran M, Jha LA, Hasan N, Panthi VK, Paudel KR, Almalki WH, Mohammed Y, Kesharwani P. Environ Res. 2023 Nov 1;236(Pt 2):116823. doi: 10.1016/j.envres.2023.116823. Epub 2023 Aug 3. PMID: 37543130

It's Time for a National Surveillance System for Vaccine Confidence and Hesitancy.
Gilkey MB, Brewer NT. Pediatrics. 2023 Nov 1;152(5):e2023063169. doi: 10.1542/peds.2023-063169. PMID: 37867453

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Ramasamy MN, Kelly EJ, Seegobin S, Dargan PI, Payne R, Libri V, Adam M, Aley PK, Martinez-Alier N, Church A, Jepson B, Khan M, Matthews S, Townsend GT, Vekemans J, Bibi S, Swanson PA 2nd, Lambe T, Pangalos MN, Villafana T, Pollard AJ, Green JA; AZD2816 Study Group. Lancet Microbe. 2023 Nov;4(11):e863-e874. doi: 10.1016/S2666-5247(23)00177-5. Epub 2023 Sep 29. PMID: 37783221

Comparing the recurrence of audio-vestibular disorders following breakthrough infection of COVID-19 vs. those following vaccine administration.
Wang CC, Young YH. Am J Otolaryngol. 2023 Nov-Dec;44(6):103970. doi: 10.1016/j.amjoto.2023.103970. Epub 2023 Jul 5. PMID: 37467676

Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection.

Motwani KK, Hashash JG, Farraye FA, Kappelman MD, Weaver KN, Zhang X, Long MD, Cross RK. J Crohns Colitis. 2023 Nov 8;17(10):1681-1688. doi: 10.1093/ecco-jcc/jjad085. PMID: 37232444

The association between influenza vaccination and the perception of COVID-19 as well as COVID-19 vaccination behavior among community residents in Anhui province, China.
Guo M, Li J, Wang Y, Chen G, Chen R, Wang L. Hum Vaccin Immunother. 2023 Dec 15;19(3):2275464. doi: 10.1080/21645515.2023.2275464. Epub 2023 Nov 8. PMID: 37941303

T regulatory lymphocytes specific for SARS-CoV-2 display increased functional plasticity.
Esparcia-Pinedo L, Lancho-Sánchez Á, Tsukalov I, Pacheco MI, Martínez-Fleta P, Pérez-Miés B, Palacios-Calvo J, Sánchez-Madrid F, Martín-Gayo E, Alfranca A. Clin Immunol. 2023 Nov;256:109806. doi: 10.1016/j.clim.2023.109806. Epub 2023 Oct 11. PMID: 37827267

Bibliometric analysis of the Vogt–Koyanagi–Harada disease literature.
Li L, Yuan L, Zhou X, Hua X, Yuan X. Int Ophthalmol. 2023 Nov;43(11):4137-4150. doi: 10.1007/s10792-023-02815-x. Epub 2023 Aug 8. PMID: 37552428

Identifying beliefs driving COVID-19 vaccination: Lessons for effective messaging.
MacEwan SR, Kenah E, Dixon GN, Stevens J, Eiterman LP, Powell JR, Gage CB, Rush LJ, Panchal AR, McAlearney AS. Hum Vaccin Immunother. 2023 Dec 15;19(3):2266929. doi: 10.1080/21645515.2023.2266929. Epub 2023 Nov 10. PMID: 37947193

Discounting health gain: a different view.
Standaert B, Ethgen O. J Mark Access Health Policy. 2023 Nov 2;11(1):2275350. doi: 10.1080/20016689.2023.2275350. eCollection 2023. PMID: 37937314

Believing in conspiracy theories in Spain during the COVID-19 pandemic: Drivers and public health implications.
Nefes TS, Präg P, Romero-Reche A, Pereira-Puga M. Soc Sci Med. 2023 Nov;336:116263. doi: 10.1016/j.socscimed.2023.116263. Epub 2023 Sep 28. PMID: 37797543

Factors Associated With COVID-19 Vaccine Hesitancy in Rheumatology Outpatients in New York City.
Barbhaiya M, Schneider B, Levine JM, Bruce O, Do H, Siegel CH, Bykerk VP, Feldman CH, Jannat-Khah D, Mandl LA. J Clin Rheumatol. 2023 Nov 10. doi: 10.1097/RHU.0000000000002041. Online ahead of print. PMID: 37946323

Comparative analysis of characteristics and outcomes in hospitalized COVID-19 patients infected with different SARS-CoV-2 variants between January 2020 and April 2022 - A retrospective single-center cohort study.
Brehm TT, Heyer A, Woo MS, Fischer M, van der Meirschen M, Wichmann D, Jarczak D, Roedl K, Schmiedel S, Addo MM, Lütgehetmann M, Christner M, Huber S, Lohse AW, Kluge S, Schulze Zur Wiesch J. J Infect Public Health. 2023 Nov;16(11):1806-1812. doi: 10.1016/j.jiph.2023.08.010. Epub 2023 Aug 22. PMID: 37741015

Reinfection rates, change in antibody titers and adverse events after COVID-19 vaccination among patients previously infected with COVID-19 in Metro Manila, Philippines: a secondary analysis of a completed cohort study.

Tan-Lim CSC, Gonzales MLAM, Dans LF, Cordero CP, Alejandria MM, Dela Paz ECC, Dator MA, Infantado-Alejandro MAJ, Sulit MVV, Lansang MAD. BMC Infect Dis. 2023 Nov 1;23(1):750. doi: 10.1186/s12879-023-08743-6. PMID: 37915006

Keigai-rengyo-to as post-exposure prophylaxis for severe acute respiratory syndrome coronavirus 2 infection.
Chiba S, Shinohara K. Respir Investig. 2023 Nov;61(6):669-674. doi: 10.1016/j.resinv.2023.07.004. Epub 2023 Sep 12. PMID: 37708631

Longitudinal change trend of the TCR repertoire reveals the immune response intensity of the inactivated COVID-19 vaccine.
Ren C, Ji R, Li Y, He J, Hu W, Teng X, Gao J, Wu Y, Xu J. Mol Immunol. 2023 Nov;163:39-47. doi: 10.1016/j.molimm.2023.09.006. Epub 2023 Sep 20. PMID: 37738878

Kūpuna "Older Adults" COVID-19 Vaccination Efforts in Hawai'i: Barriers and Successes.
Ibrao M, Cadirao CM, Ariyoshi D, Lopez KS, Ilagan L, Braun KL. Hawaii J Health Soc Welf. 2023 Nov;82(11):266-272. PMID: 37969238

Seroprevalence and factors associated with SARS-CoV-2 infection among healthcare workers: cross-sectional study.
Taher WT, Bawazir AA, Sallam TA, Alsurimi K. BMC Infect Dis. 2023 Nov 6;23(1):761. doi: 10.1186/s12879-023-08760-5. PMID: 37932664

Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study.
Kocatürk E, Salameh P, Sarac E, Vera Ayala CE, Thomsen SF, Zuberbier T, Ensina LF, Popov TA, van Doorn MBA, Giménez-Arnau AM, Asero R, Criado PR, Aarestrup FM, AbdulHameed Ansari Z, Al Abri S, Al-Ahmad M, Al Hinai B, Allenova A, Al-Nesf M, Altrichter S, Arnaout R, Bartosińska J, Bauer A, Bernstein JA, Bizjak M, Bonnekoh H, Bouillet L, Brzoza Z, Calvalcanti Dela Bianca Melo AC, Campinhos FL, Carne E, Purayil SC, Cherrez-Ojeda I, Chong-Neto HJ, Christoff G, Conlon N, Jardim Criado RF, Cvenkel K, Damadoglu E, Danilycheva I, Day C, de Montjoye L, Demir S, Ferucci SM, Fomina D, Fukunaga A, Garcia E, Gelincik A, Göbel JH, Godse K, Gonçalo M, Gotua M, Grattan C, Gugala A, Guillet C, Kalyoncu AF, Karakaya G, Kasperska-Zając A, Katelaris CH, Khoshkhui M, Kleinheinz A, Kolacinska-Flont M, Kolkhir P, Košnik M, Krasowska D, Kumaran MS, Kuprys-Lipinska I, Kurowski M, Kuznetsova EV, Larenas-Linnemann D, Lebedkina MS, Lee Y, Makris M, Gómez RM, Nasr I, Neisinger S, Oda Y, Kara RÖ, Palitot EB, Papapostolou N, Salvador Parisi CA, Pesque D, Peter J, Petkova E, Ridge K, Rudenko M, Rutkowski K, Saini SS, Salman A, Sanchez J, Şekerel B, Serdotetskova SA, Serpa FS, Dikicier BS, Sidiropoulos N, Sikora A… See abstract for full author list ➔ J Allergy Clin Immunol. 2023 Nov;152(5):1095-1106. doi: 10.1016/j.jaci.2023.07.019. Epub 2023 Aug 12. PMID: 37574079

Have mRNA vaccines sentenced DNA vaccines to death?
Cagigi A, Douradinha B. Expert Rev Vaccines. 2023 Nov 8. doi: 10.1080/14760584.2023.2282065. Online ahead of print. PMID: 37941101

Impact of vaccination against severe COVID-19 in the French population aged 50 years and above: a retrospective population-based study.

Tan-Lhernould L, Tamandjou C, Deschamps G, Platon J, Sommen C, Chereau F, Parent du Châtelet I, Cauchemez S, Vaux S, Paireau J. BMC Med. 2023 Nov 8;21(1):426. doi: 10.1186/s12916-023-03119-8. PMID: 37940955

The impact of geo-political socio-economic factors on vaccine dissemination trends: a case-study on COVID-19 vaccination strategies.
Chauhan R, Varma G, Yafi E, Zuhairi MF. BMC Public Health. 2023 Nov 2;23(1):2142. doi: 10.1186/s12889-023-17000-z. PMID: 37919737

Significant increase in anti-SARS-CoV-2 antibodies after administration of heterologous mRNA-based vaccine booster in individuals receiving two doses of inactivated COVID-19 vaccine: A single-center study in healthcare workers in Jakarta, Indonesia.
Setiadi W, Effendi Q, Johar E, Yohan B, Wibowo DP, Syahrani L, Pramono AA, Kartapradja HH, Yudhaputri FA, Dewi BE, Malik SG, Myint KSA, Soebandrio A, Safari D. J Infect Public Health. 2023 Nov;16(11):1848-1851. doi: 10.1016/j.jiph.2023.09.012. Epub 2023 Sep 25. PMID: 37837920

COVID-19 vaccination likelihood among federally qualified health center patients: Lessons learned for future health crises.
Peacock E, Craig LS, Wilson M, Williams L, Dahir SA, Tang W, Cyprian A, Dery M, Gilliam D, Nguyen D, Smith K, Valliere M, Williams S, Wiltz G, Winfrey K, Davis T, Arnold C, Theall K, Sarpong D, Krousel-Wood M. Am J Med Sci. 2023 Nov;366(5):321-329. doi: 10.1016/j.amjms.2023.07.013. Epub 2023 Aug 22. PMID: 37619894

Comparison of post-COVID-19 vaccination hypermetabolic lymphadenopathy on ^{18}F-fluorodeoxyglucose PET/CT between virus-vector vaccine and mRNA vaccine.
Chiang MT, Wang JT, Lin WY, Yen RF, Huang JY, Lu CC. Eur J Med Res. 2023 Nov 15;28(1):513. doi: 10.1186/s40001-023-01456-1. PMID: 37964395

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in children under 5 years.
Strumann C, Ranzani O, Moor J, Berner R, Töpfner N, Chao CM, Moor MB. J Clin Invest. 2023 Nov 1;133(21):e173329. doi: 10.1172/JCI173329. PMID: 37669113

Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan.
Arashiro T, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, Oba K, Yanai A, Arioka H, Uehara Y, Ihara G, Kato Y, Yanagisawa N, Nagura Y, Yanai H, Ueda A, Numata A, Kato H, Oka H, Nishida Y, Ishii K, Ooki T, Nidaira Y, Asami T, Jinta T, Nakamura A, Taniyama D, Yamamoto K, Tanaka K, Ueshima K, Fuwa T, Stucky A, Suzuki T, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Vaccine. 2023 Nov 13;41(47):6969-6979. doi: 10.1016/j.vaccine.2023.10.021. Epub 2023 Oct 13. PMID: 37839947

The Impact of Pandemic-Related Restrictions on Dementia Risk Factors in Older Adults.
Simone T, Peltz C, Rosenberg DE, Barnes DE, Fleckenstein LE, Dublin S, Yaffe K. J Appl Gerontol. 2023 Nov 6:7334648231210671. doi: 10.1177/07334648231210671. Online ahead of print. PMID: 37930366

Understanding caregivers' decision to vaccinate childhood cancer survivors against COVID-19.
Ilic A, Haardoerfer R, Michel G, Escoffery C, Mertens AC, Marchak JG. Cancer Med. 2023 Nov 8. doi: 10.1002/cam4.6675. Online ahead of print. PMID: 37937725

Role of Enhancing Aerobic Capacity in Countering COVID-19-induced Liver Injury in Elderlies.
A Mohamed A, A Abdalla A, Jan YK. Endocr Metab Immune Disord Drug Targets. 2023 Nov 1. doi: 10.2174/0118715303250788231018080821. Online ahead of print. PMID: 37937559

Increased Vaccine Uptake Among Eligible Patients at a Veterans Affairs Hospital Through an Inpatient COVID-19 Vaccination Program, Atlanta, Georgia, 2021.
Fujita AW, Goolsby TA, Powell KM, Cartwright EJ. Public Health Rep. 2023 Nov 4:333549231203238. doi: 10.1177/00333549231203238. Online ahead of print. PMID: 37924253

SARS CoV-2 infection among Healthcare Workers from different public health units in Brazil.
de Oliveira FCE, Silva MFS, Fernandes MDCR, Garcia MML, Dinelly Pinto ACM, Severino FG, Alves JSM, Fonseca CAG, de Carvalho Araújo FM, de Andrade LOM, Gambim Fonseca MH. Mol Immunol. 2023 Nov;163:13-19. doi: 10.1016/j.molimm.2023.09.001. Epub 2023 Sep 15. PMID: 37717421

Deglycosylated RBD produced in Pichia pastoris as a low-cost sera COVID-19 diagnosis tool and a vaccine candidate.
Idrovo-Hidalgo T, Pignataro MF, Bredeston LM, Elias F, Herrera MG, Pavan MF, Foscaldi S, Suireszcz M, Fernández NB, Wetzler DE, Paván CH, Craig PO, Roman EA, Ruberto LAM, Noseda DG, Ibañez LI, Czibener C; Argentinian AntiCovid Consortium; Ugalde JE, Nadra AD, Santos J, D'Alessio C. Glycobiology. 2023 Nov 7:cwad089. doi: 10.1093/glycob/cwad089. Online ahead of print. PMID: 37944064

Peripheral facial palsy post SARS-CoV-2 vaccine: A regional pharmacovigilance cases series.
Chamboux M, Simon C, Beau-Salinas F, Maurier A, Agier MS, Thillard EM, Largeau B, Jonville-Bera AP. Therapie. 2023 Nov-Dec;78(6):705-709. doi: 10.1016/j.therap.2023.02.005. Epub 2023 Feb 16. PMID: 36849281

Two years of COVID-19 vaccination in Nigeria: a review of the current situation of the pandemic: a literature review.
Ogunniyi TJ, Rufai BO, Uketeh SN, Turzin JK, Oyinloye EA, Effiong FB. Ann Med Surg (Lond). 2023 Sep 13;85(11):5528-5532. doi: 10.1097/MS9.0000000000001310. eCollection 2023 Nov. PMID: 37915653

COVID-19 vaccination among patients with schizophrenia prescribed clozapine.
Panchal Y, Gannon JM, Tatar JM, Balasubramani GK. Schizophr Res. 2023 Nov;261:31-33. doi: 10.1016/j.schres.2023.09.005. Epub 2023 Sep 8. PMID: 37690168

Omega-3 polyunsaturated fatty acids and the psychiatric post-acute sequelae of COVID-19: A one-year retrospective cohort analysis of 33,908 patients.
Liu TH, Ho CH, Chen DT, Wu JY, Huang PY, Lai CC, Hsieh KY, Su KP. Brain Behav Immun. 2023 Nov;114:453-461. doi: 10.1016/j.bbi.2023.09.008. Epub 2023 Sep 15. PMID: 37716377

Examining Excess Mortality Among Critical Workers in Minnesota During 2020-2021: An Occupational Analysis.
Karnik H, Wrigley-Field E, Levin Z, Chen YH, Zabel EW, Ramirez M, Leider JP. Am J Public Health. 2023 Nov;113(11):1219-1222. doi: 10.2105/AJPH.2023.307395. PMID: 37820305

Mobile Distribution of COVID-19 Vaccines to Migrant Farmworkers in Minnesota.
Hoard J, Thomas CM, Eckerstorfer M, Atoma B, Adamek D, Quintanilla D, Kirsch JD. J Agromedicine. 2023 Nov 8. doi: 10.1080/1059924X.2023.2278804. Online ahead of print. PMID: 37937807

Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databases.
Zheng B, Campbell J, Carr EJ, Tazare J, Nab L, Mahalingasivam V, Mehrkar A, Santhakumaran S, Steenkamp R, Loud F, Lyon S, Scanlon M, Hulme WJ, Green ACA, Curtis HJ, Fisher L, Parker E, Goldacre B, Douglas I, Evans S, MacKenna B, Bell S, Tomlinson LA, Nitsch D; OpenSAFELY Collaborative and LH&W NCS (or CONVALESCENCE) Collaborative. Clin Kidney J. 2023 Aug 29;16(11):2048-2058. doi: 10.1093/ckj/sfad184. eCollection 2023 Nov. PMID: 37915915

Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance.
O'Meara TR, Nanishi E, McGrath ME, Barman S, Dong D, Dillen C, Menon M, Seo HS, Dhe-Paganon S, Ernst RK, Levy O, Frieman MB, Dowling DJ. J Allergy Clin Immunol. 2023 Nov;152(5):1107-1120.e6. doi: 10.1016/j.jaci.2023.06.031. Epub 2023 Aug 16. PMID: 37595760

One-year Antibody Durability Induced by EuCorVac-19, a Liposome-Displayed COVID-19 RBD Subunit Vaccine, in Healthy Korean Subjects.
Lovell JF, Miura K, Baik YO, Lee C, Lee JY, Park YS, Hong I, Lee JH, Kim T, Seo SH, Kim JO, Song M, Kim CJ, Choi JK, Kim J, Choo EJ, Choi JH. Int J Infect Dis. 2023 Nov 7:S1201-9712(23)00765-8. doi: 10.1016/j.ijid.2023.11.004. Online ahead of print. PMID: 37944586

Health-care Worker Engagement in Federally Qualified Health Centers and Associations with Confidence in Making Health-care Recommendations: Evidence from the Louisiana Community Engagement Alliance.
Peacock E, Saltzman LY, Denson JL, Al-Dahir S, Wilson M, Cyprian A, Gilliam D, Harris S, Parnell K, Nguyen D, Smith K, Williams S, Wiltz G, Winfrey K, Williams L, Krousel-Wood M. Med Clin North Am. 2023 Nov;107(6):963-977. doi: 10.1016/j.mcna.2023.06.009. Epub 2023 Jun 30. PMID: 37806728

Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice.
Barbey C, Su J, Billmeier M, Stefan N, Bester R, Carnell G, Temperton N, Heeney J, Protzer U, Breunig M, Wagner R, Peterhoff D. Eur J Pharm Biopharm. 2023 Nov;192:41-55. doi: 10.1016/j.ejpb.2023.09.015. Epub 2023 Sep 27. PMID: 37774890

Outcomes of patients with acute coronary syndrome according to COVID-19 vaccination status.
Hilu R, Abu Ghosh Z, Leibowitz D, Arow Z, Ovdat T, Or T, Pereg D, Alcalai R. Coron Artery Dis. 2023 Nov 1;34(7):470-474. doi: 10.1097/MCA.0000000000001270. Epub 2023 Jul 28. PMID: 37799043

Sex differences in the cardiac stress response following SARS-CoV-2 infection of ferrets.
Rouhana S, Jacyniak K, Francis ME, Falzarano D, Kelvin AA, Pyle WG. Am J Physiol Heart Circ Physiol. 2023 Nov 1;325(5):H1153-H1167. doi: 10.1152/ajpheart.00101.2023. Epub 2023 Sep 22. PMID: 37737732

Innovative approaches for the control of ticks and tick-borne diseases.
de la Fuente J, Mazuecos L, Contreras M. Ticks Tick Borne Dis. 2023 Nov;14(6):102227. doi: 10.1016/j.ttbdis.2023.102227. Epub 2023 Jul 5. PMID: 37419001

To vaccinate or not to vaccinate? The interplay between pro- and against- vaccination reasons.
Caserotti M, Girardi P, Sellaro R, Rubaltelli E, Tasso A, Lotto L, Gavaruzzi T. BMC Public Health. 2023 Nov 9;23(1):2207. doi: 10.1186/s12889-023-17112-6. PMID: 37946143

Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries.
Riefolo F, Castillo-Cano B, Martín-Pérez M, Messina D, Elbers R, Brink-Kwakkel D, Villalobos F, Ingrasciotta Y, Garcia-Poza P, Swart-Polinder K, Souverein P, Saiz LC, Bissacco CA, Leache L, Tari M, Crisafulli S, Grimaldi L, Vaz T, Gini R, Klungel O, Martín-Merino E. Vaccine. 2023 Nov 13;41(47):7007-7018. doi: 10.1016/j.vaccine.2023.10.011. Epub 2023 Oct 17. PMID: 37858451

COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit.
Gilioli A, Bresciani P, Franceschini E, Messerotti A, Pioli V, Colasante C, Bettelli F, Giusti D, Forghieri F, Morselli M, Colaci E, Potenza L, Gennari W, Pecorari M, Marasca R, Candoni A, Mussini C, Trenti T, Comoli P, Luppi M, Cuoghi A. Int J Hematol. 2023 Nov;118(5):652-655. doi: 10.1007/s12185-023-03638-3. Epub 2023 Aug 2. PMID: 37532827

mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis.
Blanco Y, Escudero D, Lleixà C, Llufriu S, Egri N, García RR, Alba M, Aguilar E, Artola M, Aldea Novo M, Alvarez S, Caballero E, Cabrera-Maqueda JM, Fonseca E, Guasp M, Hernando A, Martinez-Hernandez E, Olivé-Cirera G, Lopez-Contreras J, Martín-Aguilar L, Martinez-Martinez L, Rombauts A, Rodés M, Sabater L, Sepulveda M, Solana E, Tejada-Illa C, Vidal-Fernández N, Vilella A, Fortuny C, Armangué T, Dalmau JO, Querol L, Saiz A. Neurol Neuroimmunol Neuroinflamm. 2023 Sep 7;10(6):e200163. doi: 10.1212/NXI.0000000000200163. Print 2023 Nov. PMID: 37679040

The impact of vaccination and outpatient treatment on the economic burden of covid-19 in the United States omicron era: a systematic literature review.
Pierre V, Draica F, Di Fusco M, Yang J, Nunez-Gonzalez S, Kamar J, Lopez S, Moran MM, Nguyen J, Alvarez P, Cha-Silva A, Gavaghan M, Yehoshua A, Stapleton N, Burnett H. J Med Econ. 2023 Nov 15:1-39. doi: 10.1080/13696998.2023.2281882. Online ahead of print. PMID: 37964554

Leukopenia associated with lamotrigine initiation after COVID-19 vaccine booster: A case report and literature review.
Murata T, Uno K, Ito M, Nagamine T. Int J Clin Pharmacol Ther. 2023 Nov 9. doi: 10.5414/CP204452. Online ahead of print. PMID: 37942926

Sense of safety and opinions about COVID-19 vaccinations in Polish school teachers: the role of conspiracy theories belief and fear of COVID-19.
Nowakowska I, Markiewicz M, Pankowski D, Wytrychiewicz-Pankowska K, Banasiak A, Pisula E. J Soc Psychol. 2023 Nov 2;163(6):895-916. doi: 10.1080/00224545.2022.2151404. Epub 2022 Dec 7. PMID: 36476155

Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies.
Evans JP, Liu SL. J Immunol. 2023 Nov 15;211(10):1459-1467. doi: 10.4049/jimmunol.2300315. PMID: 37931210

Cerebral venous sinus thrombosis cases detected in on-call CT venographies in Sweden, 2019-2022.
Torkzad MR, Bjørkelund OA, Labruto F. J Thromb Thrombolysis. 2023 Nov;56(4):548-554. doi: 10.1007/s11239-023-02883-x. Epub 2023 Aug 20. PMID: 37598388

Review of short-term and long-term adverse effects of covid-19 vaccination during pregnancy.
Ramasauskaite Ramašauskaitė D, Grinciute Grinciūtė D. Travel Med Infect Dis. 2023 Nov 9:102667. doi: 10.1016/j.tmaid.2023.102667. Online ahead of print. PMID: 37951411

Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study.
Kirsebom FCM, Andrews N, Stowe J, Ramsay M, Lopez Bernal J. Lancet Infect Dis. 2023 Nov;23(11):1235-1243. doi: 10.1016/S1473-3099(23)00365-1. Epub 2023 Jul 12. PMID: 37453440

Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study.
Congdon S, Narrowe Z, Yone N, Gunn J, Deng Y, Nori P, Cowman K, Islam M, Rikin S, Starrels J. Sci Rep. 2023 Nov 11;13(1):19688. doi: 10.1038/s41598-023-46912-4. PMID: 37951998

Impact of COVID-19 on Pharmacy Education and Practice: Strategies to Boost Advocacy and Unity among Health Care Organizations.
Kahaleh AA, Ellington TM, Coker AO, Tillery E, Manasco KB, Truong HA, Kebodeaux CD, Edwards KL, Hayatshahi A, Gumina G, Hughes JA, Fuentes DG. Am J Pharm Educ. 2023 Nov 10:100091. doi: 10.1016/j.ajpe.2023.100091. Online ahead of print. PMID: 37953084

Science battles viral diseases: a roundtable discussion with leading experts on COVID-19, hepatitis and AIDS.
Zhu H. Natl Sci Rev. 2022 Dec 6;10(11):nwac277. doi: 10.1093/nsr/nwac277. eCollection 2023 Nov. PMID: 37818113

Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case-control study.
González S, Olszevicki S, Gaiano A, Salazar M, Regairaz L, Varela Baino AN, Bartel E, Varela T, González Martínez VV, Pesci S, Marín L, Irassar JI, Ceriani L, Garcia E, Kreplak N, Estenssoro E, Marsico F. Lancet Reg Health Am. 2023 Sep 28;27:100607. doi: 10.1016/j.lana.2023.100607. eCollection 2023 Nov. PMID: 37808936

Potent Antibody Response Elicited by a Third Booster Dose of Inactivated COVID-19 Vaccine in Healthy Subjects.
Ji R, Zhang J, Liang D, Quan H, Wu Y, Peng A, Li W, Lu S, Zhang X, Ke C, Wang D, Xu J. Viral Immunol. 2023 Nov;36(9):593-599. doi: 10.1089/vim.2023.0072. Epub 2023 Sep 29. PMID: 37782911

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States.
Kohli MA, Maschio M, Joshi K, Lee A, Fust K, Beck E, Van de Velde N, Weinstein MC. J Med Econ. 2023 Nov 14:1-22. doi: 10.1080/13696998.2023.2281083. Online ahead of print. PMID: 37961887

Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.
Eybpoosh S, Biglari A, Sorouri R, Ashrafian F, Sadat Larijani M, Verez-Bencomo V, Toledo-Romani ME, Valenzuela Silva C, Salehi-Vaziri M, Dahmardeh S, Doroud D, Banifazl M, Mostafavi E, Bavand A, Ramezani A. PLoS Pathog. 2023 Nov 1;19(11):e1011744. doi: 10.1371/journal.ppat.1011744. eCollection 2023 Nov. PMID: 37910480

Vaccination after developing long COVID: Impact on clinical presentation, viral persistence, and immune responses.
Nayyerabadi M, Fourcade L, Joshi SA, Chandrasekaran P, Chakravarti A, Massé C, Paul ML, Houle J, Boubekeur AM, DuSablon C, Boudreau V, Bovan D, Darbinian E, Coleman EA, Vinci S, Routy JP, Hétu PO, Poudrier J, Falcone EL. Int J Infect Dis. 2023 Nov;136:136-145. doi: 10.1016/j.ijid.2023.09.006. Epub 2023 Sep 17. PMID: 37717649

Cell-based passive immunization for protection against SARS-CoV-2 infection.
Sawula E, Miersch S, Jong ED, Li C, Chou FY, Tang JK, Saberianfar R, Harding J, Sidhu SS, Nagy A. Stem Cell Res Ther. 2023 Nov 6;14(1):318. doi: 10.1186/s13287-023-03556-5. PMID: 37932852

Integrative proteomics and metabolomics study reveal enhanced immune responses by COVID-19 vaccine booster shot against Omicron SARS-CoV-2 infection.
Wang B, Yang W, Tong Y, Sun M, Quan S, Zhu J, Zhang Q, Qin Z, Ni Y, Zhao Y, Wang K, Zhang C, Zhang Y, Wang Z, Song Z, Liu H, Fang H, Kong Z, Ding C, Guo W. J Med Virol. 2023 Nov;95(11):e29219. doi: 10.1002/jmv.29219. PMID: 37966997

Adhesive capsulitis following COVID-19 vaccination: a case report and review of literature.
Alshehri M, Alsalman M, Alsebayel FM. J Surg Case Rep. 2023 Nov 12;2023(11):rjad611. doi: 10.1093/jscr/rjad611. eCollection 2023 Nov. PMID: 37965532

BNT162b2-vaccine-induced neutralization responses are immune correlates of clinical protection against SARS-CoV-2 in heart transplant recipients.
Peled Y, Patel JK, Raanani E, Eilon R, Fardman A, Beigel R, Atari N, Kliker L, Elkader BA, Mandelboim M, Afek A. Clin Transplant. 2023 Nov;37(11):e15091. doi: 10.1111/ctr.15091. Epub 2023 Aug 12. PMID: 37572313

Inactivated COVID-19 vaccines in peri-pregnancy period: Evaluation of safety for both pregnant women and neonates.
Yang C, Zheng Z, Zheng P, Chen J, Huang Q, Chen Y, Zhou Y, Chen P, Li Y, Wu Y. Vaccine. 2023 Nov 8:S0264-410X(23)01322-1. doi: 10.1016/j.vaccine.2023.11.011. Online ahead of print. PMID: 37949755

Seroprevalence of anti-SARS-CoV-2 antibodies before and after implementation of anti-COVID-19 vaccination among hospital staff in Bangui, Central African Republic.
Manirakiza A, Malaka C, Mossoro-Kpinde HD, Yambiyo BM, Mossoro-Kpinde CD, Fandema E, Niamathe Yakola C, Doyama-Woza R, Kangale-Wando IM, Kosh Komba JE, Nzapali Guiagassomon SMB, Namsenei-Dankpea LJG, Coti-Reckoundji CSG, Bouhouda M, Gody JC, Grésenguet G, Vernet G, Vernet MA, Nakoune E. PLOS Glob Public Health. 2023 Nov 1;3(11):e0001497. doi: 10.1371/journal.pgph.0001497. eCollection 2023. PMID: 37910467

Immunity testing against COVID-19 from blood by an IoT-enabled and AI-controlled multiplexed microfluidic platform.
Bhuiyan NH, Shim JS. Biosens Bioelectron. 2023 Nov 3;244:115791. doi: 10.1016/j.bios.2023.115791. Online ahead of print. PMID: 37952323

Comparison of the first and sixth waves of the SARS-COV-2 coronavirus pandemic in patients with immune-mediated disease.
Lobo Rodríguez C, López-Calleja AM, Morales de Los Ríos Luna P, Sánchez Vázquez S, Molinero Sampedro Á, López-Esteban A. Reumatol Clin (Engl Ed). 2023 Nov;19(9):507-511. doi: 10.1016/j.reumae.2023.02.011. Epub 2023 Jun 1. PMID: 37286470

Locations of COVID-19 vaccination provision: Urban-rural differences.
Ryan GW, Kahl AR, Callaghan D, Kintigh B, Askelson NM. J Rural Health. 2023 Nov 13. doi: 10.1111/jrh.12811. Online ahead of print. PMID: 37957524

Evaluation of intentions to get vaccinated against influenza, COVID 19, pertussis and to get a future vaccine against respiratory syncytial virus in pregnant women.
Cubizolles C, Barjat T, Chauleur C, Bruel S, Botelho-Nevers E, Gagneux-Brunon A. Vaccine. 2023 Nov 12:S0264-410X(23)01280-X. doi: 10.1016/j.vaccine.2023.10.067. Online ahead of print. PMID: 37957038

Impact of COVID-19 on HPV Vaccination Rates in New York City and Long Island.
Bower M, Kothari U, Akerman M, Krilov LR, Fiorito TM. Pediatr Infect Dis J. 2023 Nov 13. doi: 10.1097/INF.0000000000004149. Online ahead of print. PMID: 37963272

Exacerbation of Minimal Change Disease Following mRNA COVID-19 Vaccination.
Pirzadeh A, Emami S, Zuckerman JE, Nobakht N. Am J Case Rep. 2023 Nov 9;24:e941621. doi: 10.12659/AJCR.941621. PMID: 37941318

Using a Bayesian hierarchical approach to study the association between non-pharmaceutical interventions and the spread of Covid-19 in Germany.
Khazaei Y, Küchenhoff H, Hoffmann S, Syliqi D, Rehms R. Sci Rep. 2023 Nov 2;13(1):18900. doi: 10.1038/s41598-023-45950-2. PMID: 37919336

Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Mittal A, Solera JT, Ferreira VH, Kothari S, Kimura M, Pasic I, Mattsson JI, Humar A, Kulasingam V, Ierullo M, Kumar D, Hosseini-Moghaddam SM. Transplant Cell Ther. 2023 Nov;29(11):706.e1-706.e7. doi: 10.1016/j.jtct.2023.08.008. Epub 2023 Aug 13. PMID: 37582470

Herpes Zoster Reactivation After mRNA and Adenovirus-Vectored Coronavirus Disease 2019 Vaccination: Analysis of National Health Insurance Database.
Yoon JG, Kim YE, Choi MJ, Choi WS, Seo YB, Jung J, Hyun HJ, Seong H, Nham E, Noh JY, Song JY, Kim WJ, Kim DW, Cheong HJ. J Infect Dis. 2023 Nov 11;228(10):1326-1335. doi: 10.1093/infdis/jiad297. PMID: 37549237

An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission.

Li W, Wang T, Rajendrakumar AM, Acharya G, Miao Z, Varghese BP, Yu H, Dhakal B, LeRoith T, Karunakaran A, Tuo W, Zhu X. Nat Commun. 2023 Nov 6;14(1):7114. doi: 10.1038/s41467-023-42796-0. PMID: 37932271

Who is motivated to accept a booster and annual dose? A dimensional and person-centered approach.
Waterschoot J, Van Oost P, Vansteenkiste M, Brisbois M, Schmitz M, Morbée S, Klein O, Luminet O, Van den Bergh O, Raemdonck E, Yzerbyt V. Appl Psychol Health Well Being. 2023 Nov;15(4):1293-1318. doi: 10.1111/aphw.12437. Epub 2023 Feb 7. PMID: 36748440

Female Leadership during COVID-19: The Effectiveness of Diverse Approaches towards Mitigation Management during a Pandemic.
Ozdenerol E, Bingham-Byrne RM, Seboly J. Int J Environ Res Public Health. 2023 Nov 6;20(21):7023. doi: 10.3390/ijerph20217023. PMID: 37947579

Recruiting a Hard-to-Reach, Hidden and Vulnerable Population: The Methodological and Practical Pitfalls of Researching Vaccine-Hesitant Parents.
Hilário AP, Scavarda A, Numerato D, Mendonça J, Cardano M, Marhankova J, Gariglio L, Vuolanto P, Anderson A, Auvinen P, Bracke P, Douglass T, Hobson-West P, Lermytte E, Polak P, Rudek T. Qual Health Res. 2023 Nov;33(13):1189-1202. doi: 10.1177/10497323231196439. Epub 2023 Sep 6. PMID: 37671951

Broad and Durable Humoral Responses Following Single Hydrogel Immunization of SARS-CoV-2 Subunit Vaccine.
Ou BS, Saouaf OM, Yan J, Bruun TUJ, Baillet J, Zhou X, King NP, Appel EA. Adv Healthc Mater. 2023 Nov;12(28):e2301495. doi: 10.1002/adhm.202301495. Epub 2023 Jun 20. PMID: 37278391

Acceptability rate and barriers to COVID-19 vaccination among healthcare workers in Chukwuemeka Odumegwu Ojukwu University Teaching Hospital, Amaku-Awka, Nigeria.
Joe-Ikechebelu NN, Umeh UM, Eleje GU, Igbodike EP, Ogbuefi EO, Akanwa AO, Echendu ST, Ngene WO, Okpala AN, Okolo OC, Okechukwu CE, Akabuike JC, Agu HO, Okpala VO, Nwazor OC, Nnedum AOU, Esimone CC, Agwaniru HN, Ezeabasili EI, Joe-Ikechebelu BB. Ther Adv Infect Dis. 2023 Nov 9;10:20499361231174776. doi: 10.1177/20499361231174776. eCollection 2023 Jan-Dec. PMID: 37954403

COVID-19 Booster Dose Reminder/Recall for Adolescents: Findings From a Health-Care System in Wisconsin.
Alonge OD, Hanson KE, Eggebrecht M, Funk P, Christianson B, Williams CL, Belongia EA, McLean HQ. J Adolesc Health. 2023 Nov;73(5):953-956. doi: 10.1016/j.jadohealth.2023.06.026. Epub 2023 Aug 21. PMID: 37610391

Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry.
Sadhu S, Dandotiya J, Dalal R, Khatri R, Mykytyn AZ, Batra A, Kaur M, Chandwaskar R, Singh V, Kamboj A, Srivastava M, Mani S, Asthana S, Samal S, Rizvi ZA, Salunke DB, Haagmans BL, Awasthi A. Antiviral Res. 2023 Nov 8:105743. doi: 10.1016/j.antiviral.2023.105743. Online ahead of print. PMID: 37949319

Humoral Response After 5 Successive Doses of COVID-19 Vaccine in Kidney Transplant Patients: Comment.

Cazorla JM, Villanego F, Aguilera A, Garcia T, Orellana C, Trujillo T, Gómez AM, Mazuecos A. Transplantation. 2023 Nov 1;107(11):e319. doi: 10.1097/TP.0000000000004756. Epub 2023 Oct 21. PMID: 37870884

Humoral Response After 5 Successive Doses of COVID-19 Vaccine in Kidney Transplant Patients: Comment.
Kleebayoon A, Wiwanitkit V. Transplantation. 2023 Nov 1;107(11):e318. doi: 10.1097/TP.0000000000004755. Epub 2023 Oct 21. PMID: 37870883

Efficacy and safety of tixagevimab-cilgavimab (Evusheld®) in people with Multiple Sclerosis on Ocrelizumab: preliminary evidence.
Altieri M, Melisi RD, Conte M, Capuano R, Donnarumma G, Grimaldi E, Coppola N, De Pascalis S, Risi M, d'Ambrosio A, Bisecco A, Gallo A. Neurol Sci. 2023 Nov;44(11):4107-4110. doi: 10.1007/s10072-023-06975-7. Epub 2023 Jul 27. PMID: 37498399

Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab.
Bar-Or A, Aburashed R, Chinea AR, Hendin BA, Lucassen E, Meng X, Stankiewicz J, Tullman MJ, Cross AH. Mult Scler Relat Disord. 2023 Nov;79:104967. doi: 10.1016/j.msard.2023.104967. Epub 2023 Aug 28. PMID: 37769429

SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020-2022.
Teran RA, Gagner A, Gretsch S, Lauritsen J, Galanto D, Walblay K, Ruestow P, Korban C, Pacilli M, Kern D, Black SR, Tabidze I. Emerg Infect Dis. 2023 Nov;29(11):2257-2265. doi: 10.3201/eid2911.230577. PMID: 37877555

Comment on: COVID-19 vaccine hesitancy in inflammatory arthritis patients: serial surveys from a large longitudinal national Australian cohort.
Mungmunpuntipantip R, Wiwanitkit V. Rheumatology (Oxford). 2023 Nov 2;62(11):e322. doi: 10.1093/rheumatology/keac572. PMID: 36193990

Expediting approval for medical countermeasures to address high burden disease: an ethical justification to move beyond emergency use authorisation.
Mercuri M, Hackett K, Upshur R, Emerson CI. BMJ Glob Health. 2023 Nov;8(11):e013480. doi: 10.1136/bmjgh-2023-013480. PMID: 37918871

Dimensions of equality in uptake of COVID-19 vaccination in Wales, UK: A multivariable linked data population analysis.
Jones G, Perry M, Bailey R, Arumugam S, Edwards A, Lench A, Cooper A, Akbari A, Collins B, Harris C, Richardson G, Barry M, Harris P, Fry R, Lyons RA, Cottrell S. Vaccine. 2023 Nov 4:S0264-410X(23)01279-3. doi: 10.1016/j.vaccine.2023.10.066. Online ahead of print. PMID: 37932133

Multiantigen pan-sarbecovirus DNA vaccines generate protective T cell immune responses.
van Bergen J, Camps MG, Pardieck IN, Veerkamp D, Leung WY, Leijs AA, Myeni SK, Kikkert M, Arens R, Zondag GC, Ossendorp F. JCI Insight. 2023 Nov 8;8(21):e172488. doi: 10.1172/jci.insight.172488. PMID: 37707962

Cost-Related Barriers and Ensuring Equitable Access to Vaccines in the US.
Essien UR, Dusetzina SB. JAMA Pediatr. 2023 Nov 1;177(11):1117-1118. doi: 10.1001/jamapediatrics.2023.3260. PMID: 37669068

Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.
Hall VJ, Insalata F, Foulkes S, Kirwan P, Sparkes D, Atti A, Cole M, de Lacy E, Price L, Corrigan D, Brown CS, Islam J; SIREN Study Group. J Infect. 2023 Nov 3:S0163-4453(23)00553-4. doi: 10.1016/j.jinf.2023.10.022. Online ahead of print. PMID: 37926119

Beyond Information Provision: Analysis of the Roles of Structure and Agency in COVID-19 Vaccine Confidence in Ethnic Minority Communities.
Poduval S, Kamal A, Martin S, Islam A, Kaviraj C, Gill P. Int J Environ Res Public Health. 2023 Nov 1;20(21):7008. doi: 10.3390/ijerph20217008. PMID: 37947565

Views about vaccines and how views changed during the COVID-19 pandemic among a national sample of young gay, bisexual, and other men who have sex with men.
Marshall D, McRee AL, Gower AL, Reiter PL. Hum Vaccin Immunother. 2023 Dec 15;19(3):2281717. doi: 10.1080/21645515.2023.2281717. Epub 2023 Nov 15. PMID: 37965729

Stroke Following Coronavirus Disease 2019 Vaccination: Evidence Based on Different Designs of Real-World Studies.
Liu J, Cao F, Luo C, Guo Y, Yan J. J Infect Dis. 2023 Nov 11;228(10):1336-1346. doi: 10.1093/infdis/jiad306. PMID: 37536364

Fair-split distribution of multi-dose vaccines with prioritized age groups and dynamic demand: The case study of COVID-19.
Vahdani B, Mohammadi M, Thevenin S, Gendreau M, Dolgui A, Meyer P. Eur J Oper Res. 2023 Nov 1;310(3):1249-1272. doi: 10.1016/j.ejor.2023.03.032. Epub 2023 Apr 20. PMID: 37284206

Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months.
Younes S, Nicolai E, Al-Sadeq DW, Younes N, Al-Dewik N, Abou-Saleh H, Abo-Halawa BY, Eid AH, Pieri M, Liu N, Daas HI, Yassine HM, Nizamuddin PB, Abu-Raddad LJ, Nasrallah GK. J Infect Public Health. 2023 Nov;16(11):1729-1735. doi: 10.1016/j.jiph.2023.08.009. Epub 2023 Aug 22. PMID: 37734128

Women's experiences with solitary childbirth support in Ohio during COVID-19: Results from a qualitative study.
Church AC. Perspect Sex Reprod Health. 2023 Nov 1. doi: 10.1363/psrh.12247. Online ahead of print. PMID: 37909471

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study.
Huang ST, Huang YS, Liu WD, Pan SC, Sun HY, Lien CE, Chen C, Hsieh SM. J Formos Med Assoc. 2023 Nov;122(11):1165-1173. doi: 10.1016/j.jfma.2023.05.030. Epub 2023 Jun 14. PMID: 37321955

Clinical course and follow-up of pediatric patients with COVID-19 vaccine-associated myocarditis compared to non-vaccine-associated myocarditis within the prospective multi-center registry - "MYKKE": Short Title: Pediatric COVID-19 vaccine-associated myocarditis.
Rolfs N, Huber C, Schwarzkopf E, Mentzer D, Keller-Stanislawski B, Opgen-Rhein B, Frede W, Rentzsch A, Hecht T, Boehne M, Grafmann M, Kiski D, Graumann I, Foth R, Voges I, Schweigmann U, Ruf B, Fischer M, Wiegand G, Klingel K, Pickardt T, Friede T, Messroghli D, Schubert S, Seidel F; MYKKE consortium. Am Heart J. 2023 Nov 11:S0002-8703(23)00315-0. doi: 10.1016/j.ahj.2023.11.006. Online ahead of print. PMID: 37956921

Vaccines and global health: COVID-19 vaccine development, strategy, and implementation symposium - Summary of the meeting at Vagelos College of Physicians and Surgeons (February 22-26, 2021, New York).
James WG, Stanberry LR, LaRussa PS, Grodman MD. Vaccine. 2023 Nov 1:S0264-410X(23)01254-9. doi: 10.1016/j.vaccine.2023.10.052. Online ahead of print. PMID: 37923696

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers.
Çulpan HC, Aydın SN, Uygur A, Sayılı U, Şeker E, Balkan ILİ, Karaali R, Budak B, Keskindemirci Y, Saltoğlu N, Can G. Hum Vaccin Immunother. 2023 Dec 15;19(3):2275445. doi: 10.1080/21645515.2023.2275445. Epub 2023 Nov 15. PMID: 37964650

A quantitative evaluation of the impact of vaccine roll-out rate and coverage on reducing deaths: insights from the first 2 years of COVID-19 epidemic in Iran.
Ghafari M, Hosseinpour S, Rezaee-Zavareh MS, Dascalu S, Rostamian S, Aramesh K, Madani K, Kordasti S. BMC Med. 2023 Nov 13;21(1):429. doi: 10.1186/s12916-023-03127-8. PMID: 37953291

COVID-19 Vaccine Uptake, Attitudes Toward Vaccines, and Mandatory Vaccinations With Anxiety and Depression Levels Among 12 956 Non-Health Care Workers in Hong Kong, Nanjing, and Wuhan.
Lee PMY, Wang D, Li Y, Wang S, Yang S, Wu T, Shen H, Ji X, Chen W, Tse LA. Asia Pac J Public Health. 2023 Nov;35(8):571-575. doi: 10.1177/10105395231198594. Epub 2023 Sep 7. PMID: 37675580

A case of recurrence of pyoderma gangrenosum after COVID-19 vaccine.
Bettolini L, Bighetti S, Mezzana S, Gelmetti A, Calzavara-Pinton P, Maione V. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):e1261-e1263. doi: 10.1111/jdv.19285. Epub 2023 Jun 29. PMID: 37338337

No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial.
Naficy A, Kuxhausen A, Pirrotta P, Leav B, Miller J, Anteyi K, Danier J, Breuer T, Mwakingwe-Omari A. Clin Infect Dis. 2023 Nov 11;77(9):1238-1246. doi: 10.1093/cid/ciad361. PMID: 37335963

SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
Di Filippo M, Ferraro D, Ragonese P, Prosperini L, Maniscalco GT, Gallo A, Cavalla P, Lorefice L, Nociti V, Di Sabatino E, Clerico M, Guaschino C, Radaelli M, Fantozzi R, Buttari F, Laroni A, Gajofatto A, Calabrese M, Malucchi S, Paolicelli D, De Luca G, Tomassini V, Lanzillo R, Moccia M, Solaro C, Cocco E, Gasperini C, Tortorella C; RIREMS (Rising Researchers in MS) group. J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034-0. Online ahead of print. PMID: 37922069

PREVALENCE OF SARS-CoV-2 RNA AND ANTIBODY DETECTION, AND VACCINATION STATUS IN PATIENTS WITH OCULAR VASCULAR OCCLUSION.
Dera AU, Brockmann T, Rusch W, Weiland AL, Reisinger EC, Fuchsluger TA, Brockmann C. Retina. 2023 Nov 1;43(11):1951-1959. doi: 10.1097/IAE.0000000000003907. PMID: 37535933

Resolution of Eosinophilic Pneumonia after Coronavirus Disease 2019 without Systemic Corticosteroids.
Misaki Y, Hayashi Y, Shirata M, Terada K, Yoshizawa A, Sakamoto R, Ikezoe K, Tanizawa K, Handa T, Hirai T. Intern Med. 2023 Nov 1;62(21):3223-3230. doi: 10.2169/internalmedicine.1648-23. Epub 2023 Aug 16. PMID: 37587039

Differences in the efficacy and safety of the COVID-19 vaccination campaign in males and females. Does only sex matter?
Coscetta F, Giardino F, Bossone E, Cittadini A, Marra AM. Intern Emerg Med. 2023 Nov;18(8):2163-2164. doi: 10.1007/s11739-023-03398-2. Epub 2023 Sep 2. PMID: 37658950

Subclinical myocardial assessment after BNT162b2 messenger RNA COVID-19 vaccination in adolescents with chronic heart disease: a speckle-tracking echocardiography study.
Başkan S, Özer PK, Keskin GY, Gövdeli EA, Ömeroğlu RE. Cardiol Young. 2023 Nov;33(11):2252-2257. doi: 10.1017/S104795112200422X. Epub 2023 Jan 18. PMID: 36650738

Keratosis pilaris-like eruptions in a child following COVID-19 vaccination.
Wu PC, Chung WH, Hung YT, Chen CB. Int J Dermatol. 2023 Nov;62(11):e570-e571. doi: 10.1111/ijd.16810. Epub 2023 Aug 14. PMID: 37580953

Declines in Influenza Vaccination Coverage Among Health Care Personnel in Acute Care Hospitals During the COVID-19 Pandemic - United States, 2017-2023.
Lymon H, Meng L, Reses HE, Barbre K, Dubendris H, Shafi S, Wiegand R, Reddy GRTY, Woods A, Kuhar DT, Stuckey MJ, Lindley MC, Haas L, Qureshi I, Wong E, Benin A, Bell JM. MMWR Morb Mortal Wkly Rep. 2023 Nov 10;72(45):1244-1247. doi: 10.15585/mmwr.mm7245a6. PMID: 37943698

Discovery of highly potent covalent SARS-CoV-2 3CL^{pro} inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19.
Zhang FM, Huang T, Wang F, Zhang GS, Liu D, Dai J, Zhang JW, Li QH, Lin GQ, Gao D, Zhao J, Tian P. Eur J Med Chem. 2023 Nov 15;260:115721. doi: 10.1016/j.ejmech.2023.115721. Epub 2023 Aug 17. PMID: 37598484

Poly(2-oxazoline)/saRNA Polyplexes for Targeted and Nonviral Gene Delivery.
Hayes G, Dias-Barbieri B, Yilmaz G, Shattock RJ, Becer CR. Biomacromolecules. 2023 Nov 13;24(11):5142-5151. doi: 10.1021/acs.biomac.3c00683. Epub 2023 Oct 4. PMID: 37792545

Examining corruption risks in the procurement and distribution of COVID-19 vaccines in select states in Nigeria.
Onwujekwe O, Orjiakor C, Ogbozor P, Agu I, Agwu P, Wright T, Balabanova D, Kohler J. J Pharm Policy Pract. 2023 Nov 13;16(1):141. doi: 10.1186/s40545-023-00649-7. PMID: 37957711

Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.

Wong SY, Wellens J, Helmus D, Marlow L, Brann S, Martinez Pazos V, Weinberg A, Moran HR, McGregor C, Vermeire S, Watanabe K, Kamikozuru K, Ahuja V, Vermani S, Lindsay JO, Kingston A, Dutta U, Kaur H, Silverberg MS, Milgrom R, Chien Ng S, Mak JWY, Cadwell K, Thompson C, Colombel JF, Satsangi J; ICARUS-IBD Consortium. Inflamm Bowel Dis. 2023 Nov 2;29(11):1693-1705. doi: 10.1093/ibd/izad097. PMID: 37354560

Otolaryngology-Specific Symptoms May Be Highly Observed in Patients With a History of Covid-19 Infection After Inactivated Coronavirus Vaccination.
Avcı H, Karabulut B, Eken HD, Faraşoğlu A, Çakil T, Çoruk S, Özel H, Kaya NK, Özbalta SÖ. Ear Nose Throat J. 2023 Nov;102(11):715-719. doi: 10.1177/01455613211028493. Epub 2021 Jul 8. PMID: 34233498

Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants.
Sun CP, Chiu CW, Wu PY, Tsung SI, Lee IJ, Hu CW, Hsu MF, Kuo TJ, Lan YH, Chen LY, Ng HY, Chung MJ, Liao HN, Tseng SC, Lo CH, Chen YJ, Liao CC, Chang CS, Liang JJ, Draczkowski P, Puri S, Chang YC, Huang JS, Chen CC, Kau JH, Chen YH, Liu WC, Wu HC, Danny Hsu ST, Wang IH, Tao MH. Mol Ther. 2023 Nov 1;31(11):3322-3336. doi: 10.1016/j.ymthe.2023.09.002. Epub 2023 Sep 9. PMID: 37689971

Knowledge, acceptance, motivators and barriers of booster dose of COVID-19 vaccination among dental patients: A cross-sectional study.
Faraz A, Hina M, Atif A, Sumbul D, Mahmood SE, Riaz F, Khan MS, Ahmad A, Ahmad MT, Parvez A, Zeyaullah M. Medicine (Baltimore). 2023 Nov 10;102(45):e35747. doi: 10.1097/MD.0000000000035747. PMID: 37960831

A Systematic Review Of COVID-19 Misinformation Interventions: Lessons Learned.
Smith R, Chen K, Winner D, Friedhoff S, Wardle C. Health Aff (Millwood). 2023 Nov 15:101377hlthaff202300717. doi: 10.1377/hlthaff.2023.00717. Online ahead of print. PMID: 37967291

Association between sex hormones and anti-S/RBD antibody responses to COVID-19 vaccines in healthcare workers.
Anticoli S, Dorrucci M, Iessi E, Chiarotti F, Di Prinzio RR, Vinci MR, Zaffina S, Puro V, Colavita F, Mizzoni K, Meschi S, Vonesch N, Albano C, Ortona E, Ruggieri A, Tomao P. Hum Vaccin Immunother. 2023 Dec 15;19(3):2273697. doi: 10.1080/21645515.2023.2273697. Epub 2023 Nov 14. PMID: 37961893

Assessing the real-world effectiveness of five SARS-CoV-2 vaccines in a cohort of Mexican pensioners: a nationwide nested test-negative design study.
Hernandez-Avila M, Ortiz-Brizuela E, Tamayo-Ortiz M, Zepeda-Tello R, Gutierrez-Diaz H, Barros-Sierra Cordera D, Vieyra-Romero W, Real-Ornelas GA, Méndez Aranda M, Heras Gómez A. Lancet Reg Health Am. 2023 Oct 19;27:100612. doi: 10.1016/j.lana.2023.100612. eCollection 2023 Nov. PMID: 37886231

Update on Central Nervous System Effects of the Intersection of HIV-1 and SARS-CoV-2.
Ocampo FF, Promsena P, Chan P. Curr HIV/AIDS Rep. 2023 Nov 11. doi: 10.1007/s11904-023-00676-8. Online ahead of print. PMID: 37950846

Innovative method for rapid detection of falsified COVID-19 vaccines through unopened vials using handheld Spatially Offset Raman Spectroscopy (SORS).
Mosca S, Lin Q, Stokes R, Bharucha T, Gangadharan B, Clarke R, Fernandez LG, Deats M, Walsby-Tickle J, Arman BY, Chunekar SR, Patil KD, Gairola S, Van Assche K, Dunachie S, Merchant HA, Kuwana R, Maes A, McCullagh J, Caillet C, Zitzmann N, Newton PN, Matousek P. Vaccine. 2023 Nov 13;41(47):6960-6968. doi: 10.1016/j.vaccine.2023.10.012. Epub 2023 Oct 20. PMID: 37865599

Post-vaccination SARS-Cov-2 T-cell receptor repertoires in patients with multiple sclerosis and related disorders.
Algu P, Hameed N, DeAngelis T, Stern J, Harel A. Mult Scler Relat Disord. 2023 Nov;79:104965. doi: 10.1016/j.msard.2023.104965. Epub 2023 Aug 28. PMID: 37657307

COVID-19 vaccination attitudes, values, intentions: US parents for their children, September 2021.
Dudley MZ, Schwartz B, Brewer J, Kan L, Bernier R, Gerber JE, Budigan Ni H, Proveaux TM, Rimal RN, Salmon DA. Vaccine. 2023 Nov 9:S0264-410X(23)01295-1. doi: 10.1016/j.vaccine.2023.11.002. Online ahead of print. PMID: 37951793

Baricitinib treatment of extragenital lichen sclerosus caused by COVID-19 vaccine.
Wang X, Shi Y, Liu Y. Australas J Dermatol. 2023 Nov;64(4):574-576. doi: 10.1111/ajd.14172. Epub 2023 Oct 9. PMID: 37811701

Is decision-making based on the internet during pregnancy a predictive factor for vaccine hesitancy in pregnant women during the pandemic?
Uludağ E, Serçekuş P, Yıldırım Gökşen DF, Alataş SE, Özkan S. Women Health. 2023 Nov 6:1-9. doi: 10.1080/03630242.2023.2277879. Online ahead of print. PMID: 37933189

Detecting the most critical clinical variables of COVID-19 breakthrough infection in vaccinated persons using machine learning.
Daramola O, Kavu TD, Kotze MJ, Kamati O, Emjedi Z, Kabaso B, Moser T, Stroetmann K, Fwemba I, Daramola F, Nyirenda M, van Rensburg SJ, Nyasulu PS, Marnewick JL. Digit Health. 2023 Nov 5;9:20552076231207593. doi: 10.1177/20552076231207593. eCollection 2023 Jan-Dec. PMID: 37936960

The anti-SARS-CoV-2 BNT162b2 vaccine suppresses mithramycin-induced erythroid differentiation and expression of embryo-fetal globin genes in human erythroleukemia K562 cells.
Zurlo M, Gasparello J, Verona M, Papi C, Cosenza LC, Finotti A, Marzaro G, Gambari R. Exp Cell Res. 2023 Nov 7:113853. doi: 10.1016/j.yexcr.2023.113853. Online ahead of print. PMID: 37944576

A novel SARS-CoV-2 Beta RBD DNA vaccine directly targeted to antigen-presenting cells induces strong humoral and T cell responses.
Kuczkowska K, Bjerkan L, Stubsrud E, Husbyn HC, Chellappa S, Hauge A, Skarshaug R, Torgersen ML, Heim JB, Jørgensen MJ, Wold CW, Schleimann MH, Tolstrup M, Granum S, Fredriksen AB, Pedersen MW, Norheim G. Sci Rep. 2023 Nov 2;13(1):18902. doi: 10.1038/s41598-023-46223-8. PMID: 37919366

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).

Kijak GH, Ahani B, Arbetter D, Chuecos F, Gopalakrishnan V, Beloor J, Brady T, Nguyen A, Roe TL, Schuko N, Zhang T, Hobbs FDR, Padilla F, Kelly EJ, Montgomery H, Streicher K. Infect Dis Ther. 2023 Nov 2. doi: 10.1007/s40121-023-00882-2. Online ahead of print. PMID: 37914983

Evaluation of self-amplifying mRNA platform for protein expression and genetic stability: Implication for mRNA therapies.
Deo S, Desai K, Patare A, Wadapurkar R, Rade S, Mahudkar S, Sathe M, Srivastava S, Prasanna P, Singh A. Biochem Biophys Res Commun. 2023 Nov 5;680:108-118. doi: 10.1016/j.bbrc.2023.09.016. Epub 2023 Sep 13. PMID: 37738900

An educational intervention in the emergency department seeking to improve COVID-19 vaccination rates among unvaccinated patients aged 20-64.
DeWaard S, Dewyer Z, Al Assil T, Gallap R, Patrick L, Fukuda N, Ford M. Infect Dis Health. 2023 Nov;28(4):276-281. doi: 10.1016/j.idh.2023.07.001. Epub 2023 Jul 29. PMID: 37524612

"Who is Anders Tegnell?" Unanswered questions hamper COVID-19 vaccine uptake: A qualitative study among ethnic minorities in Sweden.
Herzig van Wees S, Stålgren M, Viberg N, Puranen B, Ekström AM, Larsson EC. Vaccine. 2023 Nov 10:S0264-410X(23)01328-2. doi: 10.1016/j.vaccine.2023.11.016. Online ahead of print. PMID: 37953100

Using artificial intelligence algorithms to predict the overall survival of hemodialysis patients during the COVID-19 pandemic: A prospective cohort study.
Tang SY, Chen TH, Kuo KL, Huang JN, Kuo CT, Chu YC. J Chin Med Assoc. 2023 Nov 1;86(11):1020-1027. doi: 10.1097/JCMA.0000000000000994. Epub 2023 Sep 15. PMID: 37713313

Variations across Europe in hospitalization and management of pregnant women with SARS-CoV-2 during the initial phase of the pandemic: Multi-national population-based cohort study using the International Network of Obstetric Survey Systems (INOSS).
de Bruin O, Engjom H, Vousden N, Ramakrishnan R, Aabakke AJM, Äyräs O, Donati S, Jónasdóttir E, Knight M, Overtoom EM, Salvatore MA, Sturkenboom MCJM, Svanvik T, Varpula R, Vercoutere A, Bloemenkamp KWM; INOSS COVID-19 Working Group. Acta Obstet Gynecol Scand. 2023 Nov;102(11):1521-1530. doi: 10.1111/aogs.14643. Epub 2023 Aug 18. PMID: 37594175

Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ, Mordant FL, Amarilla AA, Modhiran N, Liang B, Li Z, Wijesundara DK, Lackenby JA, Griffin P, Bennet JK, Hensen L, Zhang W, Nguyen THO, Tran MH, Tapley P, Barnes J, Reading PC, Kedzierska K, Ranasinghe C, Subbarao K, Watterson D, Young PR, Munro TP. EBioMedicine. 2023 Nov;97:104842. doi: 10.1016/j.ebiom.2023.104842. Epub 2023 Oct 20. PMID: 37865043

Can Vaccination with Various Types of Vaccines Make Communities Safer against COVID-19?
SeyedAlinaghi S, Mirzapour P, Mehraeen E. Infect Disord Drug Targets. 2023 Nov 3. doi: 10.2174/0118715265264961231025092542. Online ahead of print. PMID: 37937568

Determinants of Sickness Absence Duration After Mild COVID-19 in a Prospective Cohort of Canadian Healthcare Workers.

Adisesh A, Durand-Moreau Q, Labrèche F, Ruzycki S, Zadunayski T, Cherry N. J Occup Environ Med. 2023 Nov 1;65(11):958-966. doi: 10.1097/JOM.0000000000002945. Epub 2023 Aug 12. PMID: 37590394

Spray dried lipid nanoparticle formulations enable intratracheal delivery of mRNA.
Friis KP, Gracin S, Oag S, Leijon A, Sand E, Lindberg B, Lázaro-Ibáñez E, Lindqvist J, Whitehead KA, Bak A. J Control Release. 2023 Nov;363:389-401. doi: 10.1016/j.jconrel.2023.09.031. Epub 2023 Sep 30. PMID: 37741463

Correction to: Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study.
[No authors listed] Rheumatology (Oxford). 2023 Nov 2;62(11):3772. doi: 10.1093/rheumatology/kead492. PMID: 37750762

ChAdOx1 SARS-CoV-2 vaccination: A putative precipitant of adrenal crises.
Maguire D, McLaren DS, Rasool I, Shah PM, Lynch J, Murray RD. Clin Endocrinol (Oxf). 2023 Nov;99(5):470-473. doi: 10.1111/cen.14566. Epub 2021 Aug 6. PMID: 34358373

Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats.
Wang H, Wang Y, Yuan C, Xu X, Zhou W, Huang Y, Lu H, Zheng Y, Luo G, Shang J, Sui M. NPJ Vaccines. 2023 Nov 2;8(1):169. doi: 10.1038/s41541-023-00766-z. PMID: 37919316

Sequential cellular and humoral responses after repetitive COVID-19 vaccination in patients treated with anti-CD20 antibodies.
Nishikubo M, Shimomura Y, Yamamoto R, Maruoka H, Nasu S, Sakizono K, Nagai Y, Hiramoto N, Yonetani N, Kondo T, Miyakoshi C, Doi A, Ishikawa T. Br J Haematol. 2023 Nov 14. doi: 10.1111/bjh.19207. Online ahead of print. PMID: 37964419

The interplay of drug therapeutics and immune responses to SARS-CoV-2.
Fumagalli V, Iannacone M. Cell Mol Immunol. 2023 Nov 14. doi: 10.1038/s41423-023-01098-7. Online ahead of print. PMID: 37964122

Inhibitory effects of SARS-CoV-2 Spike protein and BNT162b2 vaccine on erythropoietin-induced globin gene expression in erythroid precursor cells (ErPCs) from β-thalassemia patients.
Cosenza LC, Marzaro G, Zurlo M, Gasparello J, Zuccato C, Finotti A, Gambari R. Exp Hematol. 2023 Nov 6:S0301-472X(23)01761-7. doi: 10.1016/j.exphem.2023.11.002. Online ahead of print. PMID: 37939833

Minding the "T"s beyond the "B"s: Shaping vaccines for future pandemics.
Kalimuddin S, Ooi EE. PLoS Biol. 2023 Nov 7;21(11):e3002351. doi: 10.1371/journal.pbio.3002351. eCollection 2023 Nov. PMID: 37934720

Impact of nutritional status on antibody titer after booster mRNA COVID-19 vaccine among elderly adults in Japan.
Mori M, Doi T, Murata M, Moriyama Y, Akino K, Moriyama T, Maekawa T, Doi N. J Infect Dis. 2023 Nov 14:jiad495. doi: 10.1093/infdis/jiad495. Online ahead of print. PMID: 37962870

Systematic review of seroprevalence of SARS-CoV-2 antibodies and appraisal of evidence, prior to the widespread introduction of vaccine programmes in the WHO European Region, January-December 2020.

Vaughan A, Duffell E, Freidl GS, Lemos DS, Nardone A, Valenciano M, Subissi L, Bergeri I, K Broberg E, Penttinen P, Pebody R, Keramarou M. BMJ Open. 2023 Nov 6;13(11):e064240. doi: 10.1136/bmjopen-2022-064240. PMID: 37931969

Characterization of Pre-Existing Neutralizing Antibody to Human Adenovirus Types 5 and 49 and Simian Type 23 in Chinese Population.
Zou P, Wang Q, Zhang P, Luo S, Wang C, Zhang E, Zhang L, Li C, Li T. Viral Immunol. 2023 Nov;36(9):617-625. doi: 10.1089/vim.2023.0023. Epub 2023 Oct 30. PMID: 37903228

Spike protein is a key target for stronger and more persistent T-cell responses-a study of mild and asymptomatic SARS-CoV-2 infection.
Ssali I, Mugaba S, Watelo AK, Bemanzi J, Katende JS, Oluka GK, Ankunda V, Baine C, Kato L; COVID-19 Immunoprofiling Team; Onyachi N, Muwanga M, Jjuuko M, Kayiwa J, Nsereko C, Auma BO, Weiskopf D, Sette A, Lutalo T, Musenero M, Kaleebu P, Serwanga J. Int J Infect Dis. 2023 Nov;136:49-56. doi: 10.1016/j.ijid.2023.09.001. Epub 2023 Sep 6. PMID: 37683720

Obtaining a high titer of polyclonal antibodies from rats to the SARS-CoV-2 nucleocapsid protein and its N- and C-terminal domains for diagnostic test development.
de Almeida MT, Barbosa AP, Bomfim CG, Visnardi AB, Vinces TC, Ceroni A, Durigon EL, Guzzo CR. J Immunol Methods. 2023 Nov;522:113558. doi: 10.1016/j.jim.2023.113558. Epub 2023 Sep 11. PMID: 37704125

Transient Adrenal Insufficiency Following Pfizer/BioNTech Coronavirus Disease-2019 Vaccine Overdose.
Altunbas E, Unal E, Onur O, Caglayik DY. J Emerg Nurs. 2023 Nov;49(6):835-840. doi: 10.1016/j.jen.2023.07.008. Epub 2023 Sep 16. PMID: 37715759

"How" Versus "Why" Messaging to Increase Uptake of Booster Vaccination Against COVID-19: Results of a Pragmatic Randomized Trial.
Haff N, Choudhry NK, Bhatkhande G, Keller PA, Robertson T, Oran R, Horn D, Crum KL, Oduol T, Hanken K, Lauffenburger JC. J Gen Intern Med. 2023 Nov 6. doi: 10.1007/s11606-023-08492-x. Online ahead of print. PMID: 37932539

What's trending? Reach and content of the Society for Maternal-Fetal Medicine on social media.
Strang AR, Backley S, Wade K, Easter SR, Samuel A, Parchem JG. Am J Obstet Gynecol MFM. 2023 Nov;5(11):101159. doi: 10.1016/j.ajogmf.2023.101159. Epub 2023 Sep 13. PMID: 37709050

Enhanced immunogenicity elicited by a novel DNA vaccine encoding the SARS-CoV-2 S1 protein fused to the optimized flagellin of *Salmonella typhimurium* in mice.
Song L, Wang Q, Wen Y, Tan R, Cui Y, Xiong D, Jiao X, Pan Z. Microbiol Spectr. 2023 Nov 1:e0254923. doi: 10.1128/spectrum.02549-23. Online ahead of print. PMID: 37909745

Coverage with Selected Vaccines and Exemption from School Vaccine Requirements Among Children in Kindergarten - United States, 2022-23 School Year.
Seither R, Yusuf OB, Dramann D, Calhoun K, Mugerwa-Kasujja A, Knighton CL. MMWR Morb Mortal Wkly Rep. 2023 Nov 10;72(45):1217-1224. doi: 10.15585/mmwr.mm7245a2. PMID: 37943705

Total-Body Multiparametric PET Quantification of ^{18}F-FDG Delivery and Metabolism in the Study of Coronavirus Disease 2019 Recovery.
Wang Y, Nardo L, Spencer BA, Abdelhafez YG, Li EJ, Omidvari N, Chaudhari AJ, Badawi RD, Jones T, Cherry SR, Wang G. J Nucl Med. 2023 Nov;64(11):1821-1830. doi: 10.2967/jnumed.123.265723. Epub 2023 Aug 17. PMID: 37591539

Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine.
Chaiwarith R, Winichakoon P, Salee P, Sudjaritruk T, Wipasa J, Chawansuntati K, Yasri S, Thongwitokomarn H, Krasaewes K, Ruangsirinusorn S, Praparattanapan J, Solai N, Nuket K, Boonmee D, Chaichana O, Mueangmo O, Saheng J, Wongjak W. Sci Rep. 2023 Nov 13;13(1):19736. doi: 10.1038/s41598-023-45735-7. PMID: 37957189

[[Translated article]]Symmetrical Drug-Related Intertriginous Flexural Exanthema Induced by the Pfizer/BioNTech Comirnaty COVID-19 Vaccine.
Román Mendoza NM, Luna Bastante L, Sánchez Gilo A, Vicente Martin FJ. Actas Dermosifiliogr. 2023 Nov 1:S0001-7310(23)00862-1. doi: 10.1016/j.ad.2023.10.029. Online ahead of print. PMID: 37923074

mRNA SARS-CoV-2 Vaccination Before vs During Pregnancy and Omicron Infection Among Infants.
Goh O, Pang D, Tan J, Lye D, Chong CY, Ong B, Tan KB, Yung CF. JAMA Netw Open. 2023 Nov 1;6(11):e2342475. doi: 10.1001/jamanetworkopen.2023.42475. PMID: 37948079

Resilience in childhood vaccination: analysing delivery system responses to shocks in Lebanon.
Ismail SA, Tomoaia-Cotisel A, Noubani A, Fouad FM, Bell S, Borghi J, Blanchet K. BMJ Glob Health. 2023 Nov;8(11):e012399. doi: 10.1136/bmjgh-2023-012399. PMID: 37931939

Rethinking Immunological Risk: A Retrospective Cohort Study of Severe SARS-Cov-2 Infections in Individuals With Congenital Immunodeficiencies.
Nguyen AA, Habiballah SB, LaBere B, Day-Lewis M, Elkins M, Al-Musa A, Chu A, Jones J, Fried AJ, McDonald D, Hoytema van Konijnenburg DP, Rockowitz S, Sliz P, Oettgen HC, Schneider LC, MacGinnitie A, Bartnikas LM, Platt CD, Ohsumi TK, Chou J. J Allergy Clin Immunol Pract. 2023 Nov;11(11):3391-3399.e3. doi: 10.1016/j.jaip.2023.07.042. Epub 2023 Aug 5. PMID: 37544429

Comparison of Four T-cell Assays and Two Binding Antibody Assays in SARS-CoV-2 Vaccinees With or Without Omicron Breakthrough Infection.
Seo YJ, Oh I, Nam M, Shin S, Roh EY, Song EY. Ann Lab Med. 2023 Nov 1;43(6):596-604. doi: 10.3343/alm.2023.43.6.596. Epub 2023 Jun 30. PMID: 37387492

[Clinical trials approved by Aifa for Covid-19: report of the main results to fill the unmet medical need.].
Confalonieri C, Orcesi A, Lasala R, Bolzoni M, Tansini M, Cattadori E. Recenti Prog Med. 2023 Nov;114(11):669-674. doi: 10.1701/4133.41270. PMID: 37902541

Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib.
Liu Z, Alexander JL, Eng KY, Ibraheim H, Anandabaskaran S, Saifuddin A, Constable L, Seoane RC, Bewshea C, Nice R, D'Mello A, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HRT, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Boyton RJ, Hart AL,

Lees CW, Goodhand JR, Kennedy NA, Pollock KM, Ahmad T, Powell N; VIP study investigators. J Crohns Colitis. 2023 Nov 6:jjad182. doi: 10.1093/ecco-jcc/jjad182. Online ahead of print. PMID: 37941436

Impact of Technological Developments on Infectious Disease Epidemiology: Lessons From the First 100 Years of the American Journal of Epidemiology.
Foxman B, Mehta S. Am J Epidemiol. 2023 Nov 3;192(11):1820-1826. doi: 10.1093/aje/kwac064. PMID: 35362021

How to debunk misinformation? An experimental online study investigating text structures and headline formats.
Kotz J, Giese H, König LM. Br J Health Psychol. 2023 Nov;28(4):1097-1112. doi: 10.1111/bjhp.12670. Epub 2023 Jun 1. PMID: 37263771

Schnitzler syndrome associated with recurrent subacute thyroiditis and SARS-CoV-2 vaccine-A case review.
Kanabaj K, Sokołowska-Wojdyło M, Wilkowska A, Nowicki RJ. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):e1264-e1265. doi: 10.1111/jdv.19305. Epub 2023 Jul 14. PMID: 37415365

Serial SARS-CoV-2 Antibody Titers in Vaccinated Dialysis Patients: Prevalence of Unrecognized Infection and Duration of Seroresponse.
Hsu CM, Weiner DE, Manley HJ, Li NC, Miskulin D, Harford A, Sanders R, Ladik V, Frament J, Argyropoulos C, Abreo K, Chin A, Gladish R, Salman L, Johnson D, Lacson EK Jr. Kidney Med. 2023 Aug 25;5(11):100718. doi: 10.1016/j.xkme.2023.100718. eCollection 2023 Nov. PMID: 37786901

Maternal vaccination provision in NHS maternity trusts across England.
Anderson EC, Blair PS, Finn A, Ingram J, Amirthalingam G, Cabral C. Vaccine. 2023 Nov 9:S0264-410X(23)01284-7. doi: 10.1016/j.vaccine.2023.10.069. Online ahead of print. PMID: 37951792

Exploration of mRNA nanoparticles based on DOTAP through optimization of the helper lipids.
Ma X, Wu F, Peng C, Chen H, Zhang D, Han T. Biotechnol J. 2023 Nov;18(11):e2300123. doi: 10.1002/biot.202300123. Epub 2023 Aug 10. PMID: 37545293

Severity of influenza-associated hospitalisations by influenza virus type and subtype in the USA, 2010-19: a repeated cross-sectional study.
Sumner KM, Masalovich S, O'Halloran A, Holstein R, Reingold A, Kirley PD, Alden NB, Herlihy RK, Meek J, Yousey-Hindes K, Anderson EJ, Openo KP, Monroe ML, Leegwater L, Henderson J, Lynfield R, McMahon M, McMullen C, Angeles KM, Spina NL, Engesser K, Bennett NM, Felsen CB, Lung K, Shiltz E, Thomas A, Talbot HK, Schaffner W, Swain A, George A, Rolfes MA, Reed C, Garg S. Lancet Microbe. 2023 Nov;4(11):e903-e912. doi: 10.1016/S2666-5247(23)00187-8. Epub 2023 Sep 25. PMID: 37769676

Antigen-loaded flagellate bacteria for enhanced adaptive immune response by intradermal injection.
Tao F, Ye Q, Chen Y, Luo L, Xu H, Xu J, Feng Z, Wang C, Li T, Wen Y, Hu Y, Dong H, Zhao X, Wu J. J Control Release. 2023 Nov 11;364:562-575. doi: 10.1016/j.jconrel.2023.10.055. Online ahead of print. PMID: 37926245

Lipid and cholesterols modulate the dynamics of SARS-CoV-2 viral ion channel ORF3a and its pathogenic variants.

Rout M, Mishra S, Panda S, Dehury B, Pati S. Int J Biol Macromol. 2023 Nov 8;254(Pt 3):127986. doi: 10.1016/j.ijbiomac.2023.127986. Online ahead of print. PMID: 37944718

Acquired immunity against SARS-CoV-2 infection and vaccination.
Renia L, Ng LF. EMBO Mol Med. 2023 Nov 15:e16345. doi: 10.15252/emmm.202216345. Online ahead of print. PMID: 37966373

A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants.
Kim DG, Kim U, Park IH, Ryu B, Yoo Y, Cha JS, Yoon GY, Kim SH, Oh H, Seo JY, Nam KT, Seong JK, Shin JS, Cho HS, Kim HS. Antiviral Res. 2023 Nov 7:105738. doi: 10.1016/j.antiviral.2023.105738. Online ahead of print. PMID: 37944822

'Unable to have a proper conversation over the phone about my concerns': a multimethods evaluation of the impact of COVID-19 on routine childhood vaccination services in London, UK.
Buck E, Burt J, Karampatsas K, Hsia Y, Whyte G, Amirthalingam G, Skirrow H, Le Doare K. Public Health. 2023 Nov 7;225:229-236. doi: 10.1016/j.puhe.2023.09.026. Online ahead of print. PMID: 37944278

Natural killer cell responses during SARS-CoV-2 infection and vaccination in people living with HIV-1.
Alrubayyi A, Touizer E, Hameiri-Bowen D, Charlton B, Gea-Mallorquí E, Hussain N, da Costa KAS, Ford R, Rees-Spear C, Fox TA, Williams I, Waters L, Barber TJ, Burns F, Kinloch S, Morris E, Rowland-Jones S, McCoy LE, Peppa D. Sci Rep. 2023 Nov 3;13(1):18994. doi: 10.1038/s41598-023-45412-9. PMID: 37923825

Mondor's disease following the third dose of BNT162b2 m-RNA COVID-19 vaccine.
Drago F, Cittadini G, Garlaschi A, Ciccarese G. Int J Dermatol. 2023 Nov 13. doi: 10.1111/ijd.16910. Online ahead of print. PMID: 37953650

An Exploratory Qualitative Analysis of Explanations for COVID-19-Related Racial Disparities Among St. Louis Residents: "I Don't Really Pay Attention to the Racial Stuff Very Much".
Kroll C, Johnson MA, Kepper MM, Verdecias N, Kreuter MW. Prev Chronic Dis. 2023 Nov 9;20:E100. doi: 10.5888/pcd20.230103. PMID: 37943728

The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study.
Tran HA, Deng L, Wood N, Choi P, Singleton S, Clarke L, Khanlari S, Maitland-Scott I, Bird R, Brown S, Manoharan B, Tan CW, Gold M, Hissaria P, Melody S, Chunilal S SD, Buttery J, Clothier H, Crawford NW, Phuong L, Pepperell D, Effler P, Parker C, Carter N, Macartney K, McStea M, Miller T, Nissen M, Larter C, Kay E, Chen VM. Lancet Reg Health West Pac. 2023 Sep 4;40:100894. doi: 10.1016/j.lanwpc.2023.100894. eCollection 2023 Nov. PMID: 37701717

Immune targets to stop future SARS-CoV-2 variants.
Silva Souza M, Pires Farias J, Barros Luiz W, Birbrair A, Durães-Carvalho R, de Souza Ferreira LC, Amorim JH. Microbiol Spectr. 2023 Nov 15:e0289223. doi: 10.1128/spectrum.02892-23. Online ahead of print. PMID: 37966210

Selective adaptation of SARS-CoV-2 Omicron under booster vaccine pressure: a multicentre observational study.

Duerr R, Dimartino D, Marier C, Zappile P, Wang G, François F, Ortigoza MB, Iturrate E, Samanovic MI, Mulligan MJ, Heguy A. EBioMedicine. 2023 Nov;97:104843. doi: 10.1016/j.ebiom.2023.104843. Epub 2023 Oct 20. PMID: 37866115

Factors for hesitancy towards vaccination against COVID-19 among the adult population in Puducherry, India - a cross sectional study.
Dinesh RJ, Dhanalakshmi R, Jency PJ, Srividya A, Vijayakumar B, Kumar A. BMC Public Health. 2023 Nov 10;23(1):2217. doi: 10.1186/s12889-023-17095-4. PMID: 37950181

Paediatric inflammatory multisystem syndrome in Canada: population-based surveillance and role of SARS-CoV-2 linkage.
El Tal T, Morin MP, Morris SK, Farrar DS, Berard RA, Kakkar F, Moore Hepburn C, Baerg K, Beaufils C, Bennett TL, Benseler SM, Beaudoin-Bussières G, Chan K, Cyr C, Dahdah N, Donner EJ, Drouin O, Edjoc R, Eljaouhari M, Embree JE, Farrell C, Finzi A, Forgie S, Giroux R, Kang KT, King M, Laffin Thibodeau M, Lang B, Laxer RM, Luu TM, McCrindle BW, Orkin J, Papenburg J, Pound CM, Price VE, Proulx-Gauthier JP, Purewal R, Sadarangani M, Salvadori MI, Thibeault R, Top KA, Viel-Thériault I, Haddad E, Scuccimarri R, Yeung RSM. Pediatr Res. 2023 Nov;94(5):1744-1753. doi: 10.1038/s41390-023-02668-1. Epub 2023 Jun 5. PMID: 37277605

The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study.
Inoue Y, Li Y, Yamamoto S, Fukunaga A, Ishiwari H, Ishii M, Miyo K, Ujiie M, Sugiura W, Ohmagari N, Mizoue T. Vaccine. 2023 Nov 7:S0264-410X(23)01220-3. doi: 10.1016/j.vaccine.2023.10.037. Online ahead of print. PMID: 37945490

Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2-neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy Japanese adults.
Okada H, Ishikawa K, Itoh Y, Noda Y, Eto T, Pilla Reddy V, Chen CC, Gibbs M, Johnsson E. J Infect Chemother. 2023 Nov;29(11):1061-1067. doi: 10.1016/j.jiac.2023.07.014. Epub 2023 Jul 29. PMID: 37524201

Strengthening the Pharmacovigilance System in Mexico: Implementation of VigiFlow and VigiLyze, as ICSR and Signal Detection Management Systems.
Rayón-Ramírez G, Alvarado-López S, Camacho-Sandoval R, Loera MJ, Svarch AE, Alcocer-Varela J. Pharmaceut Med. 2023 Nov;37(6):425-437. doi: 10.1007/s40290-023-00490-y. Epub 2023 Oct 7. PMID: 37804414

The Impact of Vaccination and SARS-CoV-2 Variants on the Virological Response to SARS-CoV-2 Infections during the Alpha, Delta, and Omicron waves in England.
Lunt R, Quinot C, Kirsebom F, Andrews N, Skarnes C, Letley L, Haskins D, Angel C, Firminger S, Ratcliffe K, Rajan S, Sherridan A, Ijaz S, Zambon M, Brown K, Ramsay M, Bernal JL. J Infect. 2023 Nov 3:S0163-4453(23)00547-9. doi: 10.1016/j.jinf.2023.10.016. Online ahead of print. PMID: 37926118

Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response.

Costard-Jäckle A, Schramm R, Fischer B, Rivinius R, Bruno R, Müller B, Zittermann A, Boeken U, Westenfeld R, Knabbe C, Gummert J. Clin Res Cardiol. 2023 Nov;112(11):1506-1516. doi: 10.1007/s00392-022-02075-2. Epub 2022 Aug 22. PMID: 35994091

Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders.
Fillmore NR, La J, Wu JT, Corrigan JK, Branch-Elliman W, Monach P, Brophy MT, Do NV, Munshi NC. Blood Adv. 2023 Nov 14;7(21):6767-6770. doi: 10.1182/bloodadvances.2023011063. PMID: 37647600

Disturbances of menstrual cycle after immunization against SARS-CoV-2 and their risk factors: Cross-sectional clinical study.
Lukac S, Hancke K, Janni W, Gruber T, Schmid M, El-Taie Z, Kersten M, Friedl TWP, Dayan D. Int J Gynaecol Obstet. 2023 Nov;163(2):445-452. doi: 10.1002/ijgo.15060. Epub 2023 Aug 28. PMID: 37635685

Are people living with HIV have a low vulnerability to omicron variant infection: results from a cross-sectional study in China.
Tan Y, Wu S, Guo W, Liu J, Ming F, Zou S, Tang W, Liang K, Yang J. BMC Infect Dis. 2023 Nov 14;23(1):795. doi: 10.1186/s12879-023-08768-x. PMID: 37964230

Evaluation of the COVID-19 Vaccination Campaign *¡Ándale! ¿Qué Esperas?* in Latinx Communities in California, June 2021-May 2022.
Nawaz S, Moon KJ, Anagbonu F, Trinh A, Escobedo L, Montiel GI. Public Health Rep. 2023 Nov 13:333549231204043. doi: 10.1177/00333549231204043. Online ahead of print. PMID: 37957827

Chronic alcohol use primes bronchial cells for altered inflammatory response and barrier dysfunction during SARS-CoV-2 infection.
Easley KF, Edenfield RC, Lott MEJ, Reed RC, Das Sarma J, Mehta AJ, Staitieh BS, Lipp EK, Cho IK, Johnson SK, Jones CA, Bebin-Blackwell AG, Levy JM, Tompkins SM, Easley CA 4th, Koval M. Am J Physiol Lung Cell Mol Physiol. 2023 Nov 1;325(5):L647-L661. doi: 10.1152/ajplung.00381.2022. Epub 2023 Oct 3. PMID: 37786945

Patient receptivity to receiving vaccinations in the dental clinic at a rural federally qualified health center.
Darisi RD, Hillier B, Buckland AJ, Harris E, Holzberg JR. J Am Dent Assoc. 2023 Nov 9:S0002-8177(23)00556-1. doi: 10.1016/j.adaj.2023.09.006. Online ahead of print. PMID: 37943218

The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
El-Ashwah S, Salmanton-García J, Bilgin YM, Itri F, Žák P, Weinbergerová B, Verga L, Omrani AS, Silva MGD, Szotkowski T, Marchetti M, Buquicchio C, Nucci M, Schönlein M, Farina F, Besson C, Prezioso L, Nizamuddin S, Dávila-Valls J, Martín-Pérez S, Bonuomo V, Van Doesum J, Tisi MC, Passamonti F, Méndez GA, Meers S, Maertens J, López-García A, Glenthøj A, Bonnani M, Rinaldi I, Ormazabal-Vélez I, Labrador J, Kulasekararaj A, Espigado I, Demirkan F, De Jonge N, Collins GP, Calbacho M, Blennow O, Al-Khabori M, Adžić-Vukičević T, Arellano E, Mišković B, Mladenović M, Nordlander A, Ráčil Z, Ammatuna E, Cordoba R, Hersby DS, Gräfe S, Emarah Z, Hanakova M, Sacchi MV, Ijaz M, Rahimli L, Nunes Rodrigues R, Zambrotta GPM, Marchesi F, Cornely OA, Pagano L. Leuk Lymphoma. 2023 Nov 15:1-10. doi: 10.1080/10428194.2023.2280886. Online ahead of print. PMID: 37966980

Vaccine Nationalism Counterintuitively Erodes Public Trust in Leaders.
Colombatto C, Everett JAC, Senn J, Maréchal MA, Crockett MJ. Psychol Sci. 2023 Nov 13:9567976231204699. doi: 10.1177/09567976231204699. Online ahead of print. PMID: 37955906

Polythylene glycol severe allergy and SARS-CoV-2 vaccines: usefulness of testing with PEG 1500 extract.
Gaspar A, Moura AL, Cruz C, Borrego LM. Eur Ann Allergy Clin Immunol. 2023 Nov;55(6):261-270. doi: 10.23822/EurAnnACI.1764-1489.275. Epub 2022 Dec 2. PMID: 36458507

Oral Chronic Graft-versus-Host Disease in Post-Hematopoietic Stem Cell Transplant Patients Following SARS-CoV-2 Vaccination: Case Reports.
Epstein JB, Hernandez RS, Nakamura R, Yost SE, Ali H. Case Rep Oncol. 2023 Nov 3;16(1):1287-1292. doi: 10.1159/000533821. eCollection 2023 Jan-Dec. PMID: 37928865

Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system.
Bruxvoort KJ, Sy LS, Hong V, Lewin B, Qian L, Huang X, Holmquist KJ, Han B, Xu S. Vaccine. 2023 Nov 10:S0264-410X(23)01324-5. doi: 10.1016/j.vaccine.2023.11.012. Online ahead of print. PMID: 37953096

Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time.
Kenny G, O'Reilly S, Wrigley Kelly N, Negi R, Gaillard C, Alalwan D, Saini G, Alrawahneh T, Francois N, Angeliadis M, Garcia Leon AA, Tinago W, Feeney ER, Cotter AG, de Barra E, Yousif O, Horgan M, Doran P, Stemler J, Koehler P, Cox RJ, O'Shea D, Olesen OF, Landay A, Hogan AE, Lelievre JD, Gautier V, Cornely OA, Mallon PWG; All Ireland Infectious Diseases Cohort Study; VACCELERATE Consortium EU-COVAT-1-AGED Part A Study Group. Nat Commun. 2023 Nov 2;14(1):7015. doi: 10.1038/s41467-023-42717-1. PMID: 37919289

A Pan-Ebolavirus Monoclonal Antibody Cocktail Provides Protection Against Ebola and Sudan Viruses.
Liu G, He S, Chan M, Zhang Z, Schulz H, Cao W, Rahim MN, Audet J, Garnett L, Wec A, Chandran K, Qiu X, Banadyga L. J Infect Dis. 2023 Nov 13;228(Supplement_7):S691-S700. doi: 10.1093/infdis/jiad205. PMID: 37288609

Optimisation of SARS-CoV-2 peptide stimulation and measurement of cytokine output by intracellular flow cytometry and bio-plex analysis.
Taylor JV, Callery EL, Rowbottom A. J Immunol Methods. 2023 Nov;522:113556. doi: 10.1016/j.jim.2023.113556. Epub 2023 Sep 6. PMID: 37683822

Thrombotic microangiopathy concurrent with disseminated intravascular coagulation after SARS-CoV-2 vaccination.
Wen YK. Clin Nephrol. 2023 Nov;100(5):237-239. doi: 10.5414/CN111208. PMID: 37485884

Plasma from patients with Vaccine-induced immune thrombotic thrombocytopenia displays increased fibrinolytic potential and enhances tPA but not uPA-mediated plasminogen activation.
Keragala CB, McFadyen JD, Ho H, McCutcheon FM, Liu Z, Stevens H, Monagle P, Chunilal S, Medcalf RL, Tran H. J Thromb Haemost. 2023 Nov 7:S1538-7836(23)00797-3. doi: 10.1016/j.jtha.2023.10.027. Online ahead of print. PMID: 37944898

A deterministic compartmental model for the transition between variants in the spread of Covid-19 in Italy.
Saviano M, Fierro A, Liccardo A. PLoS One. 2023 Nov 14;18(11):e0293416. doi: 10.1371/journal.pone.0293416. eCollection 2023. PMID: 37963148

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults.
Roa CC Jr, de Los Reyes MRA, Plennevaux E, Smolenov I, Hu B, Gao F, Ilagan H, Ambrosino D, Siber G, Clemens R. J Infect Dis. 2023 Nov 2;228(9):1253-1262. doi: 10.1093/infdis/jiad262. PMID: 37439701

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
Dayan GH, Rouphael N, Walsh SR, Chen A, Grunenberg N, Allen M, Antony J, Asante KP, Bhate AS, Beresnev T, Bonaparte MI, Celle M, Ceregido MA, Corey L, Dobrianskyi D, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Kee JJ, Kibuuka H, Koutsoukos M, Masotti R, Michael NL, Neuzil KM, Reynales H, Robb ML, Villagómez Martínez SM, Sawe F, Schuerman L, Tong T, Treanor J, Wartel TA, Diazgranados CA, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00008 Study Team. Lancet Respir Med. 2023 Nov;11(11):975-990. doi: 10.1016/S2213-2600(23)00263-1. Epub 2023 Sep 13. PMID: 37716365

Stanford Vax Crew: A Model for Agile, Community-Centered Vaccination Campaigns.
Cheng M, Murtagh C, Macias B, Torres DT, Newman W. Health Secur. 2023 Nov 14. doi: 10.1089/hs.2023.0027. Online ahead of print. PMID: 37962567

Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave.
Goh YS, Fong SW, Tay MZ, Rouers A, Chang ZW, Chavatte JM, Hor PX, Loh CY, Huang Y, Tan YJ, Wang B, Ngoh EZX, Mohd Salleh SN, Lee RTC, Lim G; NCID Study Group; COVID-Study Group; Maurer-Stroh S, Wang CI, Leo YS, Lin RTP, Lam MC, Lye DC, Young BE, Ng LFP, Renia L. Sci Rep. 2023 Nov 7;13(1):19331. doi: 10.1038/s41598-023-46800-x. PMID: 37935965

The Impact Of Provincial Proof- Of-Vaccination Policies On Age-Specific First-Dose Uptake Of COVID-19 Vaccines In Canada.
Fitzpatrick T, Camillo CA, Hillis S, Habbick M, Roerig M, Muhajarine N, Allin S. Health Aff (Millwood). 2023 Nov;42(11):1595-1605. doi: 10.1377/hlthaff.2022.01237. PMID: 37931201

Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
Mori Y, Uchida N, Wake A, Miyawaki K, Eto T, Nakamura T, Iwasaki H, Ito Y, Tanimoto K, Katayama Y, Imamura Y, Takahashi T, Fujisaki T, Kamimura T, Choi I, Ishitsuka K, Yoshimoto G, Ogawa R, Sugita J, Takamatsu Y, Tanimoto K, Hidaka T, Miyamoto T, Akashi K, Nagafuji K. Vaccine. 2023 Nov 13;41(47):6899-6903. doi: 10.1016/j.vaccine.2023.08.066. Epub 2023 Oct 20. PMID: 37866994

Designing Cell Delivery Peptides and SARS-CoV-2-Targeting Small Interfering RNAs: A Comprehensive Bioinformatics Study with Generative Adversarial Network-Based Peptide Design and *In Vitro* Assays.
González RD, Simões S, Ferreira L, Carvalho ATP. Mol Pharm. 2023 Nov 8. doi: 10.1021/acs.molpharmaceut.3c00444. Online ahead of print. PMID: 37941379

Effect of biologic therapy on the humoral immune response to the BNT162b2 vaccine in patients with asthma.
Shirata M, Ito I, Oguma T, Nagasaki T, Oi I, Hamao N, Nishioka K, Hirai T. Respir Investig. 2023 Nov;61(6):733-737. doi: 10.1016/j.resinv.2023.07.006. Epub 2023 Sep 13. PMID: 37714091

Iatrogenic encephalopathy or reversible splenial lesion syndrome (RESLES)?
Cerimagic D. Clin Neurol Neurosurg. 2023 Nov 4;235:108046. doi: 10.1016/j.clineuro.2023.108046. Online ahead of print. PMID: 37949040

A 51-Year-Old Woman With Progressive Dyspnea and Diffuse Bilateral Pulmonary Nodules.
Boonsong T, Nakwan N, Chareonlap C, Kaenmuang P, Kanjanapradit K, Chang A. Chest. 2023 Nov;164(5):e147-e150. doi: 10.1016/j.chest.2023.06.003. Epub 2023 Nov 7. PMID: 37945197

Effects of Vaccination on the Two-strain Transmission Dynamics of COVID-19: Dougherty County, Georgia, USA as a Case Study.
Pantha B, Mohammed-Awel J, Vaidya NK. Math Med Biol. 2023 Nov 14:dqad007. doi: 10.1093/imammb/dqad007. Online ahead of print. PMID: 37963602

Comparison of SARS-CoV-2 Vaccination Skepticism, Reasons, and Concerns Between Mass Vaccination Centers and General Practices in Germany 2021.
Schrimpf A, Jentzsch A, Geier AK, Bleckwenn M. Patient Prefer Adherence. 2023 Nov 7;17:2855-2870. doi: 10.2147/PPA.S433331. eCollection 2023. PMID: 37953979

Willingness to receive and recommend hypothetical mpox vaccination and associated factors in Chinese adults: a community-based survey in Shenzhen, China.
Ren F, Miao J, Liu J, Xia B, Chen Z, Xu Y, Zhang R, Fan J, Lin W. Public Health. 2023 Nov 10;225:267-276. doi: 10.1016/j.puhe.2023.10.014. Online ahead of print. PMID: 37952343

Corporate Moral Responsibility, Distributive Justice, the Common Good, and Catholic Social Teaching: The Case of Gilead Sciences and Remdesivir.
Ballano I. Linacre Q. 2023 Nov;90(4):437-451. doi: 10.1177/00243639221116216. Epub 2022 Aug 22. PMID: 37969421

Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer.
Rodilla AM, Valanparambil RM, Mack PC, Hsu CY, Cagan J, Tavolacci SC, Carreño JM, Brody R, Moore A, King JC, Gomez JE, Rohs N, Rolfo C, Bunn PA Jr, Gerber DE, Minna JD, Krammer F, Ramalingam SS, García-Sastre A, Shyr Y, Ahmed R, Hirsch FR. Cancer Cell. 2023 Nov 13;41(11):1838-1840. doi: 10.1016/j.ccell.2023.09.017. Epub 2023 Oct 19. PMID: 37863065

Identifying Barriers to HPV Vaccination for Patients With Sickle Cell Disease and Childhood Cancer Survivors.
Rahim MQ, Jacob SA, Coven SL, Miller M, Meagher CG, Lozano G, Zimet G, Ott MA. J Pediatr Hematol Oncol. 2023 Nov 1;45(8):e940-e947. doi: 10.1097/MPH.0000000000002752. Epub 2023 Sep 8. PMID: 37696002

The potential of anti-coronavirus plant secondary metabolites in COVID-19 drug discovery as an alternative to repurposed drugs: a review.
Alipour Z, Zarezadeh S, Ghotbi-Ravandi AA. Planta Med. 2023 Nov 13. doi: 10.1055/a-2209-6357. Online ahead of print. PMID: 37956978

Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial.
Hill M, Iro M, Sadarangani M, Absoud M, Cantrell L, Chong K, Clark C, Easton A, Gray V, Kneen R, Lim M, Liu X, Pike M, Solomon T, Vincent A, Willis L, Yu LM, Pollard AJ; IgNiTE study team. BMJ Open. 2023 Nov 9;13(11):e072134. doi: 10.1136/bmjopen-2023-072134. PMID: 37945292

Effectiveness of the Original Monovalent Coronavirus Disease 2019 Vaccines in Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Adults With Disabilities: VISION Network, June 2021-September 2022.
Patel P, Schrader KE, Rice CE, Rowley E, Cree RA, DeSilva MB, Embi PJ, Gaglani M, Grannis SJ, Ong TC, Stenehjem E, Naleway AL, Ball S, Natarajan K, Klein NP, Adams K, Kharbanda A, Ray C, Link-Gelles R, Tenforde MW. Open Forum Infect Dis. 2023 Sep 29;10(11):ofad474. doi: 10.1093/ofid/ofad474. eCollection 2023 Nov. PMID: 37965644

Psychometric validation of a 7C-model of antecedents of vaccine acceptance among healthcare workers, parents and adolescents in France.
Oudin Doglioni D, Gagneux-Brunon A, Gauchet A, Bruel S, Olivier C, Pellissier G, Thilly N, Sicsic J, Raude J, Mueller JE. Sci Rep. 2023 Nov 14;13(1):19895. doi: 10.1038/s41598-023-46864-9. PMID: 37963903

Immune escape of SARS-CoV-2 variants to therapeutic monoclonal antibodies: a system review and meta-analysis.
Shi H, Sun J, Zeng Y, Wang X, Liu S, Zhang L, Shao E. Virol J. 2023 Nov 15;20(1):266. doi: 10.1186/s12985-023-01977-5. PMID: 37968649

The impact of frailty syndrome on humoral response to SARS-CoV-2 mRNA vaccines in older kidney transplant recipients.
Schmalz M, Vankova H, Rajnochova-Bloudickova S, Hruba P, Fialova M, Gurka J, Magicova M, Striz I, Zahradka I, Viklicky O. Int Urol Nephrol. 2023 Nov;55(11):2959-2965. doi: 10.1007/s11255-023-03557-6. Epub 2023 Apr 7. PMID: 37027078

Evaluation of Humoral Response following SARS-CoV-2 mRNA-Based Vaccination in Liver Transplant Recipients Receiving Tailored Immunosuppressive Therapy.
Manzia TM, Sensi B, Conte LE, Siragusa L, Angelico R, Frongillo F, Tisone G. J Clin Med. 2023 Nov 3;12(21):6913. doi: 10.3390/jcm12216913. PMID: 37959382

Treatments and Severe Outcomes for Patients Diagnosed With MIS-C at Four Children's Hospitals in the United States, March 16, 2020-March 10, 2021.
Shah AB, Abrams JY, Godfred-Cato S, Kunkel A, Hammett TA, Perez MA, Hsiao HM, Baida N, Rostad CA, Ballan W, Ede K, Laham FR, Kao CM, Oster ME, Belay ED. Pediatr Infect Dis J. 2023 Nov 1;42(11):990-998. doi: 10.1097/INF.0000000000004065. Epub 2023 Oct 11. PMID: 37862698

COVID-19 Vaccination-related Complex Regional Pain Syndrome Masquerading as Erythromelalgia: A Case Report.

Lorentzen KL, Bygum A. Acta Derm Venereol. 2023 Nov 13;103:adv13400. doi: 10.2340/actadv.v103.13400. PMID: 37955530

Mechanistic and thermodynamic characterization of antiviral inhibitors targeting nucleocapsid N-terminal domain of SARS-CoV-2.
Dhaka P, Singh A, Choudhary S, Peddinti RK, Kumar P, Sharma GK, Tomar S. Arch Biochem Biophys. 2023 Nov 11:109820. doi: 10.1016/j.abb.2023.109820. Online ahead of print. PMID: 37956938

Intranasal G5-BGG/pDNA vaccine elicits protective systemic and mucosal immunity against SARS-CoV-2 by transfecting mucosal dendritic cells.
Zhang H, Liu Z, Lihe H, Lu L, Zhang Z, Yang S, Meng N, Xiong Y, Fan X, Chen Z, Lu W, Xie C, Liu M. Adv Healthc Mater. 2023 Nov 14:e2303261. doi: 10.1002/adhm.202303261. Online ahead of print. PMID: 37961920

SARS-CoV-2 vaccination can only be held responsible for tinnitus after alternative pathophysiology has been ruled out.
Finsterer J, Scorza FA. Am J Otolaryngol. 2023 Nov-Dec;44(6):103998. doi: 10.1016/j.amjoto.2023.103998. Epub 2023 Jul 10. PMID: 37454431

Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients.
Capecchi M, De Leo P, Abbattista M, Mancini I, Agosti P, Biganzoli M, Suffritti C, Ferrari B, Lecchi A, La Marca S, Padovan L, Scalambrino E, Clerici M, Tripodi A, Artoni A, Gualtierotti R, Peyvandi F. Haematologica. 2023 Nov 1;108(11):3152-3155. doi: 10.3324/haematol.2022.282478. PMID: 36951158

Skin atrophy after skin tests with corticosteroids for the diagnosis of SARS-CoV-2 vaccine excipients hypersensitivity.
Fabbri V, Ortolani VGR, Caron L, Bono L, Ratti CP, Iemoli E. Eur Ann Allergy Clin Immunol. 2023 Nov;55(6):319-322. doi: 10.23822/EurAnnACI.1764-1489.282. Epub 2023 Jan 13. PMID: 36637174

Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit.
Hsieh HC, Chen CC, Chou PH, Liu WC, Wu SC. Antiviral Res. 2023 Nov 8:105752. doi: 10.1016/j.antiviral.2023.105752. Online ahead of print. PMID: 37949318

Epidemiology of respiratory viruses among children during the SARS-CoV-2 pandemic: A systematic review and meta-analysis.
Dallmeyer LK, Schüz ML, Fragkou PC, Omony J, Krumbein H, Dimopoulou D, Dimopoulou K, Skevaki C. Int J Infect Dis. 2023 Nov 9:S1201-9712(23)00761-0. doi: 10.1016/j.ijid.2023.10.023. Online ahead of print. PMID: 37951460

Addressing Antivaccine Sentiment on Public Social Media Forums Through Web-Based Conversations Based on Motivational Interviewing Techniques: Observational Study.
Scales D, Hurth L, Xi W, Gorman S, Radhakrishnan M, Windham S, Akunne A, Florman J, Leininger L, Gorman J. JMIR Infodemiology. 2023 Nov 14;3:e50138. doi: 10.2196/50138. PMID: 37962940

A multi-platform approach to identify a blood-based host protein signature for distinguishing between bacterial and viral infections in febrile children (PERFORM): a multi-cohort machine learning study.
Jackson HR, Zandstra J, Menikou S, Hamilton MS, McArdle AJ, Fischer R, Thorne AM, Huang H, Tanck MW, Jansen MH, De T, Agyeman PKA, Von Both U, Carrol ED, Emonts M, Eleftheriou I, Van der Flier M, Fink C, Gloerich J, De Groot R, Moll HA, Pokorn M, Pollard AJ, Schlapbach LJ, Tsolia MN, Usuf E, Wright VJ, Yeung S, Zavadska D, Zenz W, Coin LJM, Casals-Pascual C, Cunnington AJ, Martinon-Torres F, Herberg JA, de Jonge MI, Levin M, Kuijpers TW, Kaforou M; PERFORM consortium. Lancet Digit Health. 2023 Nov;5(11):e774-e785. doi: 10.1016/S2589-7500(23)00149-8. PMID: 37890901

Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses.
Novak F, Bajwa HM, Coia JE, Nilsson AC, Nielsen C, Holm DK, Østergaard K, Hvidt MVM, Byg KE, Johansen IS, Mittl K, Rowles W, Zamvil SS, Bove R, Sabatino JJ Jr, Sejbaek T. J Neurol Neurosurg Psychiatry. 2023 Nov;94(11):934-937. doi: 10.1136/jnnp-2022-330757. Epub 2023 Apr 25. PMID: 37185261

Identification of key mutations responsible for the enhancement of receptor-binding affinity and immune escape of SARS-CoV-2 Omicron variant.
Wang WB, Ma YB, Lei ZH, Zhang XF, Li J, Li SS, Dong ZY, Liang Y, Li QM, Su JG. J Mol Graph Model. 2023 Nov;124:108540. doi: 10.1016/j.jmgm.2023.108540. Epub 2023 Jun 9. PMID: 37352723

Determinants of parental self-reported uptake of influenza vaccination in preschool children during the COVID-19 pandemic.
Qu S, Yang M, He W, Xie H, Zhou M, Campy KS, Tao X. Hum Vaccin Immunother. 2023 Dec 15;19(3):2268392. doi: 10.1080/21645515.2023.2268392. Epub 2023 Nov 14. PMID: 37964617

Flying Into the Future With Large Language Models.
Kanjilal S. Clin Infect Dis. 2023 Nov 14:ciad635. doi: 10.1093/cid/ciad635. Online ahead of print. PMID: 37963099

Impact of COVID-19 on care-seeking patterns for hay fever in Japan: A retrospective claims database cohort study.
Akasaki Y, Iwagami M, Sung J, Nagino K, Adachi T, Morita H, Tamari M, Kainuma K, Kan-O K, Ogata H, Sakashita M, Futamura M, Kurashima Y, Nakajima S, Masaki K, Ogawa Y, Sato S, Miyagawa A, Midorikawa-Inomata A, Fujimoto K, Okumura Y, Fujio K, Huang T, Hirosawa K, Morooka Y, Nakao S, Murakami A, Kobayashi H, Inomata T. Allergy. 2023 Nov 15. doi: 10.1111/all.15947. Online ahead of print. PMID: 37966466

A CAF01-adjuvanted whole asexual blood-stage liposomal malaria vaccine induces a $CD4^+$ T-cell-dependent strain-transcending protective immunity in rodent models.
Okoth WA, Ho M-F, Zaman M, Cooper E, Som P, Burgess M, Walton M, Nevagi RJ, Beattie L, Murphy D, Stanisic DI, Good MF. mBio. 2023 Nov 14:e0254723. doi: 10.1128/mbio.02547-23. Online ahead of print. PMID: 37962347

SARS-CoV-2 vaccination in primary antibody deficiencies: an overview on efficacy, immunogenicity, durability of immune response and safety.
Cusa G, Sardella G, Garzi G, Firinu D, Milito C. Curr Opin Allergy Clin Immunol. 2023 Nov 15. doi: 10.1097/ACI.0000000000000955. Online ahead of print. PMID: 37962877

Immune thrombocytopenic purpura in an elderly patient with cerebral hemorrhage after the fourth mRNA-1273 COVID-19 vaccination.
Kobayashi M, Kobayashi S, Hayashi T, Tachibana M, Saito T, Ogura K, Miyakoshi S. Geriatr Gerontol Int. 2023 Nov 15. doi: 10.1111/ggi.14737. Online ahead of print. PMID: 37967853

Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines.
Leach AJ, Wilson N, Arrowsmith B, Beissbarth J, Mulholland EK, Santosham M, Torzillo PJ, McIntyre P, Smith-Vaughan H, Skull SA, Oguoma VM, Chatfield M, Lehmann D, Binks MJ, Licciardi PV, Andrews R, Snelling T, Krause V, Carapetis J, Chang AB, Morris PS. Int J Pediatr Otorhinolaryngol. 2023 Nov 6;175:111776. doi: 10.1016/j.ijporl.2023.111776. Online ahead of print. PMID: 37951020

Reverse Engineering of a Pathogenic Antibody Reveals the Molecular Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia.
Ivanov DG, Ivetic N, Du Y, Nguyen SN, Le SH, Favre D, Nazy I, Kaltashov IA. J Am Chem Soc. 2023 Nov 10. doi: 10.1021/jacs.3c07846. Online ahead of print. PMID: 37949820

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20231101:20231115 as the publication date 77 records*

1.WO/2023/207717DEVELOPMENT AND USE OF BROAD-SPECTRUM VACCINE FOR H5N8 AVIAN INFLUENZA
WO - 02.11.2023
Clasificación Internacional C12N 7/01 Nº de solicitud PCT/CN2023/089267 Solicitante NANJING ADVANCED ACADEMY OF LIFE AND HEALTH Inventor/a WANG, Guiqin
Provided are development and use of a broad-spectrum vaccine for H5N8 avian influenza, and particularly, provided are preparation methods for a recombinant protein vaccine, an inactivated vaccine and a nucleic acid vaccine, and use thereof. Experiments show that the prepared recombinant protein vaccine, inactivated vaccine and nucleic acid vaccine can effectively prevent infection with avian influenza virus.

2.WO/2023/211281ANTIVIRAL VACCINE COMPOSITION
WO - 02.11.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/NL2023/050232 Solicitante ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM Inventor/a KATSIKIS, Peter D.
The present invention provides an antiviral vaccine composition, comprising a viral coat, matrix or core/capsid (glyco)protein as antigen, and an adjuvant combination of a CpG oligonucleotide and a STING agonist.

3.20230348935VACCINE COMPOSITIONS FOR MUCOSAL IMMUNE RESPONSE
US - 02.11.2023
Clasificación Internacional A61K 9/19 Nº de solicitud 18246279 Solicitante NANT HOLDINGS IP, LLC Inventor/a Patrick SOON-SHIONG Vaccine compositions are provided that comprise a lyophilized, adenovirus-based expression vector, and a stabilizing compound, such as such as aragonite. Further provided are compositions that include a solid dosage form made from aragonite for loading and delivery of a vaccine composition.

4.WO/2023/213946NEW MULTIVALENT HVT VECTOR VACCINE
WO - 09.11.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2023/061805 Solicitante INTERVET INTERNATIONAL B.V. Inventor/a LANGEREIS, Martijn, Alexander
The present invention regards a new recombinant HVT (rHVT) construct, useful as multivalent vector vaccine for poultry. The rHVT comprises 4 heterologous genes from poultry pathogens: the VP2 gene from IBDV, the F gene from NDV, and the gD and gI genes from ILTV. The VP2 and F genes are inserted in the Us genome region of the rHVT. The gD-gI genes are inserted in the UL genome region, between the UL54 and the LORF3 genes. The new rHVT-VP2-F-gD-gI proved to be genetically stable in vitro and in vivo, and expressed all inserted genes well. Also it was an effective vaccine against severe challenge infections with NDV, IBDV, and ILTV.

5.20230346904BACTERIAL AND VIRAL VACCINE STRATEGY
US - 02.11.2023
Clasificación Internacional A61K 39/095 Nº de solicitud 17988688 Solicitante ORBIS HEALTH SOLUTIONS LLC Inventor/a Thomas E. Wagner

The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making bacterial and viral vaccines

6.20230355738BACTERIOPHAGE-BASED, NEEDLE AND ADJUVANT-FREE, MUCOSAL COVID-19 VACCINE
US - 09.11.2023
Clasificación Internacional A61P 37/04 Nº de solicitud 18138183 Solicitante The Catholic University of America Inventor/a Venigalla B. RAO
A bacteriophage T4-based, multivalent/multicomponent, needle and adjuvant-free, mucosal vaccine by engineering spike trimers on capsid exterior and nucleocapsid protein in the interior is disclosed herein. Intranasal administration of this T4-COVID vaccine induces higher virus neutralization antibody titers against multiple variants, balanced Th1/Th2 antibody and cytokine responses, stronger $CD4^+$ and $CD8^+$ T cell immunity, and higher secretory IgA titers in sera and bronchoalveolar lavage with no effect on the gut microbiota, compared to vaccination of mice intramuscularly. The vaccine is stable at ambient temperature, induce apparent sterilizing immunity, and provide complete protection against original SARS-CoV-2 strain and its Delta variant with minimal lung histopathology. This mucosal vaccine is an excellent candidate for boosting immunity of immunized and/or as a second-generation vaccine for the unimmunized population. This needle-free platform could be used to develop effective vaccines against many other respiratory infectious pathogens including Flu and any future emerging epidemic and pandemic pathogens.

7.20230355748DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF
US - 09.11.2023
Clasificación Internacional A61K 39/295 Nº de solicitud 18149742 Solicitante Takeda Vaccines, Inc. Inventor/a Derek WALLACE
The invention relates to a single unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

8.20230346935TUMOR COMPLEX ANTIGEN, MULTIVALENT DENDRITIC CELL (DC) VACCINE, AND USE THEREOF

US - 02.11.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18246194 Solicitante Helen LIU Inventor/a Helen LIU
A tumor complex antigen, a multivalent dendritic cell (DC) vaccine, and a use thereof are provided. In the present disclosure, monocytes of a patient are stimulated in vitro, loaded with a variety of tumor cell lysates with strong immunogenicity against different Epstein-Barr virus (EBV)-associated tumors, and induced into mature dendritic cells (mDCs) by various cytokines and specific agonists to obtain a complete DC vaccine with corresponding tumor antigens. The DC vaccine can be injected back into the patient to activate an immune system, stimulate innate immunity (such as inducing natural killer (NK) cells), and stimulate lymphocytes to produce an acquired immune response and cytotoxic T cells, thereby accurately killing tumor cells. Compared with radiotherapy and chemotherapy, the DC vaccine is particularly safe and has almost no side effects. In addition, the production of the DC vaccine involves a short production cycle of about 1 week and a low cost.

9.WO/2023/209556A BACTERIOPHAGE-BASED, NEEDLE AND ADJUVANT-FREE, MUCOSAL COVID-19 VACCINE
WO - 02.11.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/IB2023/054229 Solicitante THE CATHOLIC UNIVERSITY OF AMERICA Inventor/a RAO, Venigalla B.
A bacteriophage T4-based, multivalent/multicomponent, needle and adjuvant-free, mucosal vaccine by engineering spike trimers on capsid exterior and nucleocapsid protein in the interior is disclosed herein. Intranasal administration of this T4-COVID vaccine induces higher virus neutralization antibody titers against multiple variants, balanced Th1/Th2 antibody and cytokine responses, stronger $CD4^+$ and $CD8^+$ T cell immunity, and higher secretory IgA titers in sera and bronchoalveolar lavage with no effect on the gut microbiota, compared to vaccination of mice intramuscularly. The vaccine is stable at ambient temperature, induce apparent sterilizing immunity, and provide complete protection against original SARS-CoV-2 strain and its Delta variant with minimal lung histopathology. This mucosal vaccine is an excellent candidate for boosting immunity of immunized and/or as a second-generation vaccine for the unimmunized population. This needle-free platform could be used to develop effective vaccines against many other respiratory infectious pathogens including Flu and any future emerging epidemic and pandemic pathogens.

10.4271405IMMUNOGENE UND IMPFSTOFFZUSAMMENSETZUNGEN GEGEN SCHWEINEDYSENTERIE
EP - 08.11.2023
Clasificación Internacional A61K 39/02 Nº de solicitud 21845070 Solicitante HIPRA SCIENT S L U Inventor/a OSORIO ARGUELLO JESÚS MARÍA
The invention relates to an immunogenic or vaccine composition comprising an inactivated bacterium from the species Brachyspira hyodysenteriae, to a method for producing said composition and to the medical use of this composition for inducing an immune response against a bacterium from the species Brachyspira hyodysenteriae or for protecting against an infection caused by a bacterium from the species Brachyspira hyodysenteriae. Further, the invention relates to a method for selecting a bacterium from the species Brachyspira hyodysenteriae useful for manufacturing a vaccine against swine dysentery.

11.20230346924MRNA VACCINE COMPRISING ADJUVANT CAPABLE OF KINETIC CONTROL
US - 02.11.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 18040318 Solicitante PROGENEER INC. Inventor/a Yong Taik Lim

The present invention relates to an mRNA vaccine comprising an adjuvant of which an immune activating function is kinetically controlled and, more specifically, to an mRNA vaccine comprising an adjuvant characterized in that, after mRNA is transcribed into proteins, the activating function of the adjuvant is sequentially active. The present invention relates to a key technology for optimizing the time interval between mRNA antigen expression and immune activation in order to effectively control antigen expression and antigen immunogenicity, which conflict. In order to optimize an mRNA antigen expression amount and the active time of an adjuvant, the present invention provides a key technology, which kinetically controls the action of an immune activating substance to increase the expression amount and immunogenicity of an antigen at the same time, and thus remarkably increases the efficacy of an mRNA vaccine.

12.20230346901METHODS AND VACCINE COMPOSITIONS TO TREAT CANCERS
US - 02.11.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 17786908 Solicitante INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor/a Jean-Luc POYET

The present invention relates to a method for obtaining a population of oncogenic cells modified comprising the following steps: i) obtaining a population of oncogenic cells from a subject suffering from a cancer; and ii) treating said cells with a fusion protein comprising an AAC-11 leucine-zipper (LZ) derived peptide which is fused to at least one heterologous polypeptide. Inventors have evaluated here the antileukemic efficacy of RT53, an anticancer peptide with potential immunological properties. Their results indicate that RT53 possesses a direct antileukemic effect, even at late stage. They also demonstrated that single injection of a vaccine consisting of leukemic blasts exposed to RT53, which induces the hallmarks of immunogenic cell death, was highly effective in preventing leukemia development in both prophylactic and therapeutic settings. The vaccine comprising RT53-treated APL cells generated long-term antileukemic protection and depletion experiments indicated that CD4+ T cells were of crucial importance for vaccine efficacy. Combined, their results provide the rational for the exploration of RT53-based therapies for the treatment of cancer, such as acute leukemia.

13.20230346913PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA
US - 02.11.2023
Clasificación Internacional A61K 39/145 Nº de solicitud 18350646 Solicitante DYADIC INTERNATIONAL INC. Inventor/a Mark EMALFARB
Recombinant expression of influenza virus surface proteins in the fungus *Myceliophthora thermophila* strain C1 is provided. The recombinant proteins are for use in influenza vaccine compositions.

14.4272755KOMBINIERTER IMPFSTOFF ZUR PRÄVENTION VON HAND-, FUSS- UND MUNDERKRANKUNGEN, HERSTELLUNGSVERFAHREN DAFÜR UND VERWENDUNG DAVON
EP - 08.11.2023
Clasificación Internacional A61K 39/125 Nº de solicitud 20967606 Solicitante SINOVAC BIOTECH CO LTD Inventor/a LI YAJING
Disclosed is a combination vaccine for preventing HFMD, comprising inactivated Enterovirus type 71, and inactivated Coxsackievirus A group type 16, type 10 and type 6. Also disclosed is the method for the preparation of the combination vaccine. The adsorption effect and stability of the prepared vaccine are good. The above antigens do not interfere with each other's antigenicity and immune effect after immunizing the subject, and have good immunogenicity and safety. The application of the combination vaccine can significantly simplify the vaccination process, improve vaccination efficiency and reduce costs.

15.20230355742FUSION GENE, RECOMBINANT NOVEL CORONAVIRUS HIGH-EFFICIENCY IMMUNE DNA VACCINE, CONSTRUCTION METHOD AND USE THEREOF
US - 09.11.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18013663 Solicitante Aurora Genevac Biotech Co., Ltd. Inventor/a Jiyun YU
A fusion gene, a recombinant novel coronavirus high-efficiency immune DNA vaccine, a construction method and use thereof are provided. The immune DNA vaccine ZD-nCor19 provided herein uses RBD protein, residues 301-538 in the S2 subunit and residues 138-369 in the N protein of the novel coronavirus as target antigens, and has specific immune synergism molecules introduced at suitable positions, and thus can simultaneously efficiently induce humoral immunity and cellular immunity, and can avoid safety problems associated with ADE that may be generated by the full-length S protein and the full-length N protein, thereby achieving dual effects of prevention and treatment. The vaccine can be used as a safe, efficient and stable vaccine variety against novel coronavirus infection.

16.20230346905PENTAVALENT VACCINE AGAINST NEISSERIA MENINGITIDIS COMPRISING A SYNTHETIC MEN A ANTIGEN
US - 02.11.2023
Clasificación Internacional A61K 39/095 Nº de solicitud 18042355 Solicitante GlaxosmithKline Biologicals SA Inventor/a Roberto ADAMO
The inventors have identified a combined vaccine for immunisation against bacterial meningitis caused by multiple pathogens.

17.4267179MULTIVALENTER HVT-VEKTORIMPFSTOFF
EP - 01.11.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21847469 Solicitante INTERVET INT BV Inventor/a LANGEREIS MARTIJN ALEXANDER
The present invention regards recombinant HVT (rHVT) constructs, useful as multivalent vector vaccine for poultry. The rHVT comprise 4 heterologous genes from poultry pathogens: the VP2 gene from IBDV, the F gene from NDV, and the gD and gl genes from ILTV. The VP2 and F genes are inserted in the Us genome region of the rHVT. The gD-gl genes are inserted in the UL genome region, either between UL44 and UL45, or between UL45 and UL46. The rHVTs proved to be genetically stable in vitro and in vivo, and expressed all inserted genes well enough to induce protective immunity in vaccinated poultry against IBDV, NDV, and ILTV.

18.4267182TEMPERATURSTABILES NUKLEINSÄUREVERFAHREN ZUR HERSTELLUNG EINES IMPFSTOFFS
EP - 01.11.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 21916373 Solicitante GJERDE DOUGLAS T Inventor/a GJERDE DOUGLAS T
Nucleic acid and the nanocomplex reagents are combined to create a vaccine. They are stable and stored separately without degradation. The vaccine components can be stored at a wide range of temperatures. The nucleic acids are stabilized and stored in a column, syringe, vial or chamber as a solid, lyophilized or precipitated. They may be stored on a solid phase surface through electrostatic forces, non-polar interactions, hydrogen bonding, polar interactions or any other mechanism. The solid surface may be media in a column which may be contained in a syringe. Nucleic acid vaccines are prepared by a two-step process. The nucleic acid component is first stabilized and then mixed with nanocomplex reagents, particle forming reagents or other reagents.

19.4267727GENOMISCHE DELETION IN DER AFRIKANISCHEN SCHWEINEPEST-IMPFUNG, DIE EIN EFFIZIENTES WACHSTUM IN STABILEN ZELLINIEN ERLAUBT

EP - 01.11.2023
Clasificación Internacional C12N 7/00 Nº de solicitud 21911760 Solicitante US AGRICULTURE Inventor/a GLADUE DOUGLAS P
Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate ("ASFV-G"). An exemplary vaccine comprises a deletion of multiple genes allowing for industrial-scale growth in stable cell lines.

20.4271698STABILE CORONAVIRUSPROTEINE UND IMPFSTOFFZUSAMMENSETZUNGEN DARAUS
EP - 08.11.2023
Clasificación Internacional C07K 14/165 Nº de solicitud 21916103 Solicitante UNIV WASHINGTON Inventor/a ELLIS DANIEL
Provided herein are compositions and methods comprising mutated coronavirus "S" spike proteins or receptor binding domains thereof that have an increased expression level, yield and stability compared to its corresponding native or wild-type coronavirus spike protein under the same expression, culture or storage conditions. These mutated spike proteins can be used for generating a protein-based vaccine against one or more coronaviruses.

21.20230346925TRIPLE VACCINE PROTECTS AGAINST BACTERIAL AND FUNGAL PATHOGENS VIA TRAINED IMMUNITY
US - 02.11.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 18213127 Solicitante University of Southern California Inventor/a Brad Spellberg
An optimized protein-free tripartite vaccine that protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram-positive bacteria, Gram-negative bacteria, and fungi.

22.WO/2023/210722IMMUNOACTIVATOR, VACCINE ADJUVANT, AND METHOD FOR INDUCING IMMUNITY
WO - 02.11.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/JP2023/016572 Solicitante TEIKYO UNIVERSITY Inventor/a SUZUKI Ryo
In order to provide an immunoactivator capable of enhancing both humoral immunity and cellular immunity, the active ingredient of the immunoactivator being derived from cell walls (derived from a natural product), to provide a vaccine adjuvant, and to provide a method for inducing immunity, the method having a step for administering the immunoactivator, an immunoactivator according to the present invention has particles having a maximum diameter within the range of 1-800 nm as the active ingredient, the particles being composed of cell-wall-derived polysaccharides.

23.4272762VERFAHREN ZUR HERSTELLUNG VON BETULIN ALS ADJUVANS IN EINEM IMPFSTOFF GEGEN CORONAVIRUS SARS-COV-2
EP - 08.11.2023
Clasificación Internacional A61K 47/10 Nº de solicitud 21915924 Solicitante BETUVAKS LLC Inventor/a ISAEV ARTUR ALEXANDROVICH
The invention relates to biotechnology, and specifically to a method for creating the adjuvant betulin, suitable for preparing a vaccine against coronavirus SARS-CoV-2. The method consists in sterilizing filtration of a solution of betulin in tetrahydrofuran through a nylon membrane with a pore diameter of 0.22 μm, decreasing the tetrahydrofuran content by adding a 25-fold volume of sterile 0.01 M tris-buffer (pH 9.0±0.1), and subsequently homogenizing by ultrasound until a homogeneous suspension results,

forming spherical amorphous homogeneous particles suitable for binding proteins of the SARS-CoV-2 virus. The proposed technique makes it possible to produce betulin with high sterility and immunogenicity, which improves the quality of the vaccine against the coronavirus.

24.4267178RNA-IMPFSTOFF GEGEN SARS-COV-2-VARIANTEN
EP - 01.11.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21836244 Solicitante CUREVAC SE Inventor/a ROTH NICOLE
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID- 19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

25.4267176CHLAMYDIA-IMPFSTOFF AUF BASIS DES MOMP-VS4-ANTIGEN-TARGETING AUF ANTIGENPRÄSENTIERENDEN ZELLEN
EP - 01.11.2023
Clasificación Internacional A61K 39/118 Nº de solicitud 21843731 Solicitante INST NAT SANTE RECH MED Inventor/a LEVY YVES
Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of *Chlamydia trachomatis* for its use as vaccine.

26.20230357364COVID-19 ANTIBODIES AND USES THEREOF
US - 09.11.2023
Clasificación Internacional C07K 16/10 Nº de solicitud 17923313 Solicitante International AIDS Vaccine Initiative, Inc. Inventor/a Devin Sok
The present application is directed to recombinant monoclonal antibodies, or antigen fragments thereof that bind a Spike protein of SARS-CoV-2. Methods of using the antibodies to treat or prevent SARS-CoV-2 (COVID-19) are also disclosed.

27.20230348856PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
US - 02.11.2023
Clasificación Internacional C12N 5/0784 Nº de solicitud 18190199 Solicitante BGI SHENZHEN Inventor/a Yuping GE
A method for activating an adaptive immune response by adding allogeneic dendritic cells (DCs) and/or viral antigen peptides to conventional DC vaccines to expand the DC vaccine antigen spectrum with the aid of exogenous DC effect, thereby enhancing the anti-tumor effect of the DC vaccine.

28.20230346915Production Of Vaccines Comprising Inactivated SARS-COV-2 Viral Particles
US - 02.11.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 17905700 Solicitante Colorado State University Research Foundation Inventor/a Raymond P. Goodrich
Provided herein are methods for inactivating a viral particle, the methods comprising contacting the viral particle with UV light in the presence of riboflavin. In some embodiments, the viral particle is a SARS-

CoV-2 particle. Vaccine compositions comprising inactivated viral particles (e.g., inactivated SARS-CoV-2 particles) are also provided. In some embodiments, the vaccine compositions comprise an adjuvant capable of promoting a Th1-type immune response.

29.4267181NUKLEINSÄURESTABILISIERENDE LÖSUNG FÜR IMPFSTOFFE, THERAPIE, DIAGNOSTIK, LAGERUNG UND TRANSPORT
EP - 01.11.2023
Clasificación Internacional A61K 39/285 Nº de solicitud 21911865 Solicitante DAYKIN MOLECULAR SYSTEMS LLC Inventor/a AGHAJANI ERIK
Chemical compositions and/or mixtures that allow nucleic acid to remain stable at ambient temperatures. The disclosed technology includes a solution and manufacturing methods thereof. The solution includes a chelating agent, a buffering agent, and a salt. The solution is configured to protect RNA and/or an RNA-based vaccine added to the solution and prevents or reduces degradation of the RNA and/or the RNA-based vaccine for a duration of 2 to 180 days over a temperature range of -20 degrees C to + 38 degrees C. The chelating agent can comprise ethylenediaminetetraacetic acid (EDTA). The buffering agent can comprise tris(hydroxymethyl)aminomethane (TRIS). The salt can comprise NaCl. The solution is configured to preserve an injectable mRNA vaccine added to the solution, and the solution is safe for injection into mammals.

30.20230346910INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS
US - 02.11.2023
Clasificación Internacional A61K 39/145 Nº de solicitud 18136808 Solicitante Najít Technologies, Inc. Inventor/a Ian J. Amanna
Provided are surprisingly effective methods for inactivating pathogens, and for producing highly immunogenic vaccine compositions containing an inactivated pathogen rendered noninfectious by exposure to a Fenton reagent, or by exposure to a Fenton reagent or a component thereof in combination with a methisazone reagent selected from the group consisting of methisazone, methisazone analogs, functional group(s)/substructure(s) of methisazone, and combinations thereof. The methods efficiently inactivate pathogens, while substantially retaining pathogen antigenicity and/or immunogenicity, and are suitable for inactivating pathogens, or for the preparation of vaccines for a wide variety of pathogens with genomes comprising RNA or DNA, including viruses and bacteria. Also provided are highly immunogenic inactivated vaccine compositions prepared by using any of the disclosed methods, and methods for eliciting an immune response in a subject by administering such vaccine compositions.

31.20230346920VACCINES AGAINST VIRAL PATHOGENS
US - 02.11.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17997886 Solicitante Hexamer Therapeutics, Inc. Inventor/a Keith Douglas Miller
The present disclosure describes a unique viral peptide (VP) vaccine for preventing or treating viral diseases. The vaccine is produced synthetically and includes no production steps in biological cells (e.g. *E. coli*, CHO cells, yeast cells) that would require subsequent endotoxin assays/removal or viral clearance procedures. The hC peptide is synthesized separately from the VP, and following self-assembly of the hC, the VP is covalently coupled to form the VP-hC conjugate which can serve as a vaccine for preventing or treating viral diseases. The hC includes heptad repeats following a specific pattern. Optionally, the VP-hC conjugate further includes one or more T-cell epitopes at the N- and/or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions comprising immunogenic compositions including VP-hC conjugate.

32.20230346908MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF MULTIPLE FLAVI VIRUS
US - 02.11.2023
Clasificación Internacional A61K 47/69 Nº de solicitud 18332022 Solicitante Emergex Vaccines Holding Limited Inventor/a Ramila Philip
The invention provides a vaccine composition comprising a flavi peptide comprising one or more CD8+ T cell epitopes.

33.4267180CORONAVIRUS-IMPFSTOFF
EP - 01.11.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 21908159 Solicitante UNIV MELBOURNE Inventor/a GODFREY DALE IAN
The present invention relates to chimeric and fusion proteins and their compositions, and the use of such proteins and compositions in the prevention and/or treatment of coronavirus infections, or respiratory diseases or conditions associated with coronavirus infections.

34.20230346909NOVEL SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME VIRUS
US - 02.11.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 18348323 Solicitante I.D.BIO. Inventor/a Yeo-Jeong CHOI
The present invention relates to a novel genotype of severe fever with thrombocytopenia syndrome viruses and use thereof as an immunogenic composition. The severe fever with thrombocytopenia syndrome viruses of the present invention are genetically different from conventional severe fever with thrombocytopenia syndrome viruses and are novel viruses taxonomically belonging to three sub-groups of genotype B. In view of the vaccine property that specific genotype viruses alone show only limited protective potential, the novel viruses of the present invention may be advantageously used as a vaccine having excellent cross-immunogenicity for SFTSV.

35.WO/2023/211279ADJUVANT COMBINATIONS FOR NEOPEPTIDE VACCINES
WO - 02.11.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/NL2023/050230 Solicitante ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM Inventor/a KATSIKIS, Peter D.
The present invention provides an anti-cancer vaccine composition comprising a cancer neoantigen comprising a CTL epitope, the composition further comprising as adjuvants a combination of a CpG ohgonucleotide and a STING agonist.

36.WO/2023/206865VACCINATION VERIFICATION SYSTEM AND METHOD BASED ON SMART CONTRACT, AND CONTRACT PLATFORM
WO - 02.11.2023
Clasificación Internacional G06F 21/45 Nº de solicitud PCT/CN2022/112336 Solicitante FANG, Weihang Inventor/a FANG, Weihang
Disclosed in the present application are a vaccination verification system and method based on a smart contract, and a contract platform. The vaccination verification system and method based on a smart contract, and the contract platform, which are provided in the present invention, can realize the decentralization of applications, such that a first client, which serves as an inoculator, a second client, which serves as a medical worker, and the contract platform can achieve high-level mutual trust; and the participation of human factors is reduced, thereby preventing information leakage and imposter phenomenon, and facilitating the rapid popularization of vaccines. In addition, vaccine manufacturers can also plan vaccine production according to registration information.

37.20230348864INFLUENZA VIRUSES WITH MUTANT PB2 GENE SEGMENT AS LIVE ATTENUATED VACCINES
US - 02.11.2023
Clasificación Internacional C12N 7/00 Nº de solicitud 17835830 Solicitante Wisconsin Alumni Research Foundation (WARF) Inventor/a Yoshihiro Kawaoka
The invention provides a recombinant biologically contained influenza virus that is a PB2 knockout virus, e.g., one that is useful to generate a multivalent vaccine, and methods of making and using that virus.

38.202303484681H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US - 02.11.2023
Clasificación Internacional C07D 487/04 Nº de solicitud 17793278 Solicitante BRISTOL-MYERS SQUIBB COMPANY Inventor/a Matthew COX
Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). (I) (II) Such compounds can be used in cancer treatment, especially in combination with an anti-cancermmunotherapy agent, or as a vaccine adjuvant.

39.20230355763NANOPARTICLE VACCINES AND USES THEREOF FOR PROPHYLAXIS AND TREATMENT OF ATHEROSCLEROSIS USING PEPTIDE 210 AS AN ANTIGEN
US - 09.11.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18312194 Solicitante CEDARS-SINAI MEDICAL CENTER Inventor/a Prediman K. Shah
Described herein are nanoparticle bound self-antigens as an immune and vaccine formulations to elicit self-regulations and reduce atherosclerosis. The use of apolipoprotein B100 (ApoB-100) peptide P210 was investigated in self-assembling peptide amphiphile micelles (P210-PAM) as a vaccine formulation to reduce atherosclerosis in ApoE$^{-/-}$ mice. Demonstrated herein, P210 provided T cell activation and memory response in peripheral blood mononuclear cells of human subjects with atherosclerotic cardiovascular disease, and dendritic cell uptake of P210-PAM and its co-staining with major histocompatibility complex class I (MHC-I) molecules supported its use as an immunogenic composition. In ApoE$^{-/-}$ mice, immunization with P210-PAM dampened P210-specific CD4^{+} T cell proliferative response and CD8^{+} T cell cytolytic response, modulated macrophage phenotype, and significantly reduced aortic atherosclerosis. P210-PAM immunization also reduced atherosclerosis in chimeric mice with human MHC-I allele.

40.3868741SAMMENSÆTNING OMFATTENDE EN PYRIMIDINFORBINDELSE OG ET PATOGENAFLEDT ANTIGEN
DK - 06.11.2023
Clasificación Internacional C07D 239/49 Nº de solicitud 21164640 Solicitante Sumitomo Pharma Co., Ltd. Inventor/a KIMURA, Hidenori
The present invention provides a compound of the formula (1) :wherein X, R^1, R^2, R^3, R^4, R^5, R^6, Y^1, Y^2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

41.WO/2023/208990COMBINATION THERAPY FOR THE TREATMENT OF CANCER COMPRISING A FAS AXIS ANTAGONIST AND A T-REG CELL DEPLETING AGENT ANTAGONIST,
WO - 02.11.2023
Clasificación Internacional A61K 39/395 Nº de solicitud PCT/EP2023/060899 Solicitante F. HOFFMANN-LA ROCHE AG Inventor/a AMANN, Maria

The present disclosure is directed to the combination of a Fas axis antagonist, such as an anti-FasL antibody, and a Treg cell depletion therapy, for example an anti-CD25 antibody, optionally with a cancer vaccine, for use in the treatment of cancer.

42.20230357327PREFUSION-STABILIZED HMPV F PROTEINS
US - 09.11.2023
Clasificación Internacional C07K 14/08 Nº de solicitud 18296771 Solicitante BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor/a Jason MCLELLAN
Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.

43.4268899FERRITIN-NANOPARTIKEL MIT CHEMOTHERAPEUTISCHEM MITTEL
EP - 01.11.2023
Clasificación Internacional A61P 35/00 Nº de solicitud 23184063 Solicitante COLEMAN SRL Inventor/a MAZZUCCHELLI SERENA
The present invention concerns the field of cancer therapy, and in particular to the use of nanoparticles for the preservation of T cells.In particular, the present invention relates to the use of nanoparticles for the treatment of recurrent cancer and for use as a cancer vaccine.

44.WO/2023/214082SIGNAL SEQUENCES FOR NUCLEIC ACID VACCINES
WO - 09.11.2023
Clasificación Internacional A61K 39/02 Nº de solicitud PCT/EP2023/062066 Solicitante SANOFI Inventor/a GIRERD-CHAMBAZ, Yves
Provided herein is a nucleic acid (e.g., messenger RNA) vaccine encoding at least one antigenic prokaryotic polypeptide linked to one or both of a viral secretion signal peptide and a transmembrane domain. Also provided are methods of vaccination against a prokaryotic infection with the nucleic acid described herein.

45.20230355751COMPOSITIONS AND METHODS FOR A MULTI-ADJUVANT ONLY APPROACH TO IMMUNOPROPHYLAXIS FOR PREVENTING INFECTIONS
US - 09.11.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 18142216 Solicitante University of Southern California Inventor/a Brad Spellberg
This disclosure provides a new vaccine composition and methods for its use. The composition contains an effective amount of each of: an aluminum hydroxide, a mono-phosphoryl lipid (MPL), and a whole glucan particles (WGP) but no an antigen that raises an immune response against a bacterial or fungal infection.

46.4271417GLYCOSYLIERTES KLEBSIELLA PNEUMONIAE-O-ANTIGEN UND VERFAHREN ZUR HERSTELLUNG UND VERWENDUNGEN DAVON
EP - 08.11.2023
Clasificación Internacional A61K 47/65 Nº de solicitud 21916427 Solicitante VAXNEWMO LLC Inventor/a HARDING CHRISTIAN
Provided herein is a bioconjugate comprising a *K. pneumoniae* O-antigen covalently linked to a fusion protein comprising a ComP protein or a glycosylation tag fragment. The *K. pneumoniae* O-antigen bioconjugate of this disclosure can be used as a conjugate vaccine including multivalent conjugate vaccines comprising multiple *K. pneumoniae* O-antigens.

47.WO/2023/208076CATIONIC LIPID NANOPARTICLE HAVING HIGH TRANSFECTION EFFICIENCY AND PREPARATION METHOD THEREFOR

WO - 02.11.2023
Clasificación Internacional A61K 9/51 Nº de solicitud PCT/CN2023/090998 Solicitante BEIJING D-NANO PHARMA CO., LTD Inventor/a TONG, Shuwen
A nucleic acid-loaded calcium-containing cationic lipid nanoparticle, comprising a cationic lipid, a neutral lipid, a PEGylated lipid, and cholesterol and/or a cholesterol ester. The cationic lipid nanoparticle can be used for preparing a gene-based drug for localized injection into the body or a nucleic acid vaccine for localized or whole-body injection into the body.

48.4268817VERWENDUNG EINES PCSK9-INHIBITORS BEI DER HERSTELLUNG EINES PRODUKTS ZUR BEHANDLUNG MEHRERER ERKRANKUNGEN
EP - 01.11.2023
Clasificación Internacional A61K 31/437 Nº de solicitud 21833682 Solicitante CHEN MIN Inventor/a WANG YICHEN
Provided in the present invention is the use of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in a product for treating multiple diseases. The PCSK9 inhibitor is a PCSK9 small molecule compound, or a PCSK9 interfering RNA, or a PCSK9 monoclonal antibody, or a PCSK9 mimetic peptide, or a PCSK9 mimetic antibody protein, or a PCSK9 antisense oligonucleotide or a PCSK9 vaccine.

49.20230346773USE OF PCSK9 INHIBITOR IN PREPARATION OF PRODUCT FOR TREATING MULTIPLE DISEASES
US - 02.11.2023
Clasificación Internacional A61K 31/4725 Nº de solicitud 18024010 Solicitante Min CHEN Inventor/a Min CHEN
Provided in the present invention is the use of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in a product for treating multiple diseases. The PCSK9 inhibitor is a PCSK9 small molecule compound, or a PCSK9 interfering RNA, or a PCSK9 monoclonal antibody, or a PCSK9 mimetic peptide, or a PCSK9 mimetic antibody protein, or a PCSK9 antisense oligonucleotide or a PCSK9 vaccine.

50.WO/2023/212668METHOD FOR ENHANCING IMMUNITY
WO - 02.11.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/US2023/066330 Solicitante XANADU BIO, INC. Inventor/a IWASAKI, Akiko
The invention relates to a method of enhancing immunity, mRNA-based vaccines for SARS-CoV-2 have demonstrated the enormous potential of mRNA therapeutics for safe and effective use in the general population. However, more recent studies have demonstrated decreasing vaccine effectiveness in terms of asymptomatic infection as well as symptomatic and severe infections starting around 4 months post second dose with mRNA-lipid nanoparticles (LNP) based regimens.

51.WO/2023/215869INACTIVATED STAPHYLOCOCCUS COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
WO - 09.11.2023
Clasificación Internacional A61K 39/085 Nº de solicitud PCT/US2023/066663 Solicitante BIOLOGICAL MIMETICS, INC. Inventor/a DOLLERY, Stephen J.
Presented herein are inactivated Staphylococcal bacterial immunogens. Also described herein are compositions including Staphylococcal immunogens. Methods for preparing and using the same are also described. Immunogens may enable a host immune response that can protect the host from infection and/or disease. Differential analysis of antigens that stimulate protective (immunogenic) and non-protective immunity can be used to identify correlates of protection that can be developed as subunit vaccine candidates.

52.4267550IONISIERBARE LIPIDE
EP - 01.11.2023
Clasificación Internacional C07C 271/20 Nº de solicitud 21840972 Solicitante ETHERNA IMMUNOTHERAPIES NV Inventor/a DE KOKER STEFAAN
The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by formula (I). The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising nucleic acids. It further provides vaccine formulations comprising nanoparticle compositions based on the ionizable lipids disclosed herein.

53.WO/2023/214801UTR SEQUENCE FOR CONTROLLING PROTEIN EXPRESSION LEVEL AND EXPRESSION LOCATION, AND MRNA SEQUENCE INCLUDING SAME
WO - 09.11.2023
Clasificación Internacional C12N 15/11 Nº de solicitud PCT/KR2023/006052 Solicitante INDUSTRY-ACADEMIC COOPERATION FOUNDATION, DANKOOK UNIVERSITY Inventor/a JEONG, Sunjoo
The present invention relates to an mRNA including the UTR of polymorphic β-catenin. When used, the mRNA molecule, nucleic acid molecule, expression construct, and/or expression vector of the present invention can effectively enhance the expression efficiency of a target protein and extend the expression location of the target protein to the cytoplasm, thus allowing for stable extracellular secretion. In addition, the mRNA functions to regulate an expression level of exogenously introduced mRNA and thus can be utilized as an mRNA vaccine in the future.

54.20230357325COMPOSITION AND METHOD TO STABILIZE CORONAVIRUS SPIKE GLYCOPROTEINS IN PRE-FUSION CONFORMATION
US - 09.11.2023
Clasificación Internacional C07K 14/005 Nº de solicitud 18314769 Solicitante The Research Foundation for The State of University New York Inventor/a Carlos Simmerling
Compositions include coronavirus S1/S2 prefusion spike proteins with specifically designed disulfide bond that “staple” together the central helix and a region of the spike known as HR1. By preventing HR1 from detaching from CH, the prefusion spike structure is stabilized without rigidification of the central helix or changes to its interaction with the receptor binding domain. This disulfide-stapled spike is more stable in the prefusion form, allowing for a stable vaccine without the need for the stabilizing mutations that are currently in use.

55.20230346921CIRCULAR RNA VACCINES AND METHODS OF USE THEREOF
US - 02.11.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18022488 Solicitante Peking University Inventor/a Wensheng WEI
The present application provides circular RNAs (circRNAs) encoding therapeutic polyeptides (e.g., an antigenic polypeptide, a functional protein, a receptor protein, or a targeting protein). In some embodiments, the present application provides circRNA vaccines against a coronavirus such as SARS-CoV-2. In some embodiments, the circRNA vaccine comprises a circRNA comprising a nucleic acid sequence encoding an antigenic polypeptide comprising a Spike (S) protein or a fragment thereof of a coronavirus. Also provided are methods of treating or preventing a disease or condition using the circRNAs or compositions thereof.

56.WO/2023/209261USO IN VITRO DEL ETINILESTRADIOL PARA INCREMENTAR EL CRECIMIENTO VÍRICO
WO - 02.11.2023

Clasificación Internacional C12N 7/02 Nº de solicitud PCT/ES2023/070273 Solicitante UNIVERSITAT DE VALÉNCIA Inventor/a MARTÍNEZ GIL, Luis
La presente invención se refiere al uso in vitro del etinilestradiol para incrementar el crecimiento de virus con envuelta lipídica, particularmente del SARS-CoV-2 y IAV. Además, la presente invención se refiere a un método para incrementar el crecimiento in vitro de un virus que comprende una envoltura lipídica. Dicho método comprende infectar una célula o línea celular con dicho virus e incubar la célula o línea celular infectada con un medio de cultivo que comprende etinilestradiol. Consecuentemente, el uso del etinilestradiol puede mejorar los rendimientos en la producción de estos virus y reducir los costes de producción asociados, por ejemplo, a la producción de vacunas.

57.2023248200Vaccine compositions having improved stability and immunogenicity
AU - 02.11.2023
Clasificación Internacional Nº de solicitud 2023248200 Solicitante Novavax, Inc. Inventor/a Boddapati, Sarathi
Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded by and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

58.20230355740COMPOSITIONS AND METHODS OF USE THEREOF FOR PREVENTION AND TREATMENT OF INFLUENZA INFECTIONS
US - 09.11.2023
Clasificación Internacional A61K 39/145 Nº de solicitud 18245115 Solicitante University of Georgia Research Foundation, Inc. Inventor/a Amy L. Vincent
Recombinant constructs, influenza viral genomes including the recombinant constructs, influenza viruses including the constructs, and vaccine formulations formed thereof for inducing or increasing an immune response against influenza virus are provided. The compositions typically include a nucleic acid having a nucleic acid sequence encoding IgA-inducing protein (IGIP) polypeptide that can positively regulate IgA expression operably linked to expression of a hemagglutinin or a neuraminidase. When the nucleic acid is expressed by recombinant influenza virus in infected cells, it preferably enhances IgA production against influenza virus. Live attenuated virus expressing IGIP, and methods of use thereof for treating and preventing influenza infections are also provided.

59.20230346837PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS
US - 02.11.2023
Clasificación Internacional A61K 35/17 Nº de solicitud 18177594 Solicitante Immatics Biotechnologies GmbH Inventor/a Juliane Sarah WALZ
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

60.20230355729MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
US - 09.11.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18245532 Solicitante Robin BARBOUR Inventor/a Robin Barbour

The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ) peptide and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and/or alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of alpha-synuclein seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing alpha-synuclein and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and an alpha-synuclein peptide.

61.20230355741Feline Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
US - 09.11.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17923018 Solicitante Intervet Inc. Inventor/a Mark A. Mogler
The present invention provides new vaccines for felines and ferrets to aid in reducing shedding of severe acute respiratory syndrome coronavirus 2 by infected felines or ferrets. Methods of making and using the vaccines alone or in combinations with other protective agents are also provided.

62.20230355756ALPHA-SYNUCLEIN VACCINE FOR THE TREATMENT OF SYNUCLEINOPATHIES
US - 09.11.2023
Clasificación Internacional A61P 37/04 Nº de solicitud 18245533 Solicitante PROTHENA BIOSCIENCES LIMITED Inventor/a Robin Barbour
The disclosure provides peptide compositions and immunotherapy compositions comprising alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of neurodegenerative diseases, such as Parkinson’s disease, dementia with Lewy bodies (DLB), Alzheimer’s disease or other synucleinopathies, with alpha-synuclein deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of alpha-synuclein, blocking the uptake by neurons and inhibiting propagation of alpha-synuclein seeds in a subject having or at risk of developing a neurodegenerative disease containing alpha-synuclein accumulations. The methods include administering to such patients the compositions comprising alpha-synuclein peptide.

63.20230348476CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF
US - 02.11.2023
Clasificación Internacional C07D 487/04 Nº de solicitud 18297367 Solicitante 3+2 PHARMA, LLC Inventor/a Fuqiang Ruan
Provided are compounds of formula (Ia), (Ib) and (IIa), and pharmaceutically acceptable salts thereof. Additionally provided are compositions and pharmaceutical compositions comprising the compounds, therapeutic methods using same for modulating (e.g., inhibiting) CREB binding protein (CBP)/β-catenin mediated signaling in treating a condition, disease or disorder (e.g., fibrosis, cancer, neurological conditions, metabolic disorders (e.g., diabetes, etc.), and skin conditions (dermatitis, psoriasis, scarring, alopecia, etc.) mediated by aberrant CBP/β-catenin signaling, and cosmetic methods for treating skin conditions (e.g., aging, etc.). Additionally, provided are methods for enhancing vaccine efficacy using the compounds and compositions. Further provided are methods for efficiently synthesizing a clinical grade drug, comprising use, in a penultimate, or last reaction step under GMP conditions, of an intermediate 2-propynyl-compound to form a clinical grade isoxazole derivative (e.g., via 3+2 cycloaddition).

64.WO/2023/214922ANCESTRAL PROTEIN SEQUENCES AND PRODUCTION THEREOF
WO - 09.11.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/SE2023/050423 Solicitante SCHRIEVER, Karen Inventor/a SCHRIEVER, Karen

A protein, such as an antigenic protein, is produced by determining an amino acid sequence of an ancestral version of a given protein in an ancestral sequence reconstruction method based on a plurality of homologous amino acid sequences of the given protein. A domain of the amino acid sequence of the ancestral version of the given protein is replaced with a corresponding domain derived from an amino acid sequence of the given protein or a homologous version thereof. The protein thereby comprises the amino acid sequence obtained by replacing the domain of the amino acid sequence of the ancestral version of the given protein with the corresponding domain derived from the amino acid sequence of the given protein or the homologous version thereof. The protein is suitable as antigen, as vaccine candidate and/or for structural studies.

65.20230348566RE-FOLDED HUMAN SERUM ALBUMIN AND USE THEREOF FOR ANTI-TUMOR
US - 02.11.2023
Clasificación Internacional C07K 14/765 Nº de solicitud 18025637 Solicitante Academia Sinica Inventor/a Chi-Ming LIANG
Re-folded human serum albumin (rfHSA) and use thereof for anti-tumor are disclosed. The rfHSA comprises the primary amino acid sequence of naive human serum albumin, in which the rfHSA in a solution is oval shape, not fibrillar, and the naive HSA is globular. The rfHSA is used for treating cancer or a tumor in a subject in need thereof The rfHSA may also be used as a reagent for detecting the presence of a cancer cell associated with integrin β1 or serine/threonine protein kinase Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) in a tumor sample or as a reagent for inhibiting phosphorylation of Akt and ERK 1/2 in a cancer cell sample. A cell lysate of a cancer cell treated with rfHSA, a vaccine composition comprising the cancer cell lysate, and use thereof are also disclosed. Also disclosed is a method tor preparing rfHSA.

66.20230357328SARS-CoV-2 PROTEIN-DERIVED PEPTIDE AND VACCINE CONTAINING SAME
US - 09.11.2023
Clasificación Internacional C07K 14/165 Nº de solicitud 18029374 Solicitante ONCOTHERAPY SCIENCE, INC. Inventor/a TETSURO HIKICHI
The present invention provides epitope peptides which are derived from SARS-CoV-2 proteins and have the ability to induce cytotoxic T cells. The present invention also provides polynucleotides encoding the peptides, antigen-presenting cells that present the peptides, and cytotoxic T cells that target the peptides, and methods of inducing the antigen-presenting cells or CTLs. The present invention further provides compositions and pharmaceutical compositions containing them as active ingredients. Moreover, the present invention provides methods of treating and/or preventing coronavirus infectious diseases, and/or suppressing the aggravation of coronavirus infectious diseases by using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells, or pharmaceutical compositions of the present invention. The present invention also provides methods of inducing an immune response against coronavirus infection. Furthermore, the present invention provides methods of examining the history of coronavirus infection by detecting TCR sequences of a subject.

67.WO/2023/211172CHIMERIC ZIKA VIRUS ANTICANCER VACCINE USING BREAST CANCER CELL SUBLINE
WO - 02.11.2023
Clasificación Internacional A61K 35/768 Nº de solicitud PCT/KR2023/005736 Solicitante SK BIOSCIENCE CO., LTD. Inventor/a HONG, Seung-hye
The present invention relates to a pharmaceutical composition for preventing or treating breast cancer, comprising, as an active ingredient, a chimeric Zika virus using a breast cancer cell subline.

68.4273155NOROVIRUSVIRUSÄHNLICHE PARTIKEL, IMMUNZUSAMMENSETZUNG ODER KIT UND VERWENDUNG DAVON

EP - 08.11.2023
Clasificación Internacional C07K 14/08 Nº de solicitud 21914021 Solicitante GRAND THERAVAC LIFE SCIENCE NANJING CO LTD Inventor/a LI JIANQIANG
Provided is a G11.4 norovirus virus-like particle or active fragment thereof, and use thereof, the virus-like particle comprising or being composed of an amino acid sequence shown as SEQ ID NO: 4. Further, provided is a composition or a kit comprising the G11.4 norovirus virus-like particle, and use thereof. The objective of covering multiple genotypes is achieved by using a single antigen of the invention, the process difficulty of the preparation for a pharmaceutical composition or a vaccine can be reduced, and the production cost is decreased. Also, provided is a norovirus immune composition or a kit comprising GII.2, GII.4, GII.6, and GII.17 norovirus virus-like particles or active fragments thereof, and use thereof. By the composition or the kit comprising the four types of antigens provied by the invention, each of antigens can generate a cross-immune effect on other genotypes, not only multiple prevailing genotypes of noroviruses can be covered, but also a synergy of immune effects on the same genotypes to which the four types of antigens target.

69.WO/2023/209068PERSONALIZED ANTICANCER VACCINE COMPRISING GLYCOENGINEERED TUMOUR CELLS OR TUMOUR CELL FRAGMENTS
WO - 02.11.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/EP2023/061070 Solicitante CARBOCALYX GMBH Inventor/a DOLOWSCHIAK, Tamas
Disclosed herein is a glycoengineered tumor cell or a glycoengineered tumor cell fragment for use in treatment and/or prevention of cancer, in particular cancerous neoplasms, in a subject. The glycoengineered tumor cell or tumor cell fragment comprises a tumor cell surface comprising one or more carbohydrate antigen moieties. Furthermore, a pharmaceutical composition comprising such a cell or cell fragment, a method for producing such a glycoengineered tumor cell or tumor cell fragment and a method of treatment of a subject comprising the administration of such a glycoengineered tumor cell or glycoengineered tumor cell fragment to a subject is disclosed.

70.2023258376MATERIALS AND METHODS FOR CELL-FREE EXPRESSION OF VACCINE EPITOPE CONCATEMERS
AU - 09.11.2023
Clasificación Internacional Nº de solicitud 2023258376 Solicitante Leidos, Inc. Inventor/a John DRESIOS

71.20230355766DNA NANOVACCINE, PREPARATION METHOD THEREFOR AND USE THEREOF
US - 09.11.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 17774695 Solicitante NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY Inventor/a Baoquan Ding
Provided are a DNA nanovaccine, a preparation method therefor and the use thereof. The DNA nanovaccine comprises a DNA nanostructure, a tumor antigen polypeptide-DNA complex and an immunologic adjuvant, and the immunologic adjuvant comprises a double-stranded RNA immunologic adjuvant and/or a CpG immunologic adjuvant. In the present invention, a nanostructure is constructed, wherein the nanostructure is assembled from a DNA template, a DNA chain for assisting in folding and a capture DNA chain. By hybridizing the capture DNA chain with a functional component, the precise positioning and assembling of a tumor antigen molecule and an immunologic adjuvant molecule on the surface of the DNA self-assembled nanostructure is realized; in addition, a controllable DNA molecule “switch” is designed on one side of the tubular DNA nanostructure, which switch can respond to the acid environment of an endosome after entering an antigen-presenting cell, and open the tubular structure responsively to release the tumor antigen and the immunologic adjuvant molecule. The nanostructure has

a tumor antigen-specific immunostimulatory effect and is a tumor vaccine used for the immunotherapy and prevention of various types of malignant tumors.

72.4271406NANOEMULSIONSIMPFSTOFFZUSAMMENSETZUNGEN UND VERFAHREN ZUR UNTERDRÜCKUNG DER REAKTIVITÄT GEGEN MEHRERE LEBENSMITTELALLERGENE
EP - 08.11.2023
Clasificación Internacional A61K 39/07 Nº de solicitud 21916444 Solicitante UNIV MICHIGAN REGENTS Inventor/a BAKER JR JAMES R
The disclosure is directed to compositions and methods for inhibiting an allergic reaction to two or more food allergens. The compositions comprise a nanoemulsion and at least one of the two or more food allergens.

73.2023255055Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
AU - 09.11.2023
Clasificación Internacional Nº de solicitud 2023255055 Solicitante The Board of Trustees of the University of Arkansas Inventor/a Billy HARGIS

74.20230355745CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN VARIANT HAVING REDUCED ACE2-BINDING AFFINITY AND VACCINE COMPOSITION COMPRISING THE SAME
US - 09.11.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18044365 Solicitante GI CELL, INC. Inventor/a Myoung Ho JANG
Disclosed are a novel coronavirus-derived receptor-binding domain variant having reduced ACE2-binding affinity, a fusion protein comprising the same, and the use thereof. It is possible to overcome the drawbacks of conventional vaccines using the coronavirus spike protein or receptor-binding domain thereof, wherein the reduced ACE2 expression due to binding to ACE2 and negative feedback may lead to side effects of the lungs or heart, and in particular, may be fatal to patients suffering from underlying diseases of the lungs or heart. In particular, the fusion protein constructed by fusing the coronavirus receptor-binding domain with the Fc domain is imparted with a greatly improved in-vivo half-life, and has superior efficacy by further combining N protein, M protein, ORF protein, or the like of SARS-CoV-2 therewith through additional modification and thus is highly applicable to a multivalent immunogenic composition. Therefore, the coronavirus receptor-binding domain variant is useful for the prevention and treatment of coronavirus infections comprising SARS-CoV-2.

75.20230355734A FACTOR H BINDING PROTEIN B (FHBB) BASED CHIMERIC VACCINE FOR THE PREVENTION AND TREATMENT OF PERIODONTAL DISEASE
US - 09.11.2023
Clasificación Internacional A61K 39/02 Nº de solicitud 18030160 Solicitante VIRGINIA COMMONWEALTH UNIVERSITY Inventor/a Richard T. MARCONI
Provided herein are recombinant Factor H Binding Protein B (FhbB) chimeric proteins comprising several different mutant variants of the *Treponema denticola* Factor H binding protein B (FhbB). The mutant variants cannot bind Factor H. The chimeric proteins are used to vaccinate subjects against periodontal disease either systemically and/or by direct application of antibodies generated against the chimeric proteins to the oral cavity (e.g. the gums) of a patient to prevent and/or treat periodontal disease.

76.2023258370Use of amino acid sequences from Mycobacterium tuberculosis or corresponding nucleic acids thereof for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
AU - 09.11.2023

Clasificación Internacional Nº de solicitud 2023258370 Solicitante QIAGEN Australia Holding Pty. Ltd. Inventor/a Cesare Saltini

77.20230348570EPITOPE OF ANTIBODY AGAINST STRUCTURAL PROTEIN OF SARS-COV-2, ANTIBODY REACTING WITH EPITOPE, METHOD FOR DETECTING SARS-COV-2 USING ANTIBODY, DETECTION KIT FOR SARS-COV-2 CONTAINING ANTIBODY, METHOD FOR DETECTING ANTI-SARS-COV-2 ANTIBODY CONTAINING POLYPEPTIDE OF EPITOPE, DETECTION KIT FOR ANTI-SARS-COV-2 ANTIBODY CONTAINING POLYPEPTIDE OF EPITOPE, VACCINE FOR SARS-COV-2 CONTAINING POLYPEPTIDE OF EPITOPE, AND THERAPEUTIC AGENT FOR SARS-COV-2 INFECTION CONTAINING ANTIBODY
US - 02.11.2023
Clasificación Internacional C07K 16/10 Nº de solicitud 17909816 Solicitante Denka Company Limited Inventor/a Shinya OGASAWARA
The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody or the antigen-binding fragment thereof reacts with a structural protein of SARS-CoV-2 specifically, and the structural protein of SARS-CoV-2 is at least one selected from the group consisting of S-protein, N-protein, M-protein, and E-protein and a hapten, wherein the hapten that reacts with an antibody that reacts with a protein of SARS-CoV-2 specifically, and the protein of SARS-CoV-2 is at least one selected from the group consisting of S-protein, N-protein, M-protein, and E-protein.

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES